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Chapter 1 
Introduction 
The dual specific phosphatase PTEN (Phosphatase and TENsin homolog deleted 
on chromosome 10) is one of the most extensively studied proteins of the last 
decade. It was the first phosphatase identified as a tumor suppressor and in 
sporadic cancers PTEN is one of the most frequently altered genes. Its deregulation 
is also implicated in several other diseases. In addition, PTEN is critically 
important during embryonic development and is implicated as a key player in 
maintaining normal stem cell function. Unraveling of the physiological regulation 
and function of PTEN will augment our understanding of tumorigenesis and 
ultimately lead to novel therapeutic options.  
 
1.1 PTEN structure and function 
1.1.1 PTEN protein function 
In 1997 three groups independently identified a novel tumor suppressor gene at 
10q23.3, denoted PTEN, MMAC1 (Mutated in Multiple Advanced Cancers), or 
TEP1 (TGFβ regulated and Epithelial cell-enriched Phosphatase) 1-3. The PTEN 
gene encodes a protein of 403 amino acids that shares sequence homology with the 
family of protein tyrosine phosphatases (PTP), as well as with the cytoskeletal 
protein tensin 1,3. The protein contains the HCXXGXXR catalytic signature motif 
present in all PTPs and in dual specificity phosphatases, which catalyze the 
hydrolysis of phospho-seryl, -threonyl, and -tyrosyl residues. In addition, this 
phosphatase signature motif is very well conserved across evolution indicating its 
functional significance 4. Recombinant PTEN has been shown to dephosphorylate 
protein substrates in vitro on serine, threonine, and tyrosine residues indicating that 
PTEN can indeed function as a dual specificity protein phosphatase 5. The best 
known protein substrate of PTEN is Focal Adhesion Kinase (FAK) 6. In addition 
PTEN might possess protein phosphatase activity towards itself and the Plateled 
Derived Growth Factor Receptor (PDGFR) 7,8. Recombinant PTEN, however, 
exhibited a high activity towards a highly negatively charged, and multiple 
phosphorylated substrate like the (Glu-Tyr)n polymer, suggesting a preference for 
highly acidic substrates 5. Maehama and Dixon (1998) were the first to show that 
PTEN can also dephosphorylate phosphatidylinositol lipids both in vitro and in 
vivo, with a preference for the phosphate group at the D3 position of the inositol 
ring 9 (Figure 1A).   
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Figure 1. (A) Structure of phosphatidylinositol. Candidate phosphorylation sites are indicated by 
arrows. PTEN preferentially dephosphorylates PtdIns at the D3 position. (B) PTEN antagonizes the 
function of PI3K, thereby negatively regulating PI3K dependent signal transduction pathways. 
 
   Although PTEN can dephosphorylate the phospholipids PI(3)P, PI(3,4)P2, and 
PI(3,4,5)P3 in vitro, PIP3 is its most important substrate in vivo. PIP3 is a lipid 
second messenger produced by PI3K (phosphatidylinositol-3 kinase) and plays an 
important role in signal transduction pathways that regulate a variety of cell 
biological processes. PTEN and PI3K have opposing effects on the PIP3 level 
(Figure 1B) and as a consequence they counteract each other’s actions in the 
regulation of important cell biological processes like proliferation and survival. 
The lipid phosphatase activity of PTEN is critical for its tumor suppressive 
function 10.  
 
1.1.2 PTEN protein structure 
Analysis of the crystal structure of PTEN identified two major domains, the 
phosphatase domain and a C2 domain 11. Although the structure of the N-terminal 
phosphatase domain is similar to other protein phosphatases, the active site of 
PTEN is larger and more basically charged, thereby allowing binding of the lipid 
substrate PIP3 11. Many proteins involved in signal transduction and vesicle 
trafficking contain C2 domains, which mediate binding to phospholipid 
membranes 12. Whereas the majority of C2 domains bind Ca2+ via their acidic 
residues that bridge them to the membrane, the presence of more basic residues in 
PTEN predicts a direct contact with the membrane 11. The C2 domain of PTEN is 
thought to have a function both in protein stability and in the regulation of catalytic 
activity by productive orientation of the catalytic site 11,13. Besides the C2 domain, 
the carboxy-terminal tail of PTEN contains two PEST (Proline-Glutamic acid-
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Serine-Threonine) sequences, which are involved in the regulation of protein 
stability, and a PDZ binding motif (also known as Glycine-Leucine-Glycine-
Phenylalanine (GLGF) repeat) that might play a role in protein-protein interactions 
(reviewed in ref. 14) (Figure 2).  
 
 
1 403 351185 385
 
   
 
123 HCKAGKGRT 131  
          PHOSPHATASE DOMAIN                     C2 DOMAIN                  TAIL         PDZ 
DOMAIN   
Figure 2.  Schematic representation of the domain structure of PTEN. In the N-terminal phosphatase 
domain the catalytic core sequence is depicted. The C-terminal domain contains the lipid-binding C2 
domain, PEST sequences in the tail region and a PDZ domain.   
 
1.1.3 Regulation of PTEN expression and activity 
PTEN expression and activity is regulated by complex control mechanisms at both 
the mRNA and protein level. PTEN was originally identified as a gene 
transcriptionally regulated by TGFβ, and to date several factors have been 
demonstrated to regulate PTEN transcription both positively (p53, PPARγ and 
EGR-1) and negatively (c-Jun and NFκB) (reviewed in ref. 15). However, the 
physiological significance of most of these transcription factor binding sites 
remains to be elucidated. 
   Several groups have reported PTEN promoter hypermethylation as a mechanism 
to suppress PTEN expression in various types of cancer 16-23. The genomic 
sequence of PTEN is 98% identical to a highly conserved processed PTEN 
pseudogene (ψPTEN) at 9p13 and this sequence identity extends a few hundred 
base pairs into the promoter region 24. A study by Zysman et al., (2002) showed 
that the pseudogene and not PTEN is predominantly methylated in cell lines and 
tumors, indicating that data on PTEN promoter methylation must be interpreted 
with caution 18.  
   Recently, several miRNAs were reported to be involved in the regulation of 
PTEN expression 25-27. MiRNAs are short, endogenous, single-stranded RNAs that 
could modulate gene expression by inducing degradation, or inhibiting translation 
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caused by base-pairing to sequences located in the 3’UTR of their target mRNA 28. 
The first miRNA that was found to influence PTEN expression was miR-21 25. 
Inhibition of miR-21 in human hepatocellular cells significantly increased the 
expression of PTEN. In ovarian cancers over-expression miR-214 was found to 
target the 3’UTR of PTEN, leading to down-regulation of PTEN and activation of 
the Akt pathway 26. Finally, the miR-17-92 cluster was found to suppress the 
expression of PTEN in lymphocytes of miR-17-92 transgenic mice 27. Although a 
growing number of miRNAs have been implicated in promoting or suppressing 
tumorigenesis in a variety of tissues, their precise role in the regulation of PTEN 
expression and activity remains to be further elucidated.  
   At the protein level phosphorylation of the C-terminal tail of PTEN contributes to 
the regulation of its activity and stability. Several phosphorylation sites are 
involved in modulation of PTEN stability, activity, and subcellular distribution 29,30. 
The phosphorylation of Ser380, Thr382, and Thr383 by casein kinase-II decreases 
the affinity of PTEN for the membrane thereby affecting its phosphatase activity. 
Furthermore, the casein kinase-II mediated phosphorylation of PTEN increases its 
stability by preventing its proteasomal degradation 29,30. In contrast, 
phosphorylation of Thr366 plays a role in destabilizing PTEN 31.  
   It is thought that phosphorylated PTEN exists in a more closed conformation that 
masks the PDZ-binding domain. The more open conformation of unphosphorylated 
PTEN allows interaction with other PDZ domain containing proteins like MAGI-
1/2/3, hDLG, and hMAST 30,32,33. Binding of PTEN to specific PDZ-domain 
containing proteins affects its stability and phosphorylation 30,33.  
   A common mechanism to regulate protein levels posttranslationally is ubiquitin 
mediated proteasomal degradation. PTEN contains two PEST motifs (see above), 
which are frequently found in proteins targeted for degradation by the ubiquitin 
pathway. In addition, treatment of cells with proteasome inhibitors increased the 
PTEN protein level, indicating a role for ubiquitin mediated proteasomal 
degradation in the regulation of PTEN 34,35. Recently, the E3 ubiquitin ligase for 
PTEN, NEDD4-1, was identified. NEDD4-1 negatively regulates PTEN stability 
by catalyzing PTEN polyubiquitination 36.  
   PTEN activity can further be affected by reversible oxidation of Cys124 at the 
phosphatase active site, which has also been described for other PTP family 
members 37,38. Oxidation reduces the catalytic activity of the protein, and several 
reports describe the regulation of PTEN activity by redox processes 39-42. Finally, 
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the catalytic activity of PTEN can be negatively affected by acetylation at Lys125 
and Lys128. This acetylation is promoted by the interaction of PTEN with the 
nuclear histone acetyl-transferase-associated PCAF 43.  
 
1.1.4 Nuclear PTEN 
The structural characteristics of PTEN led to the general understanding that PTEN 
is localized in the cytoplasm. However, several studies described nuclear PTEN 
staining in a number of different cell types 44-46. Interestingly, PTEN was found to 
be predominantly localized to the nucleus in primary, differentiated, and resting 
cells suggesting that loss of nuclear PTEN might correlate with increased 
tumorigenicity 45,47. Despite the presence of many components of the PI3K 
signaling pathway in the nuclear compartment, Lindsay et al., (2006) reported that 
PTEN does not dephosphorylate the nuclear pool of PIP3 48. Moreover, conflicting 
data are reported about the Akt mediated effects of nuclear PTEN 49,50. Nuclear 
PTEN has been proposed to act as a pro-apoptotic factor, a regulator of 
chromosomal integrity, and as a cell cycle regulator through suppression of cyclin 
D1 activity 51-53. The mechanism underlying the migration of PTEN to the nucleus 
is not completely understood since PTEN lacks obvious nuclear import/export 
signals, although PTEN might contain two non-canonical Nuclear Localization 
Signals (NLS) 54. Recently, it was suggested that nuclear import of PTEN is 
regulated by monoubiquitination, since increased nuclear PTEN expression was 
associated with increased monoubiquitination of the protein 50,55. 
 
1.2 Somatic and germline PTEN mutations 
Since the discovery of PTEN in 1997, many papers have described its frequent 
inactivation in a wide array of sporadic human cancers, as well as its identification 
as the susceptibility gene in cancer predisposition syndromes 56-58. Germline PTEN 
mutations have been implicated Proteus syndrome and in the autosomal dominant 
disorders Cowden disease (CD), Bannayan-Zonana Syndrome (BZS, also called 
Bannayan-Riley-Ruvalcaba Syndrome), and Lhermitte-Duclos disease (LDD) 56,59-
62.  
   CD is characterized by multiple hamartomas (benign growths composed of 
tissue elements normally found at the affected site, but which are growing in 
a disorganized mass) and an increased risk of breast, thyroid, and endometrial 
cancer. LDD, or dysplastic gangliocytoma of the cerebellum, is the neurological 
 14
                                                                                                                                                   Chapter 1      
manifestation of CD 63,64. PTEN mutations have been identified in up to 80% of CD 
and LDD cases, and approximately two-thirds of these mutations were found in 
exons 5, 7 and 8 14. The characteristics of BZS include macrocephaly, lipomatosis, 
and speckled penis, and ~ 60% of cases have been found to harbor germline PTEN 
mutations 14,65. Additionally, up to 20% patients with Proteus syndrome and 
approximately 50% of Proteus-like syndrome cases contain germline PTEN 
mutations 66. Since the PTEN mutation spectra of these disorders appeared to be 
similar it has been suggested that syndromes characterized by the presence of 
PTEN germline mutations can be grouped together for clinical purposes and 
classified as PTEN Hamartoma Tumor Syndrome (PHTS) 67.  
   Somatic deletions and mutations of PTEN have been identified in a large fraction 
of tumors placing PTEN among the most commonly affected genes in human 
cancer 57. Inactivating PTEN mutations are described with high frequency in 
glioblastomas, endometrial cancers, and also in prostate cancer 1,68-70. In other 
tumor types such as breast, thyroid, bladder, ovary, small cell lung cancer, and 
hematological malignancies lower inactivation rates were found 57. PTEN point 
mutations are scattered over the entire gene although a clustering of missense 
mutations in exon 5, encoding the phosphatase domain, is observed 58. Two 
important mutants are recognized in the phosphatase core motif of PTEN, the 
C124S mutant in which both its protein and lipid phosphatase activity is 
completely blocked, and the naturally occurring G129E mutant that retained only 
the PTEN protein phosphatase activity 5,9,10.  
 
1.3 Molecular targets of PTEN 
1.3.1 PTEN signaling 
As previously mentioned PTEN counteracts the action of PI3K and thereby 
functionally antagonizes the many signaling pathways that rely on the activity of 
PI3K 71 (Figure 3). The PI3K product PIP3 is localized at the inner surface of the 
cell membrane and acts as docking site for proteins that contain a pleckstrin 
homology (PH) domain. An important PH domain containing protein that interacts 
with PIP3 is PDK1 (3-phosphoinositide-dependent protein kinase-1) 72. PDK1, 
member of the AGC (cAMP-dependent, cGMP-dependent, and protein kinase C) 
protein kinase family, has been found to activate other members of this family such 
as Akt, PKC, SGK, p70s6k, and PKN3 by phosphorylating their activation loop 73. 
Because of its function as a master upstream kinase controlling the activation of 
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various AGC kinase family members, PDK1 is involved in the regulation of 
diverse cellular processes 73. 
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Figure 3. Schematic representation of PTEN signaling pathways. PDK1 activates other members of the 
AGC protein kinase family thereby affecting many cellular responses such as proliferation and 
apoptosis.  The PDK1 targets Akt and p70s6k will be discussed in futher detail in section 1.3.2.  
 
   The activation of ILK (Integrin-Linked Kinase) is also dependent on PI3K 
signaling.  ILK contains a PH-like domain and is implicated in the regulation of 
growth, inhibition of apoptosis, and migration 74. It was found that PTEN can 
inhibit ILK activation, and inhibition of ILK was shown to abolish Akt activation 
and induce apoptosis 75-77. Recently, ILK was reported to be involved in the 
activation of the Rho GTPases Rac1 and Cdc42 78-80.  
   In addition to the ILK dependent activation of Rac1 and Cdc42, it was 
demonstrated that also GEFs (Guanine nucleotide Exchange Factors), which can 
activate Rho GTPases like Rac1 and Cdc42 by conversion of GDP to GTP, can be 
activated in a PIP3 dependent manner 79,81. Interestingly, all members of the Dbl 
protein family of GEFs contain a PH domain that might be involved in their PI3K 
dependent activation and indeed it was shown that in PTEN negative fibroblasts a 
marked increase in the active GTP-bound forms of Rac1 and Cdc42 could be 
detected 82. 
   Recently, the JNK signaling pathway was identified as a functional target of 
PTEN by gene set enrichment analysis 83.  Further research showed that PTEN null 
cells displayed an increased transcriptional activity of c-Jun, a dependence on 
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JNK1 and JunD for in vitro proliferation and tumor growth, and a synergy of JNK 
and Akt, which was further strengthened by the association of phospho-jun and 
phospho-Akt staining in human prostate cancers 83. In addition, growth factor 
induced JNK activation in PTEN null cells was found to be dependent on PI3K and 
mediated by Rac1.  
 
1.3.2 The Akt pathway 
The best studied signaling pathway that relies on the activity of PI3K and PTEN, is 
the Akt signal transduction route, which is involved in the regulation of many 
cellular processes 84. Akt is a serine/threonine kinase that is recruited to the 
membrane upon the formation of PIP3. Once located at the membrane Akt 
becomes phosphorylated by PDK1 at Thr308. Although this phosphorylation step 
is sufficient for the activation of Akt, maximal activation is achieved after 
phosphorylation of Ser473 by the so-called hydrophobic motif kinase PDK2 85. 
Although several kinases have been proposed to function as the Akt hydrophobic 
motif kinase, biochemical studies have identified the TORC2 complex as the 
elusive PDK2 86,87.  In mammals three highly homologous Akt isoforms have been 
identified, Akt1, Akt2, and Akt3. These isoforms are broadly expressed but next to 
their overlapping functions, isoform specific knockout mice revealed distinct 
phenotypes indicating the presence of isoform specific functions 88. The minimal 
substrate consensus sequence of Akt is RXRXXS/T and to date, numerous Akt 
substrates have been identified 89 (Table 1). A few prominent downstream effectors 
of Akt such as TSC1/2, mTOR, FOXO transcription factors, GSK3 (Glycogen 
Synthase Kinase-3), and MDM2 (Mouse Double-Minute 2) will be discussed in 
further detail.  
   Important targets in the Akt pathway are the FOXO transcription factors. The 
FOXO protein family consists of FOXO1, FOXO3a, FOXO4, and FOXO6. These 
transcription factors regulate the expression of many genes involved in 
proliferation and apoptosis, like CCNG2 (Cyclin G2), BIM, and FASL 90. The 
FOXO family was initially identified in humans because three family members, 
FOXO1, FOXO3a, and FOXO4, were found to be located at chromosomal 
translocation points in human tumors 91,92. Biochemical studies showed that Akt 
directly phosphorylates FOXO1, FOXO3a, and FOXO4 at three key residues 
(Thr32, Ser253 and Ser315 in the FOXO3a sequence) resulting in inactivation of 
these transcription factors due to nuclear export 93,94. FOXO6, however, remains 
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mostly nuclear because its shuttling ability is dramatically impaired due to lack of 
the conserved third Akt regulatory site 95,96. Although FOXO6 can be considered 
constitutively nuclear, its transcriptional activity is still regulated in an Akt 
dependent manner 96.  In addition to the nuclear export and following sequestration 
into the cytoplasma, Akt specific phosphorylation has also been reported to play a 
role in the proteasomal degradation of FOXO1 and FOXO3a 97,98. 
    
 Table 1. Overview of Akt target proteins 
Target protein Phosphorylation site Ref. no. 
Androgen Receptor Ser210, Ser790 99 
 
AS160 
Ser588, Thr642 100 
Ask1 Ser83 101, 102 
Bad Ser136 103 
Caspase 9 Ser196 104, 105 
Creb Ser133 106 
eNos Ser1179 107 
FOXO Thr32, Ser253, Ser315 93 
GSK3 beta Ser9 108 
Ikk alpha Thr23 109 
IRS Ser629 110 
Merlin Ser230, Thr315 111 
MDM2 Ser166, Ser186 112 
mTOR Thr2446, Ser2448 113 
P21cip1/waf Thr145 114 
P27kip1 Ser10, Thr187, Thr198 115 
Pras40 Thr246 116 
Raf1 Ser259 117 
Synip Ser99 118 
TSC2 
 
Ser939, Ser1086/1088, 
Thr1422 
119 
Wnk Thr60 120 
Xiap Ser87 121 
Y box binding protein Ser102 122 
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     An other key player of the Akt pathway is mTOR (mammalian Target Of 
Rapamycin) that functions as a serine/threonine kinase regulating protein synthesis 
and cell size 123-126.  The Akt mediated regulation of mTOR activity is complex as 
indicated in Figure 4.  
 
S6K
S6 
mTOR Rheb1
Akt 
PI3K 
PIP2 
PIP3 
 PTEN 
P 
p70 
TSC1/2
PDK1
p 
4E-BP1
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of PI3K/Akt dependent mTOR activation. 
 
Akt might directly phosphorylate mTOR since the protein contains two putative 
Akt phosphorylation sites; Thr2446 and Ser2448. It was shown both in vitro and in 
vivo that Akt indeed phosphorylates Ser2448, although the role of this 
phosphorylation remained unclear, because it was not required for signaling 
downstream of mTOR 113,127-129. Akt more indirectly affects mTOR activity through 
regulation of the TSC1 (Hamartin)/TSC2 (Tuberin) complex 119,130,131. This 
complex inhibits the activity of the small GTP-ase Rheb, which in turn leads to the 
inactivation of mTOR 119,130,132,133. Akt was found to phosphorylate and thereby 
inactivate TSC2, thus upon phosphorylation of TSC2 by Akt, the TSC1/TCS2 
complex is no longer capable of inactivating Rheb resulting in an increased activity 
of mTOR 119,130,131. 
   The important role of mTOR in translation initiation is mainly mediated through 
the effector proteins p70s6k and 4E-BP1 134. mTOR phosphorylates p70s6k at Thr389 
and thereby activates the protein which in turn phosphorylates the ribosomal 
protein S6, leading to an increase in translation of a subset of mRNAs 135. Next to 
phosphorylation by mTOR, several reports suggested that p70s6k can also be 
directly phosphorylated at Thr229 by PDK1, the kinase that is also required for the 
activation of Akt 73,136. Both phosphorylation events may however be 
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complementary to each other, since phosphorylation of p70s6k by mTOR would 
enable PDK1 to bind to and phosphorylate p70s6k thereby fully activating p70s6k 
kinase activity 137.  The other effector of mTOR, 4E-BP1 normally binds eIF4E, the 
mRNA cap-binding protein, thereby preventing cap-dependent translation by 
competitively blocking the binding of eIF4G to eIF4E. Phosphorylation of 4E-BP1 
by mTOR causes its dissociation from the eukaryotic initiation factor eIF4E, which 
can in turn bind to the 5’cap of mRNAs and recruit other members of translation 
initiation complex that finally results in increased translation initiation 138. 
   Another interesting target protein whose function is impaired upon 
phosphorylation by Akt is GSK3. Initially GSK3 was identified as an enzyme that 
regulates glycogen synthesis in response to insulin. Nowadays it is clear that GSK3 
phosphorylates a broad range of substrates and is therefore a key component in a 
large number of cellular processes and diseases 139-141. GSK3α and GSK3β are two 
closely related isoforms that are ubiquitously expressed in mammalian tissues. Two 
sites of phosphorylation directly affect its kinase activity. GSK3 activity is 
facilitated by phosphorylation of Tyr216 (GSK3β) and Tyr279 (GSK3α), although 
little is known about the regulation of this process. In contrast, phosphorylation of 
Ser9 (GSK3β) and Ser21 (GSK3α) dramatically impaired the kinase activity of 
GSK3 139,140. Several kinases are reported to phosphorylate these serine residues, 
including Akt. Interestingly, GSK3 was the first characterized physiological 
substrate of Akt 108. Akt dependent inactivation of GSK3 was reported to affect 
both apoptosis and proliferation 142,143.  
   The Akt target MDM2 (mouse double-minute 2), which was originally identified 
on double-minute chromosomes of spontaneous transformed mouse 3T3 
fibroblasts144, is an oncogene that is amplified in several types of cancer 145. MDM2 
functions as an E3 ubiquitin ligase of which the tumor suppressor p53 is one of its 
main targets 146. Akt is able to phosphorylate MDM2 at Ser166 and Ser186, and 
this phosphorylation is required for the translocation of MDM2 to the nucleus 
where it can interact with p53 112,147,148. Akt dependent phosphorylation of MDM2 
is further suggested to function in the regulation of MDM2 protein stability 149.   
 
1.4 Cell biological effects of PTEN 
PTEN has a crucial function in the regulation of multiple cellular processes. Thus 
far, the current understanding of PTEN function in tumorigenesis is primarily 
based on its lipid phosphatase activity. However, emerging evidence is suggestive 
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of other, phosphatase independent, functions of PTEN both in the cytoplasm as 
well as in the nuclear compartment that might contribute to the regulation of 
tumorigenesis 150.  In this chapter the various cellular processes that are influenced 
by PTEN will be discussed whereby the role of PTEN in cell cycle regulation, and 
in particular the G1-S transition, will be specifically emphasized.  
 
1.4.1 PTEN dependent cell cycle regulation 
Movement through the cell cycle is orchestrated by the activity of cyclin dependent 
kinases (CDK). Their activation, in turn, depends on association with cyclin 
regulatory subunits, whereas they become inactivated after association with cyclin 
dependent kinase inhibitors (CDKI). In response to mitogenic signals, like growth 
factor stimulation, cells are induced to progress from the first gap phase (G1) of the 
cell cycle to the DNA synthesis phase, the S-phase. This progression requires 
assembly of D-type cyclins with CDK4/6, and in late G1 the cyclin E/CDK2 
complex formation (Figure 5). These active complexes phosphorylate and thereby 
inactivate Retinoblastoma (RB) resulting in the release of the E2F transcription 
factors that in turn activate the transcription of the so-called S-phase genes 151. The 
CDK1/Cyclin B1 complexes are in turn pivotal in the regulation of G2/M 
transition. 
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Figure 5. Schematic overview of the mammalian cell cycle 
(A) Overview of the different phases of the mammalian cell cycle and the corresponding cdk/cyclin 
complexes. (B) Schematic representation of G1 phase of the cell cycle 
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   PTEN has been described as an important regulator of cell cycle progression. 
Both its lipid and protein phosphatase activity are thought to be involved in this 
regulation 152. A large amount of data exists on the role of the PTEN/Akt pathway 
influencing the expression of cell cycle regulators at the protein level by altered 
distribution, or phosphorylation and thereby stability 52,152-157. Recent evidence 
appeared that also PTEN dependent transcription regulation can contribute to cell 
cycle control 158 (see also chapter 3). 
   In several PTEN-null tumor cell lines it has been reported that forced expression 
of PTEN leads to the induction of G1 cell cycle arrest 154,159-162. An important 
mediator of this PTEN dependent G1 cell cycle arrest is the Akt signaling pathway. 
One mechanism by which Akt could control cell cycle regulation is by direct 
phosphorylation of the cell cycle inhibitors p21cip1/Waf1 and p27kip1 resulting in their 
accumulation in the cytoplasm 153,155-157. The effect of PTEN/Akt signaling on 
p27kip1 is, however, complex, and might occur at several levels. Next to 
cytoplasmic sequestration upon phosphorylation, Akt can also function through the 
ubiquitin ligase Skp2 to regulate proteasomal degradation of p27kip1 163-166 (Chapter 
2). Recently, it was described that PTEN together with cyclin D1 modulate the 
assembly of the SCFSkp2 complex and thereby affecting p27kip1 proteolysis 166. At 
the transcriptional level the FOXO family of transcription factors is implicated in 
the regulation of p27kip1 in several cell lines 167-169. Although PTEN induced cell 
cycle arrest was associated with altered p27kip1 expression, we and others described 
a lack of correlation between PTEN and total p27kip1 expression 160,163,170 (see also 
Chapter 2). The observed effects might be cell line specific, but, since these studies 
did not discriminate between nuclear and cytoplasmic p27kip1 expression, it is 
possible that in these cell lines PTEN signaling altered the cellular distribution of 
p27kip1 without affecting its total expression level.  
   Cyclin D1 might be another mediator of PTEN/Akt dependent cell cycle arrest. 
Several groups reported a down regulation of cyclin D1 expression upon inhibition 
of PTEN/Akt signaling, although the underlying regulatory mechanism is complex 
52, 171, 172. Roles for mTOR/p70s6k, FOXO, and GSK3 have been suggested in the 
regulation of cyclin D1 expression levels 142,171,172. Moreover, it was described that 
PTEN not only affected the expression level of cyclin D1 but also prevented its 
nuclear localization, thereby inhibiting its stimulating effect on cell cycle 
progression 52. Besides its Akt mediated effect on cyclin D1 expression, others 
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have suggested that the PTEN protein phosphatase activity was responsible for the 
down regulation of cyclin D1 152. 
   Another target that is involved in PTEN dependent cell cycle regulation is RB-
like protein 2/p130, which has an important role in the restraining of the G1/S 
phase transition 173,174. RBL2 has been reported as a FOXO target in certain cell 
lines 174. However, in LNCaP prostate cancer cells the PTEN dependent regulation 
of RBL2 is independent of the Akt/FOXO pathway (see Chapter 3). Other 
transcriptional targets of PTEN signaling involved in the regulation of G1 growth 
arrest include cyclin G2, E2F2, and Cdc25a (Chapter 3).  
   Next to the effect PTEN/Akt signaling on the G1/S transition, several reports also 
suggest a role for Akt in the regulation of the G2/M checkpoint 175-179. However, the 
mechanism by which Akt regulates progression through the G2/M phase remains 
largely unclear.  
1.4.2   Apoptosis 
Programmed cell death, or apoptosis, is a normal cellular process controlling 
excessive proliferation. In several cell lines manipulating PTEN/PI3K signaling 
has led to altered apoptosis rates 162,180-183. PTEN mediated apoptosis can be 
rescued by the expression of constitutively active Akt, implicating an important 
role of PI3K/Akt signaling in the regulation of apoptosis 159,181. However, Akt 
dependent survival may be cell line specific, since knockdown of Akt in various 
cell lines resulted in apoptosis in only half of the lines 181. Akt inhibits apoptosis 
through phosphorylation of downstream substrates including, FOXO, BAD, and 
IκB, that directly or indirectly control the apoptotic machinery 180.  
   PTEN is also involved in a specialized apoptotic pathway, termed anoikis, which 
is the induction of apoptosis in cells after loss of contact with the extra cellular 
matrix 184-186. Anoikis has been linked to altered expression of FAK, which can be 
dephosphorylated by the protein phosphatase activity of PTEN 187.  
 
1.4.3   Cell Growth 
Cell growth may be defined as the increase of cell size as well as the increase of 
total cell number (proliferation). The processes of cell size control and proliferation 
are closely coupled, since cells need to grow to a critical size before progressing 
through the cell cycle, and PTEN is implicated in the regulation of both 188 .  
 23
Chapter 1 
   The first indication that PTEN might function in cell size regulation came from 
studies in the fruitfly, Drosophila Melanogaster 189-191. It was shown that loss of 
dPTEN caused increased cell size, organ size and even animal size. Studies 
utilizing Pten conditional knockout mice demonstrated a role for Pten also in 
mammalian cell size regulation 192. However, Pten null ES cells, MEFs, and 
thymocytes do not show an apperant size control defect suggesting that PTEN may 
control cell size in a cell type specific manner 193. The control of cell size by the 
PTEN signaling pathway is thought to be due to the ability of this pathway to 
regulate protein synthesis via its downstream target mTOR and its corresponding 
effector proteins p70s6k and 4E-BP1 123,124.  
 
1.4.4 Angiogenesis 
Angiogenesis is a physiological process involving the growth of new blood vessles 
from pre-existing vessels and is a fundamental step in the transition of tumors to a 
malignant state. Already several years ago, PTEN inactivation in clinically 
localized prostate  cancers  was found  to be associated with increased  
angiogenesis 194. Further research revealed that PTEN modulates angiogenesis by 
Akt mediated regulation of HIF-1 and VEGF expression 195,196. 
1.4.5 Cell motility                                                              .                     
The movement of a cell towards a chemoattractant signal is a fundamental process 
involved in a wide range of cellular responses, including morphogenesis during 
development, wound healing, and metastasis of tumor cells 197. When cells sense a 
chemoattractant gradient, they dramatically change their shape, polarizing in the 
direction of the gradient. Several studies have shown that the generation of a 
PIP2/PIP3 gradient is a conserved mechanism for chemoattractant directional 
sensing and cell polarization, thereby implicating a regulatory role for PTEN in this 
process 198,199. Important effectors of the PTEN lipid phosphatase dependent 
control of cell motility are its downstream targets Rac1 and Cdc42 82,200.  
Furthermore, it has been suggested that PTEN negatively regulates cell migration 
by directly dephosphorylating FAK 6. Besides these phosphatase dependent 
mechanims it has also been reported that PTEN can regulate cell migration through 
its C2 domain 7,198. 
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1.4.6 Stem Cell regulation 
All stem cells have the capacity to self-renew and to differentiate in mature cell 
types in order to sustain homeostatic control in normal tissues. Pten was found to 
control the self-renewal capacity of neural stem/progenitor cells 201,202. More 
recently it was observed that Pten might also be implicated in the maintaining of 
normal stem cell function in the hematopoietic system 203,204. Like in normal tissue 
homeostasis, cancers are thought to be maintained by a minor sub-population of 
cells within the tumor called the cancer stem cells, and many pathways that are 
known to promote tumorigenesis have also been implicated in stem cell self-
renewal 205. However, Yilmaz et al., (2006) showed that in the hematopoietic 
system loss of Pten resulted in excessive proliferation of leukemic stem cells but 
also in depletion of normal hematopoietic stem cells, suggesting different self-
renewal mechanisms for maintaining pools of leukemic stem cells and normal 
hematopoietic stem cells 204.  
   Interestingly, FOXO transcription factors were recently implicated to play a 
critical role in hematopoietic stem cell homeostasis 206-208. In mice the conditional 
knock-out of FoxO1, FoxO3, and FoxO4 in the hematopoietic system resulted in a 
marked reduction of the hematopoietic stem cell number 207. However, the 
remaining hematopoietic stem cell pool showed a striking increase in the 
proportion of cells in the S/G2/M phases of the cell cycle, suggesting that FoxO 
transcription factors are important for the preservation of the replicative and self-
renewal  capacity of  hematopoietic stem cells  by maintaining  their quiescent  
state  207. 
 
1.4.7 Genomic instability 
Chromosomal instability is an important hallmark of many cancers and several 
studies have recently suggested a role for PTEN in maintaining normal 
chromosome structure and function 53,209. Loss of PTEN expression in primary 
human breast cancers has been associated with an increased prevalence for 
aneuploidy 209. It was suggested that PTEN suppresses aneuploidy through Akt 
dependent pathways. In contrast to this PTEN phosphatase dependent regulation of 
chromosomal stability, nuclear PTEN was recently shown to be involved in the 
maintenance of genomic stability through physical interaction with the centromers 
and by the control of DNA repair in a phosphatase independent manner 53. This 
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suggests that cytoplasmic and nuclear PTEN might have different functions in 
regulating certain cell biological processes.  
 
1.5 PTEN expression and function in other organisms 
The phosphatase signature motif C(X)5R of PTEN, which is essential for catalysis, 
is highly conserved across evolution suggesting that the phosphatase activity of 
PTEN could be comparable among the various species (Table 2) 4. In the fission 
yeast Schizosacchharomyces pombe the PTEN homologue, ptn1, was also found to 
suppress PIP3 levels 210. Genetic analysis of the nematode Caenorhabditis elegans 
genetic identified daf-18 as the homologue of the mammalian PTEN 211,212. 
   Daf-18 loss of function mutants displayed a reduced life-span and blocked entry 
into dauer stage, a dormant state in response to unfavorable conditions like 
starvation, by affecting the daf-2 (insulin receptor) /AGE-1 (PI3K) pathway 211-214. 
The Drosophila PTEN homolog, dPTEN, was shown to suppress hyperplastic 
growth in flies by reducing cell size and number 190. Genetic experiments indicated 
that these effects were primarily mediated by the antagonistic effect of dPTEN on 
Chico (Insulin Receptor Substrate) / Dp110 (PI3K) signaling pathway 189,190. Loss 
of function mutants displayed distinct phenotypes compared to flies in which PI3K 
was activated by overexpression of Dp110 or dAkt, suggesting that dPTEN acts 
through both PI3K dependent and independent mechanisms 215. 
 
Table 2. PTEN phosphatase signature motifs across various species 
. 
Species    Gene symbol                  Phosphatase signature motif 
H. sapiens       PTEN                        VAAIHCKAGKGRTG 
M. musculus       Pten                                    VAAIHCKAGKGRTG 
R. norvegicus       Pten                                    VAAIHCKAGKGRTG 
C. elegans       daf-18                                 VIAVHCKAGKGRTG 
D. melanogaster       dPTEN                VVAVHCKAGKGRTG 
S. Pombe       ptn1                                             VHCKAGKGRTG 
    
   Mouse Pten shares 98% homology with its human counterpart. The physiological 
functions of Pten in mouse tissues have been extensively studied utilizing different 
(conditional) knock-out models 216-219.  Homozygous knock-out of Pten was found 
to be embryonic lethal within a range of embryonic days 6.5-9.5 indicating that 
Pten is essential for embryonic development. Heterozyogous Pten+/- animals 
frequently die within a year, mostly due to leukemia. The survivors developed a 
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broad range of tumors in various other organs like, breast, endometrium, and 
prostate, indicating that Pten defects can indeed predispose to cancer 216-218. 
However, the onset and spectrum of tumor development varied among the Pten+/- 
mice of different research groups. Recently, one study reported that the genetic 
background of the animals could influence the onset, the spectrum, and the 
progression of tumorigenesis caused by Pten mutation 220. Although all published 
mutations were generated around exon 5 of the Pten gene, each group has 
employed slightly different strategies to create their specific mutation, which might 
contribute to the differences found between the various groups 220.   
   Because complete knock-out of Pten function was embryonic lethal, many 
groups generated conditional Pten knock-out mice utilizing the Cre-loxP system to 
analyze the function of Pten in specific tissues, including mammary gland, 
prostate, brain, and pancreas (reviewed in ref. 221). These various tissue specific 
Pten  knock-out models  have shown  distinct functions  of Pten  in  different 
organs 222. Moreover, using the ubiquitous ROSA26 promoter to drive inducible 
Cre recombinase, it was shown that also gender might affect tumor latency and 
spectrum 223.  Female animals quickly developed lymphomas compared to a much 
lower incidence of lymphoma formation in males, which frequently developed 
intestinal cancers 223. An indication that also in mice Pten exerts its action through 
regulation of the PI3K/Akt pathway came from a study in which Akt1 was deleted 
in Pten+/- mice. It was shown that deficiency of Akt1 is sufficient to dramatically 
inhibit tumor progression in Pten+/- mice, but despite Akt is necessary it is not 
sufficient to drive tumorigenesis in Pten deficient animals 150,224.  Furthermore, it 
was found that in a mouse line, in which Pten was conditionally deleted in the 
urigenital epithelium, Pten deficiency in the prostate leads to the activation of 
FOXO3a and p70s6k pathways, whereas in the bladder, which is less sensitive to 
tumor formation, Pten deficiency leads to decreased levels of p27kip1, increased 
levels of p21Cip1/Waf, and a decrease in proliferation rates 225. These findings 
indicated that in different tissues Pten deficiency could result in the activation of 
different downstream signaling pathways and cellular processes 225.   
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1.6 PTEN and prostate cancer 
Inactivation of PTEN has been described in a wide variety of tumors but with the 
highest frequency in glioblastomas, endometrium, and prostate cancer 57. However, 
the effects of PTEN inactivation might be tissue specific as suggested by data from 
human tumors and animal models 220,225,226. Therefore this chapter primarily 
focuses on the various aspects of PTEN in prostate cancer. 
 
1.6.1 Prostate cancer  
The human prostate is the largest of the male accessory sex glands and can be 
subdivided in three major zones, the central zone, the peripheral zone, and the 
transition zone 227. In elderly men the prostate is the site for two common diseases, 
benign prostatic hyperplasia (BPH) and prostate cancer. Whereas BPH occurs 
predominantly in the transition zone, prostate tumors mainly arise in the peripheral 
zone. The development of prostate cancer is a multistep process (Figure 6). The 
first step is the emergence of the pre-invasive, prostatic intraepithelial neoplasia 
(PIN) lesions, although proliferative inflammatory atrophy (PIA) has been 
proposed by some researchers as a precursor of PIN 228,229. PIN lesions can be 
classified in low grade and high grade and consist of excessive growth of prostatic 
epithelial cells within pre-existing glands. These cells often show enlargement of 
nuclei and especially in case of high grade PIN the lesions often show a 
discontinuous basal cell layer. High-grade PIN lesions are considered to be the 
preinvasive stage of prostate cancer carcinomas, and in time metastases might 
develop from these prostatic adenocarcinomas.   
 
 
 
 
 
 
 
 
 
 
Figure 6. Model representing the different stages of prostate cancer progression  (Adapted from Ref. 
228). 
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   Prostate cancer is the most frequently diagnosed and the second leading cause of 
male cancer death in the Western world 230.  The incidence of prostate cancer has 
significantly increased during the last decades due to increasing proportions of 
elderly men in the population and earlier disease detection due to PSA screening. 
Besides age, a positive family history, race, and diet are important risk factors 231.  
   Treatment options for prostate cancer are limited. Localized prostate cancer is 
primarily treated with radiotherapy, surgical removal of the prostate, or watchful 
waiting 232,233. Because most prostate cancers are dependent on androgens for their 
growth, metastasized prostate cancers are treated with androgen ablation therapy. 
Despite the initial rapid response, the disease recurs in most cases within a few 
years and has then become androgen independent. To date, only palliative 
treatment is available for androgen independent prostate cancer, although recently 
a survival benefit for hormone-refractory prostate cancer patients treated with 
docetaxel-based chemotherapy has been reported 234,235. 
 
1.6.2 Prostate cancer genetics 
The majority of prostate cancer cases are sporadic, but epidemiology studies have 
demonstrated familial clustering of prostate cancer, suggesting that hereditary 
factors are also important in the development of the disease 236. Although the 
association of certain genetic markers to prostate cancer is difficult because of the 
heterogeneity of the disease, linkage analysis studies have identified at least seven 
susceptibility loci for hereditary prostate cancer on different chromosomes 237. 
   In sporadic prostate cancer a number of chromosomal regions have been 
identified for their frequent deletions or amplifications 238,239. The most frequent 
alterations are losses of chromosomes 5q, 6q, 8p, 10q, 13q, 16q, 17p and 18q and 
gain of chromosomes 1q, 7, 8q, 16p, 17q and Xq. Some of these chromosomal 
aberrations could already be linked to the locations of either known or candidate 
prostate cancer tumor suppressor or onco-genes, such as the loss of PTEN at 10q, 
RB1 (13q), CDH1 (16q), APC (5q), SMAD4 (18q) and gain of MYC at 8q and the 
AR at Xq 238. Besides gains and losses a specific chromosomal abberation namely 
the fusion of the androgen regulated gene of TMPRSS2 to members the ETS 
transcription factor family, has been recently identified as a common 
rearrangement in prostate cancer 240,241.  
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1.6.3 PTEN inactivation in prostate cancer 
Already before the identification of PTEN in 1997, several studies had defined loss 
of chromosome 10q as a frequent chromosomal alteration in prostate cancer 
suggesting the presence of a tumor suppressor gene in this region 242-245. The 
finding that transfer of chromosome 10cen-q23 into a rat prostate cancer cell line 
suppressed the metastatic ability of these cells further supported this idea 246. To 
date, PTEN is considered to be the most frequently inactivated gene in prostate 
cancer. 
   In prostate cancer cell lines and xenografts complete PTEN inactivation was 
found in up to 60% of cases 247. In clinical prostate cancers the frequency of 
complete PTEN inactivation varies widely, probably due to differences in tissue 
preparation, stage of the disease and the methodology used to detect PTEN defects 
70,248-257 (Korsten et al., unpublished data) (Table 3). PTEN inactivating point 
mutations have been reported in up to 15% of primary prostate cancers, whereas 
the reported frequency of point mutations in PTEN in metastasis is 20-30% and 
25% in prostate cancer cell lines and xenografts, suggesting that mutation of PTEN 
is correlated with a later step in tumor progression 247,249,251-254,258.   
   Gene deletions are often more difficult to detect in DNA from clinical tumor 
samples, due to contaminating normal DNA in these samples. In addition, PTEN 
loss might involve only small genomic regions 259 thus the assessment of PTEN 
copy number changes requires sensitive methods, such as the q-WPR (quantitative-
Wild-type/Pseudogene Ratio analysis) technique described in chapter 5 of this 
thesis. It must therefore be noted that the reported percentages of up to 15 percent 
of homozygous PTEN deletion might be an underestimation of the frequency of 
gene deletions in clinical samples 70,248-251. A comprehensive study to detect PTEN 
inactivation in 40 locally progressive clinical prostate cancer specimens, utilizing a 
variety of complementary technical approaches, revealed that bi-allelic deletion of 
PTEN was detected in more than 20% of cases, thereby indicating that bi-allelic 
loss is the major mechanism of PTEN inactivation in these tumors (Chapter 4).       
   Besides inactivation through homozygous gene loss or point mutation, epigenetic 
mechanisms like promoter hypermethylation also contribute to PTEN inactivation 
in several tumor types 18-23. Although PTEN inactivation by methylation has been 
reported in prostate xenograft cells, in clinical prostate cancer samples evidence for 
promoter hypermethylation is lacking 260,261. 
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16.4 PTEN and Haploinsufficiency 
Whereas classical tumor suppressor genes are thought to require mutation or loss 
of both alleles to drive tumorigenesis 262,263, it became clear that for some genes 
loss of a single allele is by itself sufficient to promote tumor progression, a 
phenomenon called haploinsufficiency 264. In various malignancies, including 
prostate cancer, the rate of LOH at 10q23.3 is often higher than the apparent rate of  
inactivation of the retained PTEN allele suggesting that PTEN might be 
haploinsufficient in tumor suppression 70,248-250,253,265. A recent study, investigating 
the percentage of PTEN deletions in various stages of prostate cancer by interphase 
FISH, showed PTEN loss in 23 percent of high grade PIN and 68 percent of 
prostate cancer samples 256. This high frequency of PTEN loss observed in prostate 
cancers versus precursor lesions implicates a role for PTEN haploinsufficiency in 
the transition from preneoplastic PIN to prostate cancer. 
        
1.7 Cell biological effects of PTEN in prostate cancer 
Several studies were undertaken to investigate the biological effects of PTEN in 
prostate cancer cells 182,196,266-272 (see also Chapter 3). One approach to study the 
biological effects of the PTEN lipid phosphatase activity is the use of small 
molecules that inhibit PI3K function, like wortmannin and LY294002. This 
pharmacological inhibition of PI3K in prostate cancer cells resulted in growth 
inhibition, apoptosis or in both 266,269,271. These results are comparable with those 
obtained upon (inducible)-expression of PTEN in the PTEN negative cell lines PC3 
and LNCaP, but besides a reduced proliferation rate, forced PTEN expression in 
PC3 and LNCaP cells was also reported to inhibit migration 182,196,267,268,270,272. 
However, in the chapters 2 and 3 of this thesis it is described that G1 growth arrest 
is one of the most predominantly affected processes upon modulation of PTEN 
signaling in LNCaP and PC3 cells. In PC3 cells blocking of PI3K activity by 
wortmannin resulted in an accumulation of cells in the G0/G1 phase of the cell 
cycle and a concomitant reduction of the S and G2/M phase 163 (Chapter 2). The 
increased number of cells in G0/G1 following wortmannin treatment correlated with 
an increased p27kip1 protein expression mediated by the Akt dependent regulation 
of Skp2 163. In LNCaP cells it was shown that induced expression of PTEN lead to 
cell cycle arrest at the G1 phase, which was associated with the PTEN dependent 
transcription regulation of the cell cycle regulators Cdc25a, cyclin G2, RBL2, and 
E2F2 (Chapter 3).  
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   Since prostate cancer is a heterogenous disease, the identification of the cell of 
origin of prostate cancer will contribute to a full understanding of the disease. An 
indication for a role of PTEN/Akt signaling in these so called prostate cancer stem 
cells came from a recent study demonstrating that the Sca-1 surface antigen could 
be used to enrich for prostate cells with a regenerative capacity 273. Introduction of 
constitutively active Akt in these Sca-1 enriched prostate regenerating cells 
resulted in the initiation of prostate tumorigenesis 273. Moreover, prostate specific 
Pten inactivation leads to an increased prostatic stem/progenitor cell subpopulation 
and tumor initiation 274 (Korsten et al., unpublished).  
     
1.8 Crosstalk between PTEN/Akt and AR signaling pathways 
As for normal cells of the prostate, androgens are essential for the growth and 
survival of prostate cancer cells, and although initially most prostate cancers 
respond to androgen ablation therapy eventually the tumors will relapse and 
become androgen independent 275. One possibility whereby prostate cancers cells 
develop androgen independence is the activation of parallel or alternative signaling 
pathways. However, a role for PTEN signaling in the progression of prostate 
cancer to an androgen independent state is arguable. To date several lines of 
evidence have suggested that loss of PTEN function might be associated with the 
progression to androgen independence 275-286. Although the underlying mechanism 
remains to be fully elucidated many reports described a role for Akt in the prostate 
cancer progression from androgen-dependent to androgen-independent stage 
279,280,282,287.  In addition, one study proposed that the combined activation of Akt 
and Erk pathways stimulates epithelial AR function and counteracts antagonistic 
effects of the stroma thereby leading to androgen-independent cancer 277.           
   In contrast, we could not observe any correlation between androgen dependency 
and PTEN status in our panel of fourteen prostate cancer cell lines and xenografts 
derived from various stages of clinical prostate cancer (unpublished data). The 
xenografts PCEW, PC82, PC295, PC310, PC329, PC346, PC374 and the LNCaP 
cell line were AR dependent, or sensitive in case of PC346 and PC374, but only the 
xenografts PC310 and PC329 contain a functional PTEN protein. In addition, from 
the androgen independent cell lines and xenografts PC133, PC135, PC324, PC339, 
DU145 and PC3 only half had lost PTEN expression 247.  
   Due to the key role of the AR, as well as the loss of PTEN function and 
subsequent activation of the Akt signal transduction cascade in prostate cancer 
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growth, many reports have been focused on the investigation of a functional link 
between these two signal transduction pathways 288. Interactions between AR and 
PTEN/Akt signaling can occur at several levels of regulation. First, it was shown 
that Akt could bind to and phosphorylate the AR at either S213 and S791 99,289. 
However, these studies used an in vitro kinase assay to determine Akt dependent 
phosphorylation sites of the AR, and in vivo analysis failed to confirm 
phosphorylation of AR by Akt at the indicated sites S213 and S791 290. The effect 
of Akt dependent phosphorylation on AR activity is still a matter of debate. 
Whereas Lin et al., (2001) found that Akt mediated the suppression of AR 
transactivation, others reported that the Akt induced AR phosphorylation 
stimulated the AR transactivation 99,289. In support of the latter study are the results 
obtained by Li et al., (2001) showing that PTEN is able to repress the 
transactivation activity of the AR 291. 
   Secondly, it has been described that PTEN can affect the activity of the AR 
through regulation of its expression level 292,293. Inhibition of Akt activity 
significantly reduced the AR protein expression in both normal and tumoral 
epithelial cells 292.  
   In recent years, steroids have been found to control the activity of multiple 
signaling pathways via non-genomic mechanisms 294. This transcription 
independent action of the AR is a third mechanism of crosstalk between PI3K/Akt 
and AR pathways. It was shown by several groups that androgens could activate 
PI3K in a transcription independent manner 295,296. 
     
 1.9 Prostate cancer mouse models 
Animal models can be of great value to study the potential relationship between 
molecular mechanisms and clinical progression of a disease, but since conventional 
Pten null mice were not viable several groups generated conditional prostate 
specific Pten knock-out mice using the Cre-loxP system 297-301. All these models 
resemble to a certain extend the several stages of human prostate cancer. However, 
also differences are observed between the various models, which could be 
explained by differences in activity and cell specificity of the promoter used to 
drive Cre expression. As described previously in section 1.5 of this chapter also the 
genetic background of the mice could influence the onset, the spectrum, and the 
progression of tumorigenesis caused by Pten inactivation 220. 
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    The MMTV promoter used by Backman et al., (2004) to drive Cre expression 
had limited tissue specificity since Pten recombination was also found in skin, 
thymus, and mammary gland 297. In the MMTV-Cre;Pten-loxP/loxP mice 
hyperplastic prostates were already detected a few days after birth and by 2 weeks 
of age PIN lesions were present. Although at 14 weeks focal invasions were 
detected in half of the investigated prostates, the investigation of later stages of 
prostate cancer development was hampered in this model because the mice died 
from other malignancies 297.  
   Prostate specific recombination was achieved in the models in which Cre 
expression was regulated by either a modified rat probasin promoter (PB) or the 
human prostate specific antigen promoter (PSA) 298,300,301. In the PB-Cre;Pten-
loxP/loxP mice PIN lesions and invasive adenocarcinoma already occurred at 
respectively 6 and 9 week of age and in 50 percent of the older mice metastases 
were found 300,301. In addition, PB-Cre;Pten-loxP/loxP mice showed specific gene 
expression changes that were also seen in human prostate cancers 301. The process 
of prostate cancer development in the PSA-Cre based model was slower since 
massive hyperplasia and focal PIN were first observed at 4-5 months of age 298.     
At older age more extensive PIN lesions were detected, followed by the 
development of invasive carcinoma and in only one mouse a lymph node 
metastasis was found 298.  
   Recently, a mouse model was described in which prostate carcinogenesis is 
initiated in the fully differentiated prostate of adult mice using the inducible 
tamoxifen dependent PSA-Cre-ER(T2) 299. Within 4 weeks after Pten ablation 
these mice developed hyperplasia followed by PIN after 2-3 months. After 8-10 
months of Pten ablation some PINs had progressed to adenocarcinomas but no 
metastases were found even up to 20 months after Pten inactivation 299. 
   To drive prostate tumorigenesis, Pten functions, at least partly, through Akt since 
key downstream targets such as Akt, mTOR, and FOXO are affected as a result of 
Pten loss 298,300,301. To determine whether Akt activation was sufficient for prostate 
epithelial cell transformation the murine prostate restricted Akt kinase (MPAKT) 
model was developed 302. In these mice Akt activation resulted in the development 
of PIN lesions but progression to invasive adenocarcinomas and metastases could 
not be detected, suggesting that in the MPAKT model additional oncogenic events 
are required for prostate cancer progression 302. Chen et al., (2006), however, 
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showed that inactivation of Akt1 in Pten +/- mice is sufficient to significantly 
inhibit tumor development, including prostate neoplasia 224.           
   Whereas various data obtained from clinical prostate cancer specimens already 
suggested that PTEN might be haploinsufficient in tumor suppression, also several 
mouse models indicated that Pten haploinsufficiency contributed to tumorigenesis 
300,303-308. In the transgenic adenocarcinoma mouse prostate (TRAMP) model it was 
shown that loss of a single Pten allele significantly increased the rate of prostate 
cancer progression suggesting that haploinsufficiency of Pten promotes 
progression of prostate cancer 306. In addition, Trotman et al., (2003) showed by the 
generation of a mouse mutant series with decreasing Pten activity, that Pten is 
haploinsufficient in tumor suppression, and that Pten dosage is an important 
determinant in cancer progression 300.  However, in the prostate specific Pten 
knock-out models it was shown that mono-allelic Pten inactivation is insufficient 
for prostate cancer development 297,298,300,301. 
 
1.10 Prognostic value of PTEN/Akt pathway members in clinical prostate 
cancer 
In the management of cancer, prognostic markers are important tools in predicting 
whether a patient is at risk of experiencing a cancer progression or recurrence. 
During the last several years a marked increase was observed in the early detection 
of prostate cancer due to large scale PSA based screening. To prevent possible 
overtreatment of the increased number of newly identified cases it is of utmost 
importance to identify markers that are able to recognize tumors with the potential 
to progress to metastatic disease. In several tumor types, like gasterointestinal 
tumors and hepatocellular carcinomas, loss of PTEN function can be of prognostic 
value, and in breast cancer PTEN inactivation is associated with tumor progression 
and lymph node metastasis 309-311. Various groups reported that loss of PTEN 
expression in prostate cancer was correlated with tumor stage and grade 312,313. An 
indication that loss of PTEN protein expression could serve as an early prognostic 
marker for prostate cancer metastasis came from a study by Schmitz et al., (2007) 
showing that loss of PTEN was found in 60 percent of the investigated lymph node 
metastases and that half of these cases already exhibited loss of PTEN expression 
at first diagnosis 314. Despite the relatively small number of investigated patient 
samples, the study also indicated that patients with a low Gleason score and loss of 
PTEN expression were found to be potential candidates for the development of 
 37
Chapter 1 
metastatic disease 314. Moreover, a study investigating the clinical impact of 
genomic PTEN deletions in prostate cancer demonstrated a significant association 
between PTEN deletion and earlier onset of disease recurrence 257.  
   At the other hand, however, several reports appeared that could not confirm a 
role for PTEN as a prognostic marker in prostate cancer 315,316 (Korsten et al., 
unpublished data). Fenic et al., (2004) assessed the PTEN mRNA and protein 
expression in PIN, primary prostate carcinomas as well as metastases and found 
that total or partial loss of PTEN protein occurred with tumour progression but this 
association was not statistically significant 316. Others analyzed a panel formalin-
fixed paraffin-embedded prostate cancer specimens for PTEN mutations and found 
that although patients with PTEN mutations had a significantly higher Gleason 
score and a higher rate of metastasis, the PTEN mutation itself is not an accurate 
factor in the prediction of the prognosis 315. A study evaluating the prognostic value 
of PTEN inactivation in radical prostatectomies based on PSA recurrence data 
showed that although PTEN inactivation was more frequently found in tumors 
showing PSA progression, a statistical significant correlation between the absence 
of PTEN protein expression and PSA recurrence was not found (Korsten et al., 
unpublished data).   
   Recently, it was published that the degree of PTEN/PI3K pathway activation is 
directly related to the metastatic potential of the primary tumor for several 
carcinoma types, including prostate cancer 317. That next to PTEN also other 
members of the PTEN/Akt pathway might serve as a progression marker in 
prostate cancer was previously suggested by various studies showing that 
overexpression and activation of Akt has been associated with higher Gleason 
grades and poor clinical outcome 318-321. In addition, loss of PTEN expression, 
together with the Gleason score and the increased phosphorylation of Akt at the 
time of prostatectomy is of significant predictive value for determining the risk of 
prostate cancer recurrence 322. Further, the absence or low expression of the Akt 
downstream target p27kip1, is an important prognostic marker in a wide variety of 
tumors, including prostate cancer 323. Several studies analyzing p27kip1 expression 
in prostate adenocarcinoma by immunohistochemistry have shown that decreased 
p27kip1 expression is associated with high tumor grade and poor prognosis 323-326. 
However, the relationship between PTEN deficiency and decreased p27kip1 
expression in clinical prostate cancer is not completely clear 316,327,328. Finally, 
overexpression of 4E-BP1, a downstream target of mTOR, was found to be 
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strongly associated with prostate cancer, especially when combined with PTEN 
and mTOR expression data 329. 
 
1.11 Aim and scope of this thesis 
The research described in this thesis started only a few years after the initial 
discovery of PTEN and much had to be learned about its specific genetic and cell 
biological aspects in prostate cancer. The aim of this thesis was to contribute to the 
understanding of PTEN function in prostate cancer, which will augment our 
understanding of tumorigenesis and may ultimately lead to the development of 
novel therapeutic options for prostate cancer. The chapters 2 and 3 describe the 
investigations of the cell biological and molecular aspects of PTEN in prostate 
cancer cell lines. Chapter 2 focusses on the role of PTEN in the regulation of the 
cell cycle inhibitor p27kip1 in various prostate cancer cell lines. In chapter 3 the 
development of the novel cell line LNCaP/PTEN, which stably expresses PTEN 
under inducible control, is described. This cell line enabled us to obtain a broad 
view of the cell biological and molecular effects regulated by PTEN in prostate 
cancer. Further, in this chapter a novel mechanism by which PTEN can be involved 
in cell cycle regulation is defined. 
   Since it became clear that not only bi-allelic but also mono-allelic PTEN 
inactivation might contribute to tumorigenesis, we further investigated the 
mechanism of PTEN inactivation in clinical prostate cancer samples in chapter 4. 
Fourty locally progressive clinical prostate cancer specimens obtained by 
transurethral resection of the prostate were screened for PTEN inactivation by 
various, complementary techniques. During these investigations we developed a 
novel and accurate method, denoted quantitative wild-type/pseudogene ratio 
analysis (q-WPR), to detect gene copy number changes utilizing PTEN in prostate 
cancer as a model system, as described in chapter 5. Q-WPR is not restricted to 
PTEN but can be very valuable in prognostic studies of many genes due to its high 
sample throughput and its suitability to be used on low quality DNA and can be of 
high importance as a diagnostic tool. Finally, chapter 6 discusses the results 
described in this thesis and provides directions for future research.   
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Abstract 
We compared the involvement of PI3K/PTEN/Akt signaling in the regulation of 
the cell cycle regulator p27kip1 and investigated the mechanism of PI3K/PTEN/Akt 
modulation of p27kip1 in the prostate cancer cell lines LNCaP, PC346, PC3 and 
DU145. PI3K/PTEN/Akt signaling was manipulated by wortmannin or specific 
siRNA. The effects on PI3K/Akt downstream effectors and p27kip1 expression were 
monitored on RNA and protein levels. PI3K/Akt inhibition in LNCaP and PC346 
cells hardly affected p27kip1 expression. As shown in LNCaP cells, p27kip1 
expression inversely correlated with Skp2 expression, but Skp2 was not regulated 
by Akt. Blocking PI3K/Akt signaling in PC3 cells resulted in decreased Skp2 
protein expression and increased p27kip1. Down-regulation of PTEN in DU145 cells 
also showed PTEN/Akt dependent regulation of Skp2 and p27kip1.  In PC3 and 
DU145 cells Skp2 is the main determinant in the PI3K/Akt dependent regulation of 
p27kip1. In LNCaP and PC346 cells PI3K/Akt signaling is not a major factor in 
p27kip1 regulation. 
  
Introduction  
Uncontrolled proliferation, enhanced migration and decreased apoptosis are 
important hallmarks of tumor cells 1. The PI3K/Akt signaling pathway, which is 
negatively regulated by the tumor suppressor PTEN, is an important regulator of 
these biological processes. PTEN is frequently inactivated in human tumors 
including brain, endometrial and prostate cancer 2-5. In approximately 15% of 
primary prostate tumors and in up to 60% of metastases, hetero transplants and cell 
lines PTEN defects have been found 6-8. Absence of PTEN expression in primary 
prostate tumors is correlated with higher Gleason score and advanced pathological 
stage 9. 
   PTEN is a phosphatase that antagonizes PI3K by dephosphorylating the 
phospholipid PtdIns(3,4,5)P3 (PIP3) at position D3 of the inositol ring 10,11. 
Although PTEN primarily functions as a PIP3 lipid phosphatase it can also 
dephosphorylate proteins at either serine/threonine or tyrosine residues 11. PIP3 is 
required for the phosphorylation and activation of the serine/threonine kinase Akt, 
a key mediator of the PI3K/Akt signaling pathway.  
   The cell cycle inhibitor p27kip1 causes cell cycle arrest at G0/G1 thereby inhibiting 
cell proliferation 12,13. The p27kip1 level can be regulated by various signaling 
pathways 14-16. A role for PI3K/Akt signaling in p27kip1 regulation was first 
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suggested by Li and Sun (1998)17, who observed that PTEN induced cell cycle 
arrest was associated with altered p27kip1 expression.  
   CDKN1B, encoding p27kip1, has been identified as a direct target gene of FOXO 
transcription factors 18-20. FOXO phosphorylation by phospho-Akt leads to their 
inactivation due to cytoplasmic sequestration 21,22. A second important mechanism 
of p27kip1 regulation is specific proteasomal degradation mediated by Skp2 
dependent ubiquitination 23,24. Skp2 has been identified as the specific substrate 
recognition subunit that targets p27kip1 for degradation upon phosphorylation of 
Thr187 23,25. The PTEN/PI3K pathway could function through Skp2 to regulate 
ubiquitin dependent degradation of p27kip1 26-28.  
   Absence or low expression of p27kip1 is an important prognostic marker in a wide 
variety of tumors, including prostate cancer 29. Several studies analyzing p27kip1 
expression in prostate adenocarcinoma by immunohistochemistry have shown that 
decreased p27kip1 expression is associated with high tumor grade and poor 
prognosis 14,30-32. In several cancers including prostate cancer Skp2 is 
overexpressed and its expression is inversely correlated with the p27kip1 level 33-35.    
   The importance of the complex process of cell cycle regulation prompted us to 
study the role of PI3K/Akt signaling in the regulation of p27kip1 in prostate cancer 
cell lines. We observed a different effect of PI3K/Akt signaling on p27kip1 in the 
prostate cancer cell lines. In PTEN negative LNCaP and PC346 cells modulation of 
PI3K/Akt signaling hardly affected p27kip1 expression. The third PTEN negative 
cell line PC3 showed phospho-Akt dependent p27kip1 degradation that was 
mediated by Skp2, whereas transcription regulation by FOXO did not significantly 
contribute to regulation of p27kip1 expression in these cells. Additionally, PTEN 
positive DU145 cells also displayed a PI3K/Akt dependent regulation of p27kip1 
that was mediated by Skp2.  
 
Results 
PI3K/Akt signaling and p27kip1 expression in prostate cancer cell lines 
PI3K/Akt signaling was studied in the prostate cancer cell lines LNCaP, PC3, 
PC346, and DU145, cultured under comparable, optimal conditions. Expression 
levels of PTEN, phospho-Akt, and the direct phospho-Akt target phospho-FOXO3a 
were assayed in the four cell lines by immunoblotting (Figure 1A). High phospho-
Akt expression was found in PTEN negative LNCaP, PC3, and PC346 cells. In 
contrast, phosphorylated Akt was undetectable in the PTEN positive DU145 cell 
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line. As expected, in LNCaP, PC3, and PC346 cells high expression of inactive, 
phosphorylated FOXO3a correlated with phospho-Akt expression (Figure 1A). In 
DU145 cells phospho-FOXO3a expression could not be detected, which correlated 
with the lack of phospho-Akt expression and the presence of active PTEN in this 
cell line (Figure 1A).  
   Next, expression of the cell cycle regulator p27kip1 was determined (Figure 1B). 
The p27kip1 level did not correlate with the PTEN status of a cell line. P27kip1 
expression was low in rapidly growing PC3 and DU145 cells, and high in slowly 
growing LNCaP and PC346 cell lines. 
 
  
A                                                                 B 
 
 
 
 
 
 
 
Figure 1. PTEN dependent PI3K/Akt signaling and p27kip1 expression in prostate cancer cell lines. 
(A) Whole cell extracts were prepared from LNCaP, DU145, PC3, and PC346 cells and equal 
amounts of protein were subjected to Western Blot analysis, utilizing anti-PTEN, anti-phospho-
Akt(Ser473) and anti-phospho-FOXO3a(Thr32) antibodies. (B) P27kip1 expression was assayed in the 
prostate cancer cell lines by immunoblotting with an anti-p27kip1 antibody. ß-Actin was used as an 
equal loading control. 
 
Kinetics of regulation of PI3K/Akt signaling by wortmannin 
To further study a presumed role of PI3K/Akt signaling in p27kip1 expression, we 
first monitored the effect of PI3K inhibition by wortmannin on phospho-Akt and its 
downstream target phospho-FOXO3a in PC3, LNCaP, and PC346 cells. All three 
cell lines showed a strong reduction of both phospho-Akt and phospho-FOXO3a 
levels at 3 h after the start of the experiment, although within 24 h a renewed 
phosphorylation was observed (Figure 2A,B, and C). The kinetics of renewed Akt 
and FOXO3a phosphorylation markedly differed between the cell lines. In PC3 
cells, at 24 h after addition of wortmannin phospho-Akt and phospho-FOXO3a had 
not yet returned to the original expression level, whereas in the LNCaP cell line 
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increased phospho-FOXO3a and phospho-Akt expression were detectable at 9 to 
12 h after the start of the experiment (Figure 2A and B). Moreover, the expression 
of phospho-Akt and phospho-FOXO3a in PC346 cells was already restored at 6 to 
9 h after wortmannin addition (Figure 2C). Repeated addition of wortmannin to 
PC346 cells at 3 and 6 h following the initial treatment did not result in an 
extended reduction of phosphorylated Akt expression (Figure 2D). No changes 
were observed in total Akt expression. These data indicated that the differential 
recovery of phospho-Akt expression was not due to degradation of wortmannin, 
but rather to a differential adaptation of PI3K/Akt signaling following blockade of 
PI3K activity. 
 
A                                                                     B      
 
 
 
 
 
 
 
 
C                                                                     D 
 
 
 
 
 
 
Figure 2. The effect of PI3K inactivation by wortmannin on the expression of phospho-Akt and 
phospho-FOXO3a in PTEN negative prostate cancer cell lines. Prostate cancer cell lines PC3 (A), 
LNCaP (B), and PC346 (C) were incubated with 200 nM wortmannin. Whole cell lysates were 
prepared at the indicated time points and equal amounts of total cell lysates were immunoblotted with 
anti-Akt, anti-phospho-Akt(Ser473), anti-FOXO3a and anti-phospho-FOXO3a(Thr32) antibodies, 
respectively. (D) Consecutive doses of wortmannin (200 nM end concentration) were added to PC346 
cells at the indicated time points. Cells were harvested at 0, 3, 6 and 9 h and equal amounts of total 
cell lysates were immunoblotted with anti-phospho-Akt(Ser473). The total Akt expression remained 
unchanged throughout the experiment. Results of a representative experiment are shown. 
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Figure 3. The effect of wortmannin on p27kip1 mRNA and protein expression in PTEN negative 
prostate cancer cell lines. Protein and total RNA were isolated in parallel from wortmannin treated 
PC3 cells (A), LNCaP cells (B)  and PC346 cells (C). The  expression of  p27kip1  mRNA  and protein  
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   In all three cell lines, renewed phosphorylation of FOXO3a was more rapid than 
that of Akt itself, suggesting that a small, not yet measurable, increase in phospho-
Akt had a major effect on the FOXO3a phosphorylation status. The expression of 
total Akt and FOXO3a remained constant throughout the experiment (Figure 2A,B 
and C). Taken together these data showed that, although the initial response to 
wortmannin was comparable between the cell lines, during time PC3, LNCaP, and 
PC346 cells all behaved differently. 
                
Cell line specific effect of wortmannin on p27kip1 mRNA and protein expression 
We utilized the differential effect of wortmannin on PC3, LNCaP, and PC346 cells 
to study regulation of the PI3K/Akt downstream target p27kip1. To investigate 
whether FOXO3a activation due to inhibition of PI3K/Akt signaling (see Figure 2) 
contributed to the regulation of p27kip1 mRNA expression, Northern blot 
experiments were performed (Figure 3). In PC3 cells p27kip1 mRNA expression 
was hardly affected by wortmannin (Figure 3A), although in this cell line the most 
pronounced effect on phospho-FOXO3a was found (Figure 2A). Both LNCaP and 
PC346 cells showed a transient, small up-regulation of p27kip1 mRNA following 
dephosphorylation of FOXO3a (Figure 3B and C). However, a transient up-
regulation of p27kip1 mRNA did not result in a measurable increase of the p27kip1 
protein level in these cells (Figure 3B and C).  Despite the absence of changes in its 
mRNA level, p27kip1 protein gradually accumulated in PC3 cells, starting 9 h after 
the addition of wortmannin (Figure 3A). 
 
 
was determined by Northern and Western blotting, respectively. The Northern blots were hybridized 
with a 32P - labeled p27kip1 cDNA probe. To illustrate equal loading of the samples the blots were 
reprobed with an actin cDNA probe. For protein analysis, equal amounts of total cell lysates were 
subjected to gel electrophoresis and immunoblotted with anti-p27kip1. A duplicate blot was 
immunoblotted with anti-β-actin as a control for equal loading. Representative experiments are 
shown. The bottom panels of A, B and C represent a densitometric analysis of the expression level of 
p27kip1 protein, normalized to actin expression. Altered cell cycle distribution of PC3 cells after PI3K 
inhibition by wortmannin treatment was investigated by FACS analysis. (D) PC3 cells were either 
mock treated (DMSO) or treated with wortmannin (in DMSO) to an end concentration of 200 nM.  
Twenty-four hours after addition of wortmannin the cells were collected, stained with propidium 
iodide and subjected to cell cycle analysis. At the right the percentage of cells in each phase of the 
cell cycle is indicated. 
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   Taken together these results indicate that transcription regulation of the p27kip1 
encoding CDKN1B gene, as mediated by PI3K/Akt dependent FOXO3a activation, 
does not significantly contribute to the p27kip1 protein level in the three cell lines. In 
addition, these data suggest that in LNCaP and PC346 cells PI3K/Akt signaling is 
not a major factor in p27kip1 protein regulation. The strong effect of inhibiting 
PI3K/Akt signaling by wortmannin on p27kip1 protein expression in PC3 cells 
prompted us to study this cell line in more detail. We investigated whether the cell 
cycle distribution was affected upon wortmannin treatment. As shown in Figure 
3D, blocking of PI3K activity in PC3 cells resulted in an accumulation of cells in 
the G0/G1 phase of the cell cycle and a concomitant reduction of the S and G2/M 
phase. The increased number of cells in G0/G1 following wortmannin treatment 
correlated with the increased p27kip1 protein expression shown in Figure 3A. 
 
Skp2 protein and mRNA expression in wortmannin treated PC3 cells 
One mechanism of regulation of p27kip1 protein expression is by Skp2 mediated 
proteolysis 23,24. Like FOXO mediated regulation of p27kip1 mRNA expression, this 
process might be mediated by PI3K/Akt signaling 26. We first determined the Skp2 
protein level in the four prostate cancer cell lines. As depicted in Figure 4, Skp2 
protein expression was found in all cell lines.  
 
 
 
 
 
 
 
 74Figure 4. Skp2 protein expression in prostate cancer
cell lines. Whole cell lysates were prepared from
LNCaP, DU145, PC3 and PC346 cells and equal
amounts of protein were immunoblotted with an anti-
Skp2 antibody. β–Actin was used as an equal loading
control. 
 
 
 
 
 
 
 
 
 
 
 
Next, we analyzed the kinetics of Skp2 protein expression in PC3 cells following
wortmannin incubation. As shown in Figure 5A, Skp2 expression gradually
decreased due to PI3K inactivation. At 24 h, Skp2 was no longer detectable. This
expression pattern inversely correlated with p27kip1 protein accumulation as
depicted in Figure 3A. This strongly suggests that in PC3 cells Skp2 mediated
p27kip1 degradation significantly contributed to the regulation of the p27kip1 protein
level via PI3K/Akt signaling. PI3K/Akt dependent Skp2 regulation occurred at the
protein level because analysis of Skp2 mRNA by RT-PCR showed an unchanged
expression during wortmannin treatment (Figure 5B).   
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Figure 5. The effect of PI3K/Akt inhibition on Skp2 expression in PC3 cells. Protein and total RNA
were isolated in parallel from PC3 cells treated with 200 nM wortmannin at the indicated time
points. (A) Equal amounts of total cell lysates were immunoblotted with anti-Skp2 and anti-β-actin
antibodies. (B) Skp2 mRNA expression was measured by semi-quantitative RT-PCR. RNApol II
expression was used to show equal cDNA input. (C) PC3 cells were transfected with either Skp2
specific siRNA or siCONTROL non-targetting siRNA, or were mock treated. Cells were harvested
48 h after transfection and total cell lysates were subjected to immunoblotting with anti-Skp2 and
anti-p27kip1 antibodies. β-actin was used as equal loading control. D and E: Protein and total RNA
were isolated in parallel from PC3 cells transfected with either Akt1,2 siRNA, or siCONTROL non-
targetting siRNA and from mock treated cells. Cells were harvested 48 h after transfection. (D)
Equal amounts of total cell lysates were analyzed by Western blotting using the indicated
antibodies. (E) Semi-quantitative RT-PCR was used to assay Akt1,2 and Skp2 mRNA. RNApol II
expression indicates equal cDNA input. Mock: cells treated with transfection reagent only.
Representative experiments are shown. 
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Akt dependent regulation of Skp2 and p27kip1 in PC3 cells 
We extended our knowledge of the relationship between PI3K/Akt signaling and 
Skp2/p27kip1 expression in PC3 cells by analyzing the effect of down-regulation of 
Skp2 and Akt by specific siRNAs on p27kip1 expression. First, we showed that 
down-regulation of Skp2 by siRNA resulted in up-regulation of p27kip1 expression 
(Figure 5C). Next, we applied Akt1,2 specific siRNA to reduce (phospho-)Akt 
expression. As depicted in Figure 5D a significant reduction of Akt and phospho-
Akt expression was achieved. The reduction of phospho-Akt expression in PC3 
cells resulted in down-regulation of Skp2 and up-regulation of p27kip1 protein 
expression indicating that the Skp2 expression is indeed regulated by an active 
PI3K/Akt pathway. Our previous wortmannin experiments indicated that PI3K/Akt 
signaling only affected Skp2 protein expression and not the Skp2 mRNA level in 
PC3 cells (see Figure 5A and B). An identical observation was made in the siRNA 
experiment. RT-PCR analysis showed that introduction of Akt1,2 siRNA in PC3 
cells significantly reduced Akt1,2 mRNA expression, however, in contrast to Skp2 
protein expression, Skp2 mRNA expression was unaltered (Figure 5E). 
 
Akt independent regulation of Skp2 and p27kip1 expression in LNCaP cells 
To further study the role of Skp2 in the regulation of p27kip1 in prostate cancer cells 
we reduced Skp2 expression by siRNA in the PTEN negative LNCaP cells.  A 
significant increased expression of p27kip1 was found in these cells upon reduction 
of Skp2 protein expression, indicating a Skp2 dependent regulation of p27kip1 
(Figure 6A). However, in contrast to PC3 cells, the expression of Skp2 in LNCaP 
cells remained unchanged after inhibition of Akt signaling by specific siRNAs 
(Figure 6B). Importantly, p27kip1 expression was also not affected by down-
regulation of Akt. In agreement with the wortmannin experiments (Figure 3B), 
these results clearly indicate that in LNCaP cells, PI3K/Akt signaling is not a major 
factor in the regulation of p27kip1. 
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Figure. 6. Skp2 mediated regulation of p27kip1 is independent of Akt in LNCaP cells. LNCaP cells 
were transfected with either Skp2 specific siRNA (A), or Akt1,2 specific siRNA (B). Cells treated 
with transfection reagent only (mock) and siCONTROL non-targeting siRNA transfected cells were 
used as controls. Cells were harvested 48 h after transfection and equal amounts of total cell lysate 
were subjected to gel electrophoresis and immunoblotted with the indicated antibodies. Results of a 
representative experiment are shown. 
 
PTEN dependent regulation of Skp2 expression in DU145 cells 
In concordance with the Skp2 dependent regulation of p27kip1 found in the PTEN 
negative cell lines PC3 and LNCaP, reduction of Skp2 expression by siRNA in 
PTEN positive DU145 prostate cancer cells also resulted in a strong increase of the 
p27kip1 protein level (Figure 7A). To further define the role of PI3K/Akt signaling 
in Skp2 regulation we reduced PTEN expression by siRNA. Decreased PTEN 
expression resulted in increased phospho-Akt expression, whereas the Akt level 
remained unchanged (Figure 7B). As a result of activating PI3K signaling by 
lowering PTEN expression a significantly increased Skp2 and decreased p27kip1 
protein expression were observed (Figure 7B) indicating that, like in PC3 cells, in 
DU145 cells p27kip1 is mainly regulated by PI3K/Akt dependent regulation of 
Skp2. 
   DU145 cells were also transfected with both PTEN and Skp2 specific siRNAs. If 
Skp2 is not the main determinant of the PTEN dependent regulation of p27kip1 in 
these cells, the reduced p27kip1 level observed after activation of Akt signaling 
would be counteracted by the increased p27kip1 expression following the down 
regulation  of  Skp2. In  that  case,  the  total  p27kip1  expression  might  not change  
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Figure 7. Skp2 dependent regulation of p27kip1 is modulated by phospho-Akt in DU145 prostate 
cancer cells. Whole cell extracts were prepared from DU145 cells 48 h after transfection with Skp2 
siRNA (A), PTEN siRNA (B) or both Skp2 and PTEN siRNA (C). Cell lysates from siCONTROL 
non-targeting siRNA transfected DU145 cells or cells treated with transfection reagent only (mock) 
were used as controls. Equal amounts of total cell lysates were subjected to Western Blot analysis, 
utilizing the indicated antibodies. Representative experiments are shown. 
 
upon transfection with both PTEN and Skp2 siRNA. However, reduction of both 
Skp2 and PTEN expression in DU145 cells resulted in a significantly increased 
expression of p27kip1 suggesting that Skp2 is indeed the main determinant of 
PTEN/Akt dependent regulation of p27kip1 in these cells (Figure 7C). 
   Taken together the results indicate that in PC3 and DU145 prostate cancer cell 
lines p27kip1 expression is mainly regulated by PI3K/Akt dependent regulation of 
Skp2 protein expression. In LNCaP and PC346 cells PI3K/Akt signaling hardly 
contributes to the regulation of p27kip1. 
                          
Discussion 
P27kip1 is an important negative regulator of cell cycle progression. Its cellular level 
and localization can be regulated by many different mechanisms 15. One of the 
signaling pathways that can affect p27kip1 is PI3K/Akt signaling 17,36-38. The tumor 
suppressor PTEN, which is frequently inactivated in many tumors including 
prostate cancer, is a key factor in this signaling route by counteracting the function 
of PI3K via dephosphorylation of PIP3 2,10. In this study we compared the 
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involvement of the PI3K/Akt pathway in the regulation of p27kip1 in four prostate 
cancer cell lines. 
   P27kip1 function is controlled by the integration of several signaling pathways, 
including PI3K/Akt signaling, that could affect its mRNA and protein level, and its 
cellular localization (reviewed in refs 13, 15, 39). An important mechanism of 
p27kip1 regulation is protein degradation mediated by the SCFSkp2 complex 39. 
Phosphorylation of p27kip1 affects its stability and cellular localization. Upon 
binding of p27kip1 to the Cdk2/CyclinE complex p27kip1 becomes phosphorylated at 
Thr187 by Cdk2 thereby creating a recognition site for the SCFSkp2 complex and 
promoting proteasomal degradation 23,25. Phosphorylation of p27kip1 at Ser10, 
mediated by hKIS, is necessary for its nuclear export and also contributes to the 
regulation of protein degradation 40-42. The Ras signal transduction pathway affects 
the regulation of p27kip1 translation (reviewed in 15, 16). Furthermore, several 
mechanisms of transcriptional regulation of p27kip1 have been reported. P27kip1 
transcription can be stimulated by STAT, whereas c-Myc mediates repression of 
p27kip1 promoter activity thereby inhibiting p27kip1 transcription 18-20,43,44.  
   The effect of PI3K/Akt signaling on p27kip1 is complex, and might occur at 
several levels. FOXO is able to regulate p27kip1 transcription 18-20. Phosphorylation 
by Akt sequesters these transcription factors to the cytoplasm, resulting in down-
regulation of p27kip1 mRNA expression 21,22. Moreover, PI3K/Akt signaling can 
affect p27kip1 protein degradation by regulating the expression of the E3 ubiquitin 
ligase Skp2 26-28. Additionally, by direct phosphorylation at different sites Akt 
might affect the cellular localization or the stability of p27kip1 45-48. In the present 
study we focused on the role of both FOXO and Skp2 in p27kip1 regulation.   
   In the four prostate cancer cell lines investigated in this study, p27kip1 expression 
correlated with the growth rate (data not shown) and not with the PI3K/Akt status 
of a particular cell line (Figure 1). In two PTEN negative cell lines showing high 
p27kip1 expression, LNCaP and PC346, no clear effect of inhibition of PI3K/Akt 
signaling on p27kip1 was observed, whereas in the third PTEN deficient cell line 
PC3 and in PTEN positive DU145 cells a PTEN dependent regulation of p27kip1 
was found.         
   The three PTEN negative cell lines showed a different kinetics of recovery from 
the PI3K inhibitor wortmannin. However, it is unlikely that the more rapid renewed 
phospho-Akt expression in PC346 and LNCaP cells masks an increased p27kip1 
protein expression (compare Figures 2 and 3). The molecular mechanism that 
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underlies high p27kip1 expression in LNCaP and PC346 cells seems to overrule 
PI3K/Akt mediated p27kip1 regulation. It is tempting to speculate that an active 
androgen signaling pathway plays a role in this process, because growth of both 
cell lines is androgen regulated. In PC3 and DU145 cells, which both lack the 
androgen receptor, modulation of PI3K/Akt signaling strongly affects p27kip1 
expression.  
   In both PC3 and DU145 cells proteasomal degradation via Skp2 was the main 
determinant of the Akt mediated p27kip1 regulation. Although Skp2 could regulate 
the p27kip1 expression in LNCaP cells this regulation was independent of an active 
Akt pathway. In PC3 cells the Akt dependent regulation of Skp2 occurred at the 
protein level. PTEN dependent regulation of Skp2 has previously been described, 
but in contrast to our results in these studies PI3K/Akt signaling affected both Skp2 
protein and mRNA expression 26,27. The molecular background of this apparent 
discrepancy is not clear. It might be due to the difference in cellular context.  
   The PI3K/Akt induced increased Skp2 protein level might be caused by a 
stimulated synthesis or a decreased degradation. It has been reported that the Skp2 
protein level can be regulated via proteasomal degradation mediated by the 
APCCdh1 complex 49,50. It has also been described that connexin43 affects Skp2 
stability 51.  Recently, correlations were found between altered Skp2 expression and 
reduced FAS activity or COX-2 expression suggesting a role for these proteins in 
the regulation of Skp2 52,53. Furthermore, an inverse correlation was found between 
p107 and Skp2 protein expression 54. Whether PI3K/Akt signaling plays a role in 
this regard, or whether other molecular mechanisms are involved in PI3K/Akt 
regulated Skp2 expression remains to be elucidated.  
   It is well established that low p27kip1 expression is a marker of poor prognosis in 
human cancers including prostate cancer. However, a relationship between PTEN 
deficiency and decreased p27kip1 expression in clinical prostate cancer is not clear 
55-57. Skp2 overexpression has been described in many tumors 33,35,58. In the study of 
Yang and coworkers32 an inverse correlation between Skp2 and p27kip1 was 
reported in prostate tumors.  A weak association between Skp2 overexpression and 
PTEN inactivation was also described in this study. In contrast, Drobnjak et al. 
(2003)34 could not find a correlation between Skp2 overexpression and low p27kip1. 
In summary, these data suggest heterogeneity of the effect of PTEN inactivation on 
p27kip1 expression, which might or might not involve Skp2 overexpression, similar 
to that observed in the cell lines as described in the present study. These results 
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urge the further investigation of PI3K/Akt signaling and cell cycle regulators in 
both clinical prostate cancer specimens and model systems.  The outcome of such 
studies is essential for prediction of the efficacy of targeted therapies affecting 
PI3K/Akt signaling. 
 
Materials and Methods 
Cell culture  
Cell lines were cultured in RPMI 1640 (LNCaP) or DMEM (DU145 and PC3) 
(Bio-Whittaker Europe; Verviers, Belgium) supplemented with 5% FCS and 100 
U/ml penicillin, 100 µg/ml streptomycin at 37 °C in a humidified, 5% CO2 
atmosphere.  The PC346 cell line was maintained in DMEM/F12 supplemented 
with 10% FCS and antibiotics. This cell line, which was established from a 
transurethral resection of a primary prostate tumor, does not express a functional 
PTEN protein due to a nonsense mutation in exon 5 7,59. Culture medium was 
refreshed at 15 h prior to harvesting, or 15 h prior to the start of the time course 
experiments. The PI3K inhibitor wortmannin (Sigma Chemical, St Louis, MO) was 
added to the culture medium to a final concentration of 200 nM for the indicated 
time periods.  
 
Western blot analysis  
Cells were washed twice with ice cold PBS and directly lysed in 1 x Laemmli 
sample buffer (50 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 10 mM DTT and 
0.001% Bromophenolblue). The samples were sonicated for 30 sec in a sonication 
bath (Elma Transsonic 460H, Singen, Germany) to shear DNA and boiled for 5 
min followed by 5 min centrifugation in an eppendorf centrifuge at 14 000 rpm. 
   Equal amounts of protein were subjected to 10% or 12% SDS-PAGE. After 
electrophoresis the proteins were transferred by electroblotting to Nitrocellulose 
Transfer Membrane (Protran; Schleicher and Schuell, Dassel, Germany). 
Membranes were blocked in 5% non-fat milk in TBST (10 mM Tris-HCl pH 8.0, 
150 mM NaCl, 0.1% Tween-20) for 2 h at room temperature. Primary antibody 
incubation was performed for 1 h at room temperature. After incubation with a 
secondary horseradish peroxidase (HRP)-linked antibody proteins were visualized 
by enhanced chemiluminescence utilizing supersignal substrate from Perbio 
Science (Rockford, IL).  
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   Densitometric analyses of Western blots were performed utilizing ImageQuant 
software (Molecular Dynamics, Sunnyvale, CA).  
 
Antibodies          
Rabbit polyclonal antibodies to Akt, phospho-Akt(Ser473) and phospho-
FOXO1(Thr24)/FOXO3a(Thr32) were purchased from Cell Signaling Technology 
(Beverly, MA) and applied in a 1:1000 dilution. The mouse monoclonal anti-
human PTEN (Clone 6H2.1; 1:1000) was from Cascade Bioscience (Winchester, 
MA) and the mouse monoclonals anti-β-actin (1:10,000) and anti-p27kip1 (1:500) 
were obtained from Sigma Chemical and Novo Castra Laboratories (Newcastle 
upon Tyne, UK) respectively. The rabbit polyclonal antibodies anti-FOXO3a 
(1:1000) and anti-Skp2 (1:1000) were purchased from Upstate Biotechnologies 
(Lake Placid, NY) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. 
Goat-anti-Rabbit HRP secondary antibody was from Cell Signaling Technology 
and the secondary antibody Goat-anti-Mouse HRP was from DAKO (Glostrup, 
Denmark); both were applied in a 1:2000 dilution. 
 
Northern blot analysis  
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer's description, including an on column DNaseI 
digestion using the RNAse free DNAse set from Qiagen.  
   From each sample, 10 µg RNA was separated on a 1% formaldehyde/agarose gel, 
blotted onto Hybond-N+ membrane (Amersham Biosciences UK, Little Chalfont, 
UK) and UV-crosslinked at 150 mJ UV utilizing the GS Gene linker (Biorad 
Laboratories, Hercules, CA). The blot was prehybridized in buffer containing 0.5 
M NaPi, 7% SDS, 1% BSA, 10 mM EDTA, pH 7.2 and 10 mg haring sperm 
DNA/100 ml for 4 h at 65 °C. Probes were 32P-ATP labeled and hybridization was 
carried out overnight at 65 °C. After hybridization blots were washed in 3 x 
SSC/0.1% SDS and 1 x SSC/0.1% SDS for 30 min each and subjected to standard 
autoradiography for an appropriate time period. A 350 bp PCR fragment from 
p27kip1 cDNA was used as hybridization probe (forward primer 5'-
CTGAGGACACGCATTTGGTG-3'; reverse primer 5'-
CTTCCTTGCTTCATCAAGCAG-3'). Equal RNA loading was verified by 
reprobing the blots with an actin cDNA probe.  
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cDNA preparation and semi-quantitative RT-PCR analysis 
One µg total RNA was incubated for 1 h at 37 °C in buffer containing 50 mM Tris-
HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 1 mM dNTP’s and 200 U 
M-MLV-reverse transcriptase (Invitrogen, Carlsbad, CA), 40 U RNAguard 
(Amersham Biosciences) and 0.5 µg oligodT primer. Specific cDNA fragments 
were amplified by PCR and analyzed on a 1% agarose gel. 
The following primers were used for the RT-PCR: 
Akt1 forward 5’-CTGCGCTGGACGATAGCTTG-3’ 
Akt1 reverse  5’-CCTCAGAGACACGGCCTTAGTG-3’ 
Akt2 forward 5’-CTGACCGCTATGACAGCCTG-3’ 
Akt2 reverse  5’-GAGTCTGGGCACAAAGGTG-3’ 
Skp2 forward 5’-ACCTATCACTCAGTCGGTG-3’ 
Skp2 reverse 5’-ATGGTGGTGAAATGGGAGC-3’ 
RNApol II forward 5’-GCTGAGAGAGCCAAGGATAT-3’ 
RNApol II reverse 5’-CACCACCTCTTCCTCCTCTT-3’ 
 
siRNA and transfections 
One day prior to transfection approximately 1.5x105 cells per 60 mm dish were 
seeded in antibiotic free medium. Cells were washed in PBS and the medium was 
replaced by serum and antibiotics free medium. Transfection was carried out using 
JetSI transfection reagent from Eurogentec (Hampshire, UK) following the 
manufacturer’s description. Cells were harvested at 48 h.  Akt1 and Akt2 siRNAs 
and siControl non-targeting siRNA pool were obtained as ready-annealed, purified 
duplexes from Dharmacon Research (Lafayette, CO). Single-stranded siRNAs to 
target PTEN and Skp2 were purchased from Eurogentec and were annealed 
according to the manufacturer’s description. PTEN and Skp2 siRNA sequences 
were: 
PTEN sense 5’-AGGCACAAGAGGCCCUAGA-dTT-3’ 
    anti-sense 5’-UCUAGGGCCUCUUGUGCCU-dTT-3’ 
Skp2 sense 5’-CCUUUCUGGGUGUUCUGGA-dTT-3’ 
  anti-sense 5’-UCCAGAACACCCAGAAAGG-dTT-3’ 
All siRNA duplexes were used at a final concentration of 100 nM.  
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Cell cycle analysis 
Cell cycle distribution was analyzed by flow cytometry. PC3 cells were incubated 
with wortmannin (200 nM) for 24 h. Next, cells were trypsinized and washed in 
ice-cold PBS. Subsequently, cells were fixed by drop-wise adding to ice-cold 70% 
ethanol. Fixed cells were washed twice in PBS, and incubated in PBS containing 
100 µg/ml RNAseA and 10 µg/ml Propidium Iodide (Sigma) for 1 h at 37 °C. 
Stained cells were assayed in a FACScan (Becton Dickinson, San Jose, CA), and 
the data were analyzed utilizing CellQuest software. For each sample 1 x 104 cells 
were recorded. 
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Abstract 
The tumor suppressor PTEN is the most frequently inactivated gene in prostate 
cancer. Loss of PTEN function leads to activation of the PI3K/Akt pathway. To 
better understand the biological function of PTEN in prostate cancer we stably 
transfected PTEN negative LNCaP cells with wild-type PTEN cDNA under 
inducible control, resulting in LNCaP/PTEN cells. Induced expression of PTEN in 
these cells significantly inhibited cell growth, at least partly due to cell cycle arrest 
at the G1 phase. Expression profiling combined with pathway analysis revealed that 
PTEN dependent G1 growth arrest was associated with an altered mRNA 
expression of the G1 cell cycle regulators Cdc25a, E2F2, cyclin G2 and 
RBL2/p130. Specific inhibition of Akt signaling by siRNA resulted in 
transcriptional down-regulation of both E2F2 and Cdc25a and up-regulation of the 
FOXO target cyclin G2, comparable with the effect observed after PTEN 
induction. However, Akt did not mediate the PTEN dependent transcription 
regulation of RBL2/p130 in LNCaP/PTEN cells. Overall, these results indicated 
that PTEN dependent transcription regulation is important in cell cycle regulation. 
This PTEN regulated transcription was mediated by both Akt dependent and 
independent mechanisms.  
 
Introduction 
The tumor suppressor PTEN is inactivated in a wide variety of cancers 1. In 
prostate cancer PTEN is the most frequently inactivated gene and loss of its 
expression is correlated with the later stages of the disease 2-4. PTEN primarily acts 
as a lipid phosphatase by specifically catalyzing the removal of phosphates from 
the D3 position of phosphoinositides like PIP3, a lipid second messenger produced 
by PI3K (phosphatidylinositol-3 kinase) 5,6. Thereby PTEN counteracts PI3K and 
functionally antagonizes signaling pathways that rely on the activity of PI3K, of 
which the Akt signal transduction route is the best studied. This pathway is 
involved in the regulation of many important cell biological processes, including 
proliferation and survival 7,8. 
   The PI3K/PTEN signaling pathway appears to regulate these cell biological 
processes through a large number of downstream effectors 8. Many of these 
effectors are regulated by Akt mediated phosphorylation, but also Akt independent 
effects have been reported 8. Well known downstream effectors of Akt signaling 
are mTOR that modulates translation and the FOXO transcription factors 9.  
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   Previously, inducible expression systems have been used to study the cell 
biological and molecular functions of PTEN in several cell types 10-16. It turned out 
that PTEN expression introduced variable, cell type specific biological effects. 
Data on inducible PTEN expression in prostate cancer cells are limited. Abrogation 
of PI3K/PTEN signaling in prostate cell lines by either constitutive overexpression 
of PTEN or by small molecules that inhibit PI3K function, resulted in growth 
inhibition, apoptosis or in both 17-22.  
   The aim of the present study was to obtain further insight in the role of PTEN in 
prostate cancer. We stably introduced PTEN cDNA under inducible control in the 
PTEN negative LNCaP prostate cancer cell line and investigated transcriptional 
changes related to PTEN signaling. We showed that in these cells PTEN 
expression specifically blocks cell cycle progression at G1 phase. Our data revealed 
that the PTEN dependent cell cycle arrest correlated with the transcriptional 
regulation of various G1 cell cycle regulators. This regulation was mediated by both 
Akt dependent and independent mechanisms indicating that PTEN dependent 
transcription can be modulated by several distinct mechanisms. 
 
Results 
Generation and characterization of LNCaP/PTEN cells 
To specifically study the cell biological and molecular functions of PTEN in 
prostate cancer we introduced wild-type PTEN under inducible control in the 
PTEN null prostate cancer cell line LNCaP. First, LNCaP cells were stably 
transfected with the Tet-On vector, encoding a transactivator that is activated upon 
the addition of doxycycline (dox), resulting in the LNCaP/Tet-On parental control 
cells. These LNCaP/Tet-On cells were subsequently transfected with pBi-
EGFP/wtPTEN, resulting in LNCaP/PTEN cells  (see Materials and Methods for 
specific details). Western blot analysis showed that PTEN expression was 
undetectable in the absence of dox and induced after stimulation with 50-100 ng/ml 
dox with a maximum expression occurring after exposure to 500 ng/ml dox (Figure 
1A).   
   The PTEN expression level that was reached after 24 h treatment with 250-500 
ng/ml dox is comparable to the endogenous PTEN level in the DU145 prostate 
cancer cell line (Figure 1B), indicating that in LNCaP/PTEN cells PTEN is 
expressed at a physiological level. Time course experiments showed that PTEN 
expression was  clearly  detectable  as  soon  as  6 h after treatment of the cells with   
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Figure 1. Characterization of LNCaP/PTEN prostate cancer cells. (A) Whole cell extracts were 
prepared from LNCaP/PTEN cells incubated with dox for 24 h at the indicated concentrations. Equal 
amounts of protein were subjected to Western blot analysis, utilizing anti-PTEN, anti-phospho-
Akt(Ser473) and anti-Akt antibodies. (B) Densitometric analysis of PTEN expression in 
LNCaP/PTEN cells incubated with dox for 24 h at the indicated concentrations and control PTEN 
positive DU145 prostate cancer cells. (C) Whole cell lysates were prepared from LNCaP/PTEN cells, 
cultured in the presence or absence of 250 ng/ml dox, at the indicated time points. Equal amounts of 
total cell lysates were immunoblotted with anti-PTEN, anti-Akt, anti-phospho-Akt(Ser473) and anti-
phospho-FOXO3a(Thr32) antibodies, respectively. (D) LNCaP/PTEN and LNCaP/Tet-On were 
cultured in the presence or absence of 250 ng/ml dox. At the indicated time points the cell 
concentrations were determined by the MTT assay (OD 570 nm). 
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dox (data not shown), and that in time the expression of PTEN significantly 
increased (Figure 1C). PTEN expression inversely correlated with Akt 
phosphorylation, showing that the introduced PTEN is functionally active (Figure 
1A,C). Inhibition of PTEN/Akt signaling was further indicated by reduced 
phosphorylation of the Akt target FOXO3a upon PTEN induction (Figure 1C). 
Thethe cells with dox (data not shown), and that in time the expression of PTEN 
significantly increased (Figure 1C). PTEN expression inversely correlated with Akt 
phosphorylation, showing that the introduced PTEN is functionally active (Figure 
1A,C). Inhibition of PTEN/Akt signaling was further indicated by reduced 
phosphorylation of the Akt target FOXO3a upon PTEN induction (Figure 1C). The 
lack of detectable PTEN protein expression in the absence of dox and at early time 
points during dox incubation indicates that the system is tightly controlled. 
   To study the effect of induced PTEN expression on cell growth, LNCaP/PTEN 
and control LNCaP/Tet-On cells were cultured in the presence or absence of dox. 
At the indicated time points cell growth was assessed, using the MTT assay  
(Figure 1D). Dox treatment strongly inhibited growth of LNCaP/PTEN cells 
compared to control LNCaP/Tet-On cells, indicating that this effect was indeed 
mediated by PTEN expression. 
 
PTEN dependent gene expression profiles in LNCaP/PTEN cells 
To gain further insight into the underlying mechanisms affected by PTEN 
expression in LNCaP/PTEN cells expression profiling was performed. RNA was 
isolated from cells grown in the presence or absence of 250 ng/ml dox for 12 and 
24 h, respectively, and was subsequently analyzed on Affymetrix Human Genome 
U133A plus 2.0 gene chips to determine the global gene expression profiles. 
Approximately 80 genes showed an at least 2-fold difference in mRNA expression 
upon PTEN induction. In Figure 2A the 25 strongest up-regulated genes are 
depicted. A list of down-regulated genes is provided as supplementary data (Figure 
S1). To validate the micro-array data the expression level of DRE1, RIOK3 and 
MST1 was verified by Q-PCR. The expression of all three genes was already 
increased as early as 9 h after incubation with dox, indicating that up-regulation of 
these genes is a rapid effect (Figure 2B). The down-regulation of two randomly 
selected genes, MCM10 and TNFRSF12a, was also confirmed by Q-PCR (Figure 
S1). 
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PTEN suppresses cell growth in LNCaP/PTEN cells by cell cycle arrest in G1 
To assess the cellular processes that were most prominently affected by PTEN 
induction the micro-array data were subjected to Ingenuity Pathway Analysis 
(IPA). Functional category and pathway analysis revealed three canonical 
pathways that were most clearly affected by PTEN induction in LNCaP/PTEN 
cells: G1/S checkpoint regulation of the cell cycle, and Insulin Receptor Signaling 
and IGF-1 signaling (Figure 3A). These predictions were based on the number of 
focus genes with an altered expression level, which are characteristic for these 
functional categories, including cyclin G2, Cdc25a, RBL2 and E2F2 for G1 arrest 
and IRS2 and IGFR for Insulin and IGF signaling.  
   PTEN dependent cell cycle arrest in G1 would explain growth inhibition of 
LNCaP/PTEN cells upon dox treatment (Figure 1D). G1 arrest was functionally 
tested by assaying the cell cycle distribution of LNCaP/PTEN cells in the presence 
or absence of dox. Indeed incubation of LNCaP/PTEN cells with dox for 24 h 
resulted in an accumulation of cells in the G0/G1 phase and a concomitant decrease 
of cells in the S phase (Figure 3B). In Figure 3C the cell cycle distribution at 
additional  time  points  of  both dox- treated and non-treated LNCaP/PTEN cells is 
summarized. In the absence of PTEN expression the cell cycle distribution of 
LNCaP/PTEN cells remained constant throughout the whole experiment, but PTEN 
expression rapidly induced an accumulation of cells in G0/G1. The first effects on 
the cell cycle are already apparent at 12 h, corresponding with the inactivation of 
the Akt pathway as represented by the down-regulation of phospho-Akt (Figure 
1C). At later time points a strong decrease of the number of cells in S phase was 
observed, followed by a reduced number of cells in G2/M phase (Figure 3C). 
Overall, these data indicate that induced PTEN expression initially caused G1 arrest 
thereby indirectly affecting the other phases of the cell cycle. 
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Figure 2. Strongest up-regulated genes by PTEN induction in LNCaP/PTEN cells.  
(A) Overview of the 25 strongest up-regulated genes in LNCaP/PTEN cells after treatment with 250 
ng/ml dox for 12 h and 24 h. (B) Total RNA was isolated from LNCaP/PTEN cells incubated with 
250 ng/ml dox for the indicated time periods. DRE1, RIOK3 and MST1 mRNA expression was 
measured by Q-PCR, using PBGD expression as a reference. Representative Q-PCR analyses of 
several independent RNA isolations are shown. Data are shown as average  ± SD. 
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Figure 3. PTEN dependent cell cycle regulation of LNCaP/PTEN cells.  
(A) The average Log2 ratios of both the dox treated and non-treated samples were compared and 
differentially expressed genes (Log2 ratio >0.8) were studied by IPA to identify underlying pathways 
and biological processes. The graph represents the IPA assigned global functional categories for the 
differentially expressed genes upon PTEN induction. The -log(significance) indicates the rate of 
confidence for each category. (B) Cell cycle distribution of LNCaP/PTEN cells following dox 
incubation (250 ng/ml). At t=0 and t=24 h cells were collected, stained with propidium iodide and 
subjected to cell cycle analysis. Below the figures the percentage of cells in each phase of the cell 
cycle is indicated. (C) Overview of cell cycle distribution of LNCaP/PTEN cells cultured in the 
presence or absence of 250 ng/ml dox for the indicated time periods. 
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PTEN mediated cell cycle arrest in G1 is associated with transcriptional regulation 
of important cell cycle regulators 
Progress through the cell cycle is orchestrated by tightly regulated expression and 
activity of a many proteins, including cyclins and cyclin dependent kinases. Most 
knowledge about PTEN dependent cell cycle regulation has been derived from 
studies that investigated the role of PTEN/Akt signaling on phosphorylation and 
stability of cell cycle regulatory proteins 11,14,23-27. In the present study we focused 
on the PTEN mediated transcription regulation of cell cycle modulators. As 
mentioned above the predicted inhibition of G1/S cell cycle progression upon 
PTEN induction was based on the significantly altered expression of the cell cycle 
regulators E2F2, Cdc25a, cyclin G2 and RBL2. Both cyclin G2 and Cdc25a 
belonged to the 25 strongest up- and down-regulated genes, respectively, following 
PTEN induction (Figures 2A and S1). Q-PCR analysis confirmed the observed 
down-regulation of E2F2 and Cdc25a mRNA and the up-regulation of both RBL2 
and cyclin G2 mRNA upon induced PTEN expression in LNCaP/PTEN cells 
(Figure 4A).  
   To investigate whether the Akt/FOXO pathway was involved in the 
transcriptional regulation of these cell cycle genes we blocked Akt signaling by 
specific siRNAs.  Transfection of LNCaP/PTEN cells with Akt specific siRNA 
resulted in a decreased expression of phospho-Akt and also decreased the 
expression of phospho-FOXO3a, indicative of its activation (Figure 4B). In 
concordance with FOXO activation a significant up-regulation of cyclin G2 was 
found (Figure 4C).  However, despite FOXO activation the expression level of 
RBL2 remained constant, suggesting that in these LNCaP/PTEN cells PTEN 
dependent up-regulation of RBL2 mRNA expression was not mediated by 
Akt/FOXO (Figure 4C). Q-PCR further showed that blocking of Akt signaling 
significantly inhibited E2F2 and Cdc25a mRNA expression, indicating that 
inactivation of Akt is not only correlated with up-regulation of gene expression but 
also with down-regulation of gene expression. (Figure 4C). Taken together, our 
results showed that PTEN dependent transcription regulation could be mediated by 
distinct Akt dependent and independent processes. 
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Figure 4. PTEN dependent transcriptional regulation of cell cycle genes in LNCaP/PTEN cells. (A) 
Total RNA was isolated from LNCaP/PTEN cells incubated with 250 ng/ml dox for the indicated 
time periods. Cdc25a, E2F2, RBL2 and cyclin G2 mRNA expression was measured by Q-PCR. 
PBGD expression was used as  a   Q-PCR  reference.   Representative   Q-PCR analyses  of  several  
independent  RNA  isolations are shown. Data are resented as average ± SD. (B and C) Protein and 
total RNA were isolated in parallel from LNCaP/PTEN cells cultured in the absence of dox and 
transfected with either Akt specific siRNA or siCONTROL non-targeting siRNA. (B) Equal amounts 
of total cell lysates were analysed by Western blotting utilizing the indicated antibodies. C: Q-PCR of 
Cdc25a, E2F2, RBL2 and cyclin G2 transcripts. Expression of PBGD was used as a Q-PCR 
reference. 
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Discussion 
PTEN is the most frequently inactivated gene in prostate cancer and it is therefore 
of high interest to understand the molecular mechanisms of PTEN signaling in this 
tumor type 3,28. To study PTEN function in detail we stably transfected a PTEN 
expression vector under dox inducible control in the PTEN negative prostate 
cancer cell line LNCaP, resulting in the novel cell line LNCaP/PTEN. To 
understand the function of PTEN and to identify downstream effectors of PTEN 
signaling RNA was isolated from LNCaP/PTEN cells grown in the absence or 
presence of dox, and subjected to global expression profiling. IPA indicated that G1 
checkpoint regulation and Insulin and IGF signaling were the processes most 
prominently affected by PTEN induction in this novel cell line. Moreover, 
expression profiling and IPA indicated that the PTEN dependent G1 checkpoint 
regulation was associated with altered transcription of the cell cycle modulators 
E2F2, Cdc25a, RBL2 and cyclin G2. This transcriptional regulation was found to 
be selectively mediated by either Akt dependent or independent mechanisms.  
   Several approaches varying from the application of small molecule inhibitors to 
the use of inducible expression systems have been applied to study PTEN function 
in different cell types, however, manipulating PTEN signaling turned out to have 
variable effects that seem to be cell type specific 10-16,29. In prostate cancer cells, 
abrogation of PI3k/Akt signaling by overexpression of PTEN or by specific PI3K 
inhibitors resulted in both growth inhibition and apoptosis 17-22. Infection of LNCaP 
and PC3 cells with an adenoviral expression vector of PTEN resulted in 
significantly reduced cell growth 18,21. PTEN expression in LNCaP cells also 
affected apoptosis 21. Treatment with the PI3K inhibitor Ly294002 caused 
increased apoptosis as early as 3 h after addition to the culture medium 22. In 
contrast, overexpression of wildtype PTEN has also been reported to induce cell 
shrinkage and rounding without classical apoptosis 19.  In agreement with our 
findings a growth inhibitory effect of PTEN, due to G0/G1 arrest, was observed in 
C4-2 cells, a hormone independent LNCaP subline 15. The variable effects of PTEN 
expression even within comparable cell lines prompted us to develop a dox-
inducible expression system. The tightly controlled PTEN expression that was 
achieved with this system, which approached a physiological PTEN expression 
level, minimizes the risk of nonspecific effects due to constitutive overexpression 
or the use of small molecule inhibitors.  
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   Together with the G1 checkpoint regulation IPA indicated Insulin and IGF 
signaling as prominent PTEN regulated processes in LNCaP/PTEN cells. Important 
focus genes that showed an altered expression upon PTEN induction were IGFR 
and IRS2. These data extended previous findings indicating that in prostate cancer 
cells PTEN could inhibit cell proliferation and apoptosis by down-regulation of cell 
surface IGF-IR and experiments showing implication of PTEN in expression 
regulation of IRS2 in breast cancer cells 30,31.  
   Expression profiling also indicated down-regulation of genes, such as CDT1, 
CDC6 and MCM10, involved in DNA replication upon PTEN expression (Figure 
S1). However, this seemed a more indirect process since further Q-PCR analyses 
showed that the expression of these genes first started to decrease at 24 h after 
PTEN induction (data not shown). Little is known about a role of PTEN in DNA 
replication, however, in line with our findings Groszer et al., (2006) showed a 
significantly altered mRNA expression of cell cycle and DNA replication related 
genes in Pten null neurosphere cultures 32. CDC6, CDT1 and MCM proteins, 
including MCM10, are involved in the formation of the pre-replication complex 
and their activity is controlled by multiple mechanisms 33. Moreover, several reports 
showed that E2F transcription factors have been implicated in the transcriptional 
regulation of CDC6 and CDT1 34-36. It is tempting to speculate that PTEN 
dependent down-regulation of DNA replication genes in LNCaP/PTEN cells is due 
to PTEN/Akt mediated down-regulation of E2F2 as described here (Figure 4). 
   In the present study we focused on PTEN mediated transcription regulation of 
cell cycle genes. Besides the above mentioned down-regulation of E2F2, IPA also 
indicated that PTEN mediated G1 checkpoint control was associated with altered 
expression of Cdc25a, RBL1 and cyclin G2. So far, most studies on the role of the 
PTEN/Akt pathway in cell cycle regulation described the effects of PTEN 
signaling on the expression of cell cycle regulators at the protein level by altered 
stability, distribution or phosphorylation 11,14,23-27. Here we showed that also PTEN 
dependent transcription regulation can correlate with cell cycle control.   
   PTEN is known to modulate transcription by affecting the activity of the FOXO 
family of transcription factors.  The significance of FOXO in prostate cancer was 
previously indicated by a study in LaPC4 prostate cancer cells overexpressing 
either FOXO1 or FOXO3a 37. Modur et al., (2002) found that FOXO 
overexpression affected the expression of several genes involved in cellular 
proliferation or survival, including cyclin G2. In our micro-arrays we detected 
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besides cyclin G2 also the up-regulation of other FOXO targets that had been 
identified before in the LaPC4 cells, like ATP8a and JAK1, emphasizing that 
FOXO is an important downstream effector of PTEN signaling in LNCaP/PTEN 
cells (data not shown). In several cell types a contribution of FOXO to G1/S cell-
cycle arrest by regulating the expression of negative cell-cycle regulators, such as 
p27kip1 and RBL2, has been described 38-43. However, previously we found that in 
prostate cancer cells Akt/FOXO signaling is not a major regulator of p27kip1 mRNA 
expression 44. Here, we showed that although RBL2 was previously described as a 
FOXO target gene 41, specific inhibition of Akt signaling by siRNA did not affect 
its expression (Figure 4C), indicating a PTEN dependent but Akt/FOXO 
independent regulation of RBL2 in LNCaP/PTEN cells. 
   In addition to the up-regulation of cyclin G2 and RBL2 we observed PTEN 
dependent down-regulation of Cdc25a and E2F2 expression that was mediated by 
the Akt signaling pathway (Figure 4). Although best known as transcription 
activators, FOXO proteins may also repress transcription by competing with 
activatory transcription factors for a common binding site or by functioning as co-
repressors thereby regulating transcription through promoters which lack FOXO 
binding sites 45-47. However, a role of other, as yet unidentified, transcription 
factors in PTEN induced down-regulation of gene expression cannot be excluded.     
   Although it has been suggested that the Akt signal transduction pathway might 
have a role in regulation of the E2F protein level 48, little is known about the 
PTEN/Akt dependent transcriptional regulation of E2F2. Myc is known as an 
important activator of E2F2 expression 49,50.  However, we can exclude the 
involvement of Myc, because no evidence was found in LNCaP/PTEN cells that 
expression of other Myc target genes was modulated by PTEN induction. Recently, 
it has been described that p21Cip1/Waf, a downstream target of Akt that becomes 
activated upon PTEN induction, functions as a transcriptional  repressor  of  
Cdc25a 51, suggesting a possible mechanism by which PTEN/Akt signaling could 
modulate down-regulation of gene expression.  
   Taken together we can conclude that G1 growth arrest is one of the most 
prominent processes affected by PTEN signaling in LNCaP/PTEN cells. We 
showed that in addition to the relatively well studied effect of PTEN on the 
phosphorylation status and protein stability of particular cell cycle regulators, also 
PTEN dependent transcriptional regulation of cell cycle modulators is correlated 
with  PTEN  dependent  cell  cycle  arrest.  As  summarized  in  Figure 5,  we could  
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 Figure 5. Overview of the various
mechanisms of PTEN dependent
transcription regulation in LNCaP/PTEN
cells. By regulating the Akt/FOXO pathway
PTEN causes transcriptional up-regulation of
cyclin G2. The Akt signaling pathway also
mediates PTEN dependent down-regulation
of Cdc25a and E2F2. In contrast, up-
regulation of RBL2 is PTEN but not Akt
dependent. 
 
 
 
 
 
 
 
 
 
 
discriminate at least three different mechanisms by which PTEN regulates 
transcription. PTEN dependent transcriptional activation was either independent of 
Akt activity (RBL2) or was mediated in an Akt dependent manner, most likely via 
the regulation of FOXO (cyclin G2). Besides activating transcription PTEN also 
repressed the expression of genes (E2F2 and Cdc25a) by as yet unidentified Akt 
dependent mechanisms 
 
Materials and Methods 
Plasmid construction 
The pUB6-EM7-Zeo-BGH plasmid was generated by integrating the UBC 
promoter from pUB6HisA (Invitrogen, Carlsbad CA) into the BglII site of the 
EM7-Zeo vector (Invitrogen), resulting in pUB6-EM7-Zeo. Next, the BGH 3’UTR 
from pcDNA3.1 was cloned into the PvuII site of pUB6-EM7-Zeo, resulting in the 
pUB6-EM7-Zeo-BGH construct. 
 
Generation of LNCaP/PTEN cells 
LNCaP cells were transfected with the pTet-On vector (Clontech-Takara Bio 
Europe, Saint Germain-en-laye, France). Neomycin resistant clones were 
transiently transfected with pBi-Luc (Clontech) to test their induction capacity. 
LNCaP/Tet-On cells with a high induction capacity and low background were 
selected and subsequently transfected with pBi-EGFP/wtPTEN and pUB6-EM7-
Zeo-BGH. Zeocin resistant clones were screened for rapid PTEN expression upon 
stimulation and low background. LNCaP/Tet-On and LNCaP/PTEN clones were 
maintained in RPMI 1640 (Bio-Whittaker Europe; Verviers, Belgium) 
supplemented with 5% TET system-proved FCS (Clontech), 800 µg/ml Neomycin, 
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100 U/ml penicillin, 100 µg/ml streptomycin, and 200 µg/ml Zeocin (Invitrogen) 
for LNCaP/PTEN cells, at 37 °C in a humidified, 5 % CO2 atmosphere. A final 
concentration of 250 ng/ml dox (Clontech) was used to induce PTEN expression.  
 
Cell growth assay 
LNCaP/PTEN and LNCaP/Tet-On cells were seeded into 96-well flat-bottom 
culture plates at a density of 5x103 cells per well. After overnight attachment, 
medium was replaced by medium containing dox (250 ng/ml) and cells were 
further incubated for the indicated time periods. Control cells received medium 
without dox. At the end of the indicated incubation times 30 µl MTT reagent (5 
mg/ml in PBS) (AppliChem GmbH, Darmstadt, Germany) was added and the 
incubation was extended for 4 h at 37 oC. After carefully removing the medium, 
100 µl buffered DMSO (DMSO:Buffer (0.1 M glycine, 0.1M NaCl) ratio 8:1) was 
added to each well. Absorbance at 570 nm was determined with a microplate 
reader (BioRad, Richmond, CA).  
 
Western Blot Analysis  
Cells were washed twice with ice cold PBS and directly lysed in Laemmli sample 
buffer (50 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 10 mM DTT and 0.001% 
Bromophenolblue). The samples were boiled for 5 min, followed by 5 min 
centrifugation in an eppendorf centrifuge at 14 000 rpm. 
Equal amounts of protein were subjected to 10% or 12% SDS-PAGE. After 
electrophoresis the proteins were transferred by electroblotting to Nitrocellulose 
Transfer Membrane (Protran; Schleicher and Schuell, Dassel, Germany). 
Membranes were blocked in 5% non-fat milk in TBST (10 mM Tris-HCl pH 8.0, 
150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature. Primary antibody 
incubation was performed overnight at 4 ºC. After incubation with a secondary 
horseradish peroxidase (HRP)-linked antibody, proteins were visualized by 
enhanced chemiluminescence utilizing supersignal substrate from Perbio Science 
(Rockford, IL). Densitometric analyses of Western blots were performed utilizing 
ImageQuant software (Molecular Dynamics, Sunnyvale, CA).  
 
Antibodies          
Rabbit polyclonal antibodies to Akt, phospho-Akt(Ser473) and phospho- 
FOXO3a(Thr32) were purchased from Cell Signaling Technology (Beverly, MA), 
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and applied in a 1:1000 dilution. The mouse monoclonals anti-human PTEN 
(Clone 6H2.1; 1:1000) and anti-β-actin (1:10,000) were from Cascade Bioscience 
(Winchester, MA) and Sigma Chemical, respectively. Goat-anti-Rabbit HRP 
secondary antibody was from Cell Signaling Technology and the secondary 
antibody Goat-anti-Mouse HRP was from DAKO (Glostrup, Denmark); both 
antibodies were applied in a 1:2000 dilution. 
 
cDNA preparation and Quantitative RT-PCR analysis 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer's description, including an on column DNaseI 
digestion using the RNAse free DNAse set from Qiagen. cDNA was prepared from 
total RNA (2 µg) by reverse transcription using 400 units M-MLV RT (Invitrogen) 
and an oligo-dT12 primer. 
         Q-PCR analysis was performed in an ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). QPCR reactions were performed in 
Power SYBR green PCR Master Mix (Applied Biosystems) supplemented with 
Forward and Reverse primer (330 nM) in a total volume of 25 µl. Thermocycling 
conditions were according to the recommendations of the manufacturer. RNA 
levels were determined relative to phorphobilinogen deaminase (PBGD) by the 
standard curve method (Applied Biosystems). Primer combinations used were: 
                                    Forward 5’- 3’                             Reverse 5’- 3’ 
PBGD   5’-CATGTCTGGTAACGGCAATG-3’    5’-GTACGAGGCTTTCAATGTTG-3’ 
DRE1    5’-GAGTGCTACGATCCTGTAAC-3’   5’-CATCACGGCTGTTGATTCTTC-3’ 
RIOK3  5’-TGTCAGTCAGTCAGTAGAAC-3’   5’-GCTTCATTATCTGCTGTGATG-3’ 
MST1   5’-GACCCCATTCGACTACTGTG-3’           5’-CCACTGCTCCTTCACTAG-3’ 
CCNG2 5’-GAGCTGCCAACGATACCTG-3’   5’-TCTAAGATGGAAAGCACAGTG-3’ 
E2F2    5’-CTCCGCAGACGAGACTGG-3’              5’- CTAGGGTCGGTGCTGCTG-3’ 
Cdc25a 5’-GTTGAAGAGACCAGAACGATC-3’ 5’-AGATGCCAGGGATAAAGACTG-3’ 
RBL2    5’-CAACAACATCTACATCAAACAG-3’    5’-GAGTTTCTCCTGTGCGTATC-3’ 
 
siRNA and Transfection studies in LNCaP/PTEN cells 
One day prior to transfection approximately 1.5x105 LNCaP/PTEN cells were 
seeded per 60 mm dish. Next day, cells were washed in PBS and the medium was 
replaced by serum and antibiotics free medium. Transfection was carried out using 
Dharmafect3 transfection reagent (Dharmacon Research, Lafayette, CO) following 
the   manufacturer’s  description.  Cells  were  harvested  at  48 h.   Akt1  and  Akt2 
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siRNAs and siControl non-targeting siRNA pool were obtained as ready-annealed, 
purified duplexes from Dharmacon Research. All siRNA duplexes were used at a 
final concentration of 100 nM.  
 
Cell Cycle Analysis 
Cell cycle distribution was analyzed by flow cytometry. LNCaP/PTEN cells were 
incubated with 250 ng/ml dox for the indicated time points. Next, cells were 
trypsinized and washed in ice-cold PBS. Subsequently, cells were fixed by drop-
wise adding to ice-cold 70% ethanol. Fixed cells were washed twice in PBS, and 
incubated in PBS containing 100 µg/ml RNAseA and 10 µg/ml Propidium Iodide 
(Sigma) for 1 h at 37 °C. Stained cells were assayed in a FACScan (Becton 
Dickinson, San Jose, CA), and the data were analyzed utilizing CellQuest software. 
For each sample 1x104 cells were recorded. 
 
Affymetrix micro-array hybridization  
All samples were hybridized to Affymetrix GeneChip Human Genome U133A plus 
2.0 arrays containing 54 614 probe sets, representing approximately 47 000 
transcripts (30 000 genes). Antisense biotinylated RNA was prepared from 1 ug 
total RNA according to the Affymetrix GeneChip eukaryotic one-cycle target 
preparation protocol (Affymetrix, Santa Clara, CA). Briefly, single-stranded cDNA 
was synthesized using a T7-Oligo(dT) Promoter Primer, followed by RNase H–
facilitated second-strand cDNA synthesis. The cDNA served as a template in the 
subsequent in vitro transcription (IVT) reaction utilizing T7 RNA polymerase and 
a biotinylated nucleotide analogue/ribonucleotide mix for cRNA. The biotinylated 
cRNA targets were then cleaned up and fragmented. The amount of fragmented-
labeled cRNA was determined by standard spectrophotometric analysis, and the 
quality was checked on an Agilent 2100 Bioanalyzer (Agilent, Amstelveen, the 
Netherlands), using an RNA 6000 NANO assay. Affymetrix GeneChips were 
hybridized with 15 ug of fragmented biotinylated cRNA (45 °C for 16 h) and 
subsequently washed, stained with streptavidin phycoerythrin and imaged 
according to the GeneChip Expression Analysis Technical Manual (Affymetrix). 
All GeneChips were visually inspected for irregularities. Average Log2 ratios of 
dox treated and non-treated samples were compared and selected genes (Log2 ratio 
> 0.8) were analyzed for their functions and networks using Ingenuity Pathway 
Analysis (IPA, Ingenuity Systems Inc., Redwood City, CA). 
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Supplementary Figure S1. Strongest down-regulated genes by PTEN induction in LNCaP/PTEN 
cells. (A) Overview of the 25 strongest down-regulated genes in LNCaP/PTEN cells after treatment 
with 250 ng/ml dox for 12 h and 24 h. (B) Total RNA was isolated from LNCaP/PTEN cells 
incubated with 250 ng/ml dox for the indicated time periods. MCM10 and TNFRSF12a mRNA 
expression was measured by Q-PCR, using PBGD expression as a reference. Representative Q-PCR 
analyses of several independent RNA isolations are shown. Data are shown as average  ± SD. 
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Abstract 
PTEN is frequently inactivated during the development of many cancers, including 
prostate cancer, and both bi-allelic and mono-allelic PTEN inactivation may 
contribute to tumorigenesis. PTEN mutations in clinical cancer specimens can easily 
be recorded but mono- or bi-allelic gene deletions are often difficult to assess. We 
performed a comprehensive study to detect PTEN inactivation in 40 locally 
progressive clinical prostate cancer specimens obtained by transurethral resection of 
the prostate, utilizing a variety of complementary technical approaches. The methods 
to detect PTEN deletion included allelotype analysis, dual colour FISH and array-
based CGH. We also applied a novel semi-quantitative approach, assessing the PTEN 
(wild-type) / ψPTEN (pseudogene) ratio (WPR).  Structural analysis of PTEN was 
done by single-strand conformational polymorphism (PCR-SSCP) and sequencing. 
PTEN protein expression was assessed by immunohistochemistry. Our data predict 
complete PTEN inactivation in 12 samples (30%), nine of these by bi-allelic deletion. 
Loss of one PTEN copy was also detected by several methodologies but the number 
could not be accurately assessed. Immunohistochemistry indicated the absence of 
PTEN protein in 15 samples, and heterogeneous expression of the protein in eight 
tumors. Taken together, the data show that bi-allelic deletion is a major mechanism of 
PTEN inactivation in locally progressive prostate cancer.  
 
Introduction 
Prostate cancer is the most common cancer in men in the Western world and the 
second leading cause of male cancer death 1. Effective treatments exist for localized 
prostate cancer, but when metastases develop no curative therapy is available. 
Hormonal therapy gives a response in most patients with bone metastases, but after 
an average period of 18 months hormone refractory disease develops, after which 
only palliative procedures remain. A better understanding of the molecular 
mechanisms underlying prostate cancer is important for development of new, 
targeted therapies. In addition, there is an urgent need for improved prediction of 
the clinical course of prostate cancer to better select patients for treatment options 2. 
   Germ-line mutations of PTEN are the cause of Cowden disease, characterized by 
hamartomas at multiple sites and a predisposition to various tumor types 3. Many 
sporadic tumors contain aberrant PTEN, in particular neuroblastomas, endometrial 
cancer and prostate cancer 4,5. PTEN dephosphorylates inositol phospholipids (PtdIns-
3-P) by removal of the D3 phosphate from the inositol ring in this way counteracting 
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phosphoinositide 3-kinase (PI3K). Absence of PTEN leads to increased 
phosphorylation and thereby activation of the serine/threonine kinase phospho-Akt, a 
downstream target of phosphorylated inositols, which connects PTEN to cell cycle 
regulation, cell survival, cell size and cell polarity 6. Prostate-targeted Pten knockout 
mice develop prostate hyperplasia, high grade prostatic intraepithelial neoplasia (PIN) 
and invasive cancer 7-9. 
   The frequency and mode of PTEN inactivation reported at various stages of clinical 
prostate cancer are variable. Homozygous deletions of PTEN have been detected in up 
to 10 percent of locally confined cancers and metastases 10-14, and in 30 percent of 
prostate cancer cell lines and xenografts 15. PTEN point mutations have been described 
in 2 to 15 percent of primary prostate cancers, 20 to 30 percent of metastases, and 25 
percent of xenografts and cell lines 12,14-17. Immunohistochemical studies showed 
absence of PTEN expression in 20 to 25 percent of primary tumors 18,19. No data are 
available on PTEN inactivation in locally progressive prostate cancer.  
   Although the high frequency of PTEN inactivation by bi-allelic deletion in prostate 
cancer xenografts and cell lines, as compared to clinical tumor specimens, might be 
due to selection, an alternative explanation is the underestimation of the frequency of 
gene deletions in clinical samples. The finding that loss at 10q23 might concern only 
PTEN and a few directly flanking genes indicates that sensitive methods are needed to 
assess the PTEN copy number 20. 
    To obtain information on PTEN alterations in locally progressive prostate cancer 
tissues collected by transurethral resection (TURP), we used several complementary 
techniques, including classical allelotype analysis, dual color FISH, and a novel PCR 
approach, denoted WPR (Wild-type/Pseudogene Ratio analysis). Selected samples 
were assayed by array-CGH. Mutation analysis by PCR-SSCP and sequencing, and 
PTEN expression studies by immunohistochemistry completed the study. Our data 
show preferential bi-allelic deletion of PTEN in locally progressive prostate cancer. 
They also indicate frequent loss of one PTEN gene copy in these tumor specimens. 
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Results 
Because PTEN inactivation is the most frequent genetic alteration in late stage 
prostate cancer, PTEN downstream effectors are important candidates for therapeutic 
targeting of prostate cancer. In order to select patients for targeted therapies, 
knowledge of the status of the PTEN gene is of utmost importance. Exon sequencing 
can easily assess the structure of PTEN in tumor DNA. However, detection of PTEN 
deletions is more challenging since loss of PTEN may concern a small genomic 
fragment 15,20. We applied a variety of complementary methods to investigate PTEN 
inactivation in locally progressive prostate cancer obtained by TURP. 
 
Structural analysis of PTEN 
The structure of PTEN was assessed in 40 TUR DNAs by PCR-SSCP analysis of all 
exons. PCR-SSCP was abnormal in three DNAs (T1-8, T2-2 and T10-7). In all three 
samples inactivating mutations of PTEN were found by subsequent sequence analysis 
(summarized in Figure 1). In T1-8 a C deletion in exon 7 gave rise to a frame shift and 
a truncated protein. In T2-2 a TTAC deletion in exon 8 also introduced a frame shift 
and a shorter protein. T10-7 contained a nonsense mutation (CAG>TAG) in exon 7. 
 
Allelotype analysis 
Allelotype analysis was performed with 4 highly polymorphic markers (D10S1687, 
D10S1765, D10S541 and D10S583), mapping directly upstream or downstream of 
PTEN (See Materials and Methods, Figure 6). Nineteen DNAs from tumors obtained 
by TUR, for which corresponding normal blood DNA was available, were 
investigated. Eleven samples showed loss of at least one of the markers in the PTEN 
region (55%) (Figures 1 and 2). Among these are T1-8, T2-2 and T10-7, which 
contain an inactivating mutation in the second PTEN copy (see above). In two DNAs 
(T8-4, T10-12) markers directly adjacent to PTEN showed the presence of 2 alleles, 
whereas more distal markers showed loss of 10q, indicative of a homozygous deletion 
of PTEN. In T1-1, T3-7 and T10-2 markers directly flanking PTEN were not lost, but 
a more proximal or distal marker showed allelic imbalance, indicating bi-allelic PTEN 
loss, or no loss of PTEN at all. 
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Figure 1. Overview of alterations of PTEN  structure as obtained by mutation analysis, allelotype analysis 
(LOH), WPR analysis and FISH, and of PTEN expression by immunohistochemistry of prostate tumors 
obtained by TURP. 
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Figure 2.  Allelotype analysis of the PTEN region of DNA from locally progressive prostate cancers. See 
Figure 6 for the positions of  the markers.  
 
PTEN analysis by dual color FISH 
In 37 cases, frozen tissue sections with representative tumor were available for dual 
color FISH. Results are summarized in Figure 1. In 22 samples a normal PTEN signal 
was obtained. Eight cases showed complete absence of PTEN signals in cancer cells, 
in contrast to neighboring stromal cells, indicative of complete PTEN deletion (T1-1, 
T1-2, T1-7, T3-7, T6-9, T8-4, T10-3, T10-12). Seven tumor sections indicated loss of 
one PTEN copy. 
 
PTEN analysis by the WPR assay  
WPR is a semi-quantitative method to assess the PTEN gene copy number. In the 
WPR assay the PTEN pseudogene (ψPTEN) is used as an internal control (see 
Materials and Methods for details).  
   WPR was applied on thirty-eight TUR DNAs. Examples of relevant parts of 
sequence plots from tumor DNAs with either 2, 1 or 0 wild-type PTEN copies, as 
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confirmed by other methods, are shown in Figure 3. The results of all TUR DNAs are 
summarized in Figure 1. In 15/38 tumor DNA samples two PTEN alleles were 
detected; WPR indicated also loss of one allele in 15 samples. WPR predicted 
homozygous deletions of PTEN in eight tumor DNA’s (T1-1, T1-7, T3-7, T6-14, T7-
8, T8-4, T10-3 and T10-12).  
 
Figure 3.  Examples of PTEN  exon 9 analyzed by WPR. T10-
7 contains one PTEN allele. T1-1 and T10-12 contain a
homozygous deletion of PTEN. T30-0 shows the presence of
two PTEN alleles. A colored version of this figure is shown in
the appendix of this chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTEN copy number analysis by array-CGH 
For comparison with allelotype analysis, FISH, and WPR, two tumor samples of 
which sufficient DNA was available (T1-1, T10-12) were analyzed by array-CGH. 
FISH and WPR predicted bi-allelic PTEN loss for T1-1; in case T10-12 all three 
assays indicated complete PTEN loss (Figure 1). The array-CGH pattern of T1-1 
clearly showed losses of many chromosome regions (Figure 4A). Such a pattern is 
representative for DNA from a homogeneous high-grade tumor, containing a low 
percentage of normal cells. Tumor T10-12 contained fewer chromosomal alterations; 
one of the most prominent changes was loss of chromosome 10 (Figure 4B). In both 
tumor DNAs, but most clearly in T1-1, the chromosomal region with the lowest T/R 
ratio is 10q23, where PTEN is located, indicative of bi-allelic PTEN deletion. In T1-1 
the predicted homozygous deletion (T/R ratio approx. –2) is located in a small 1 Mbp 
region of 10q23 loss (see Figure 4C). T10-12 has lost one copy of chromosome 10 
and contains a small deletion in the second copy (Figure 4D). T10-12 seems to 
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contain a considerable number of cells without chromosome 10 losses, because the 
log2 T/R ratio of chromosome 10 is approx. -0.5; the log2 T/R ratio over the 
homozygous deletion is approximately -1 (Figure 4D).  Even in the presence of DNA 
from cells with a normal chromosome 10 copy number (non-cancer cells) the deletion 
can be visualized.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Array-CGH patterns of T1-1 and T10-12. (A, B) whole genome array-CGH. (C, D) 
Chromosome 10 profiles. Both tumors contain a homozygous deletion of PTEN. In T10-12 one complete 
copy of chromosome 10 is lost. In T1-1 the PTEN  homozygous deletion is in a small region of 10q loss. 
 
Expression of PTEN in locally progressive prostate cancer 
Immunohistochemistry showed cytoplasmic and nuclear PTEN staining in normal 
prostatic epithelium and stromal cells (intensity 2) (Figure 5A). Intraprostatic nerves 
and urothelial cells showed strong cytoplasmic staining. As summarized in Figure 1, 
15 out of 38 evaluable tumors were completely negative for PTEN (39%) (See e.g. 
T10-12, Figure 5B). Heterogeneous cytoplasmic staining with locally complete 
absence of staining was noted in eight tumors (Figure 5C). 
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Figure 5. Immunohistochemical staining of PTEN (brown) in (A) a positive control prostate. (B) Absence 
of PTEN expression in the tumor cells in T10-12. Note PTEN expression in stromal cells. (C) 
Heterogeneous cytoplasmic staining with locally complete absence of PTEN expression in prostate tumor 
T1-8. A colored version of this figure is shown in the appendix of this chapter. 
 
Discussion 
PTEN inactivation is the most frequent genetic alteration in prostate cancer. 
Previously, we have shown that PTEN can be inactivated by bi-allelic deletion or 
mutation in over 60% of prostate cancer xenografts and cell lines, derived from 
prostate tumors of different clinical background 15. In clinical prostate cancer PTEN 
inactivation is reported at a lower frequency 10,12,13,17,21. In the most complete clinical 
study 10 loss of (part of) chromosome 10q was reported in 23 out of 80 prostate cancer 
specimens obtained by radical prostatectomy (60/80) or from regional lymph node 
metastases (20/80). In 10 of these samples, 7 lymph node metastases and 3 primary 
tumors, PTEN was found to be completely inactivated by bi-allelic deletion or by 
point mutation. Recently, we observed that PTEN inactivation by deletion frequently 
occurs by loss of a small chromosomal region 20. Such small deletions might be 
overlooked in clinical prostate samples. 
   In the present study we analyzed PTEN alterations in 40 locally progressive prostate 
cancers obtained by TUR. In three samples structural analysis detected nonsense 
mutations or frameshifts in exons 7 or 8, causing the synthesis of a truncated protein. 
Furthermore, we utilized a variety of complementary methodologies, including 
allelotype analysis, dual color FISH, and the WPR method, to accurately assess the 
PTEN status in clinical prostate cancer samples. Overall, the various genetic 
approaches gave consistent results (Figure 1). In six samples both WPR and FISH 
indicated the presence of a homozygous deletion. The two homozygous deletions 
detected by allelotype analysis, and the two homozygous deletions found by array-
CGH were observed by both WPR analysis and FISH (see Figure 1). In the three 
tumors containing inactivating point mutations (T1-8, T2-2 and T10-7) both allelotype 
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analysis and WPR experiments indicated loss of the second allele.  In two cases, FISH 
indicated homozygous deletions that were not found by WPR (T1-2 and T6-9); also in 
2 cases results were the opposite (T6-14 and T7-8). In three of four discrepant cases, 
immunohistochemistry confirmed the absence of PTEN expression, indicating a likely 
total number of nine specimens containing a homozygous deletion of PTEN. 
Discrepancies might be due to small deletions, precluding detection by FISH or array-
CGH (see Figure 6). Further, tumors might be heterogeneous, affecting results of 
FISH experiments. Both tumor heterogeneity and presence of normal cell DNA can 
affect WPR data, array-CGH and allelotype analysis. WPR has the advantage of 
producing a quick result in every sample, requiring only 50 ng of DNA. The number 
of six to ten homozygous deletions in forty clinical tumor specimens (15-25%) is 
lower than reported in xenografts and cell lines (35%), but higher than previous 
reports in clinical samples (0-15%), utilizing different methodologies 10,14.  
      Fifteen samples (40%) were completely negative for PTEN expression by 
immunostaining, among those are 10 showing complete genetic inactivation of PTEN 
by one or more genetical analyses. Eight samples (20%) stained heterogeneously with 
fields of complete absence of PTEN, of which six could not be explained by genetic 
defects. Our data therefore indicate, in addition to genetic alterations, down-regulation 
of PTEN protein expression. Down-regulation might be by promoter 
hypermethylation, other epigenetic mechanisms or by mutations in regulatory gene 
sequences. Evidence for promoter hypermethylation has been reported in prostate 
cancer xenografts 22, however, others observed that PTEN promoter hypermethylation 
is rare or absent in clinical prostate cancer 15,23.       
   The higher frequency of loss of 10q23, as compared to complete PTEN inactivation 
gave rise to the speculation that 10q23 might contain a second tumor suppressor gene 
or that mono-allelic PTEN inactivation might contribute to tumorigenesis. The latter 
hypothesis is supported by studies in mouse models of prostate cancer, although we 
have recently shown that in a prostate targeted Pten knock-out model, mono-allelic 
Pten inactivation by itself is insufficient for tumorigenesis 8. However, there is ample 
evidence that a Pten+/- genetic background can induce tumorigenesis or accelerate 
tumor progression in compound mouse prostate cancer models including Nkx3.1, 
Ink4a/Arf or Cdkn1b inactivation, and in TRAMP transgenic mice 24-27. In the present 
study we postulate many tumor specimens with mono-allelic loss of PTEN (Figure 1). 
However, the limited accuracy of our data shows the complexity in discriminating 
between 2 copies and 1 copy of PTEN. More quantitative experiments are essential to 
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assess the frequency of mono-allelic PTEN inactivation in prostate cancer. We 
hypothesize that mono-allelic PTEN inactivation in late stage prostate cancer will 
synergistically cooperate with genetic or epigenetic alterations in other signaling 
pathways. Complete PTEN inactivation might further accelerate tumor progression.  
   In our study, aberrant PTEN expression appeared not to be predictive of survival, 
neither did it correlate with clinical stage. However, the sample size is limited. The 
TURP specimens were generally taken from patients progressive under hormonal 
therapy. Even if absence of PTEN expression would be predictive of a more 
aggressive course of the disease, this might not have become apparent because only 
aggressive cancers were included in this study. 
   In conclusion, we show aberrant PTEN expression in up to 58% of locally 
progressive prostate cancers, with bi-allelic deletion being the predominant 
mechanism of genetic inactivation. 
 
Materials and Methods 
Tumor samples 
The study was approved by the institutional ethical committee. Tumor tissues 
collected by TURP were obtained from 40 symptomatic prostate cancer patients after 
informed consent. These patients had clinical signs of bladder outlet obstruction 
and/or haematuria (locally progressive prostate cancer). Twenty-seven tumors were 
progressive under hormone treatment. Twelve patients underwent TUR while 
hormonal therapy was not yet initiated; the status of one patient was unknown. All 
specimens were reviewed by a clinical pathologist (ThHvdK). From approximately 
half of the patients DNA from blood cells was available. The tissue specimens were 
snap-frozen and stored in liquid nitrogen until use. In addition paraffin-embedded 
tissue sections were available from all patients.  
 
DNA isolation 
Standard protocols were used to isolate genomic DNA from TURPs and blood 28. 
Tumor DNA was isolated by macrodissection from five consecutive 5 µm cryostat 
tissue sections containing at least 80% tumor according to standard procedures, 
including overnight proteinase K incubation at 55 ºC, phenol extraction and ethanol 
precipitation. DNAs were dissolved in TE buffer (10 mM Tris HCl, pH 7.8; 1 mM 
EDTA). For array-CGH DNA was further purified by RNAse treatment. 
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Allelotype analysis 
For allelotype analysis, 100 ng tumor DNA and normal DNA were analyzed. Typical 
PCR settings were 30 cycles of 1 min at 95 ºC, 1 min at 55 ºC and 1 min at 72 ºC in 
15 µ1 standard reaction buffer, supplemented with 1 µCi α32PdATP (Amersham 
Biosciences, Buckinhamshire, UK). Four polymorphic markers flanking the PTEN 
gene were used: D10S1687, D10S1765, D10S541 and D10S583 (see Figure 6 for map 
positions). Products were separated on a denaturing polyacrylamide gel and visualized 
by exposure to X ray film. 
 
Array-based-CGH 
The human 3600 BAC/PAC genomic clone set, covering the full genome at 1 Mb-
spacing for array production was obtained from the Sanger Institute (see Figure 6 for 
BACs  mapping  in  and  close  to PTEN). Degenerated oligonucleotide PCR-products  
were  prepared  for  spotting  on CodeLink® slides (Amersham Biosciences) according 
to Fiegler 29 with some modifications 30. DNA labeling and hybridization were 
performed essentially as described 29. Briefly, 450 ng of test or reference DNA, 60 
µl1x Random primer solution (Invitrogen) and water was heated for 10 min at 100 °C, 
and subsequently cooled on ice. After the addition of 15 µl dNTP mix (1 mM dCTP, 2 
mM dATP, 2 mM dGTP and 2 mM dTTP), 2µl of 1mM Cy3- or Cy5-dCTP (test and 
reference respectively) (Amersham Biosciences) and 120 U Klenow fragment 
(Invitrogen), the mixture was gently mixed and incubated overnight at 37 °C. In one 
tube the Cy3-test sample and Cy5-reference sample were mixed with 125 µg Cot-I 
DNA (Invitrogen), 42.5 µl 3 M NaAc. Next, 1 ml cold 100% ethanol was added. In a 
second tube, 40 µg denatured herring sperm was mixed with 125 µg human Cot-I 
DNA, 16.5 µl 3 M NaAc and 400 µl cold 100% ethanol. After gentle mixing, the 
mixes were precipitated for 3 h at –20 °C. Hybridizations of arrays were performed as 
described 29. Following hybridization, slides were washed for 15 min at 48 °C in 50% 
formamide/2x SSC, for 30 min at 48 °C in 2 x SSC/0.1% SDS, for 10-15 min at room 
temperature in 0.1 M sodium phosphate, 0,1% NP40, and dipped in ddH2O, before 
drying by centrifugation for 3 min at 750 x g. The arrays were scanned in a ScanArray 
Express HT (Perkin Elmer, Boston, MA). The resulting TIFF images were analyzed 
with GenePix Pro 5.0 software (Axon Instruments) and subsequently analyzed and 
visualized with an excel macro 30. 
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Figure 6. Overview of the PTEN region on chromosome 10q23.3. The upper part of the figure shows the 
position of PTEN in Mb from the top of 10p. Below are indicated the positions of the PAC (190P6) 
utilized for FISH, the BAC clones encompassing and flanking PTEN in the BAC array, and the positions 
of the markers utilized in allelotype analysis. 
 
Wild-type/Pseudogene Ratio analysis (WPR) 
WPR is based on the simultaneous PCR amplification, from identical primers, of an 
exon 9 fragment of PTEN that maps on chromosome 10q23 and the corresponding 
sequence of the highly homologous PTEN pseudogene on 9p. The amplified 
fragments contain a single nucleotide difference between PTEN  (T) and ψPTEN (C), 
resulting in a double peak in the sequence plot at the mismatch position.  Because in 
most prostate cancers chromosome 9p is normal 31, the T/C ratio is indicative for the 
PTEN copy number.  
   Fifty ng DNA was amplified using Taq polymerase (Promega, Madison, WI). 
Amplification settings were 35 cycles of 1 min at 95 ºC, 1 min at 50 ºC and 1 min at 
72 ºC using a T1 thermocycler (Biometra, Goettingen, Germany). PTEN exon 9 
primers:  PTENex9F2: 5’-TAGTGACAATGAACCTGATCA–3’ and PTENex9R: 
5’-GGTAATCTGACACAATGTCCTA–3’. The PCR products were loaded on a 1% 
agarose gel, amplified 135 bp fragments were isolated from gel and purified using 
Qiaquick gel extraction columns according to the manufacturer’s description (Qiagen, 
Hilden, Germany). Fragments were sequenced using the ABI Prism BigDye 
terminator v3.1 ready reaction cycle sequencing kit (Applied Biosystems, Foster City, 
CA) and primer PTENex9F2 (25 cycles of 96 °C for 10 sec, 50 °C for 5 sec, 60 °C for 
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4 min (ramping 1 °C/sec). Sequence reactions were run on the ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems). To determine the PTEN copy number the 
T/C ratio at the mismatch position in the amplified fragments was corrected for 
differences in T and C signal intensity, based on the average signal of flanking T and 
C sequences. T/C< 0.4 was indicative of bi-allelic PTEN loss, 0.4 ≤ T/C < 0.8 as 
mono-allelic PTEN loss, and T/C ≥ 0.8 as allele retention. 
 
Dual color fluorescent in situ hybridization 
Frozen tissue sections (4 µm) were fixed on microscope slides treated with 3-
aminopropyltriethoxysilane (Sigma, St. Louis, MO). The slides were air-dried at room 
temperature for 1 h, then submerged in methanol-acetone (1:1, v/v) at –20 °C for 20 
min, washed twice in PBS containing 0.5% (v/v) Tween 20 (Sigma). Subsequently, 
tissue sections were treated with 0.0005% pepsin (Sigma) in 0.01 M HCl for 3 min at 
37 °C, washed 5 times in water for 1 min and 5 times in PBS for 1 min. The slides 
were post-fixed in 1% formaldehyde in PBS for 10 min, washed 5 times in PBS for 1 
min and 5 times in water for 1 min, dehydrated in an increasing ethanol series (70%, 
80%, 90% and 100%, 5 min each) and air dried. The probes used were labeled by nick 
translation and hybridized essentially as described 32. The chromosome 10 centromere 
probe pα10 RR8 was lissamin-11-dUTP (Roche, Mannheim, Germany) labeled and 
PAC 190P6, containing PTEN exons 3 to 9 inclusive (Figure 6; Genome Systems, St 
Louis, MO), was digoxigenin-11-dUTP labeled and visualized with FITC-conjugated 
sheep antidigoxigenin (Roche). To verify the results, the labels of the probes were 
interchanged. Labeled probes (100 ng each) and 0.5 µg Cot1 DNA were dissolved in 
10 µl hybridization mixture containing 50% formamide/2xSCC/10% dextransulfate. 
Results were visualized using a Leica DM fluorescent microscope with a 
DAPI/FITC/Cy3 triple band-pass filter. 
 
PTEN mutation analysis by single-strand conformation polymorphism and 
sequencing 
Fragments for PCR-SSCP analysis were obtained for all PTEN exons using primer 
sets and PCR conditions as described previously 15. Amplification reactions were in a 
15 µl volume in the presence of 1 µCi [α32P]dATP. The products were separated over 
a 6% non-denaturing polyacrylamide gel containing 5 or 10% glycerol at 7 W 
overnight at room temperature. Sequencing of samples containing an aberrant band 
was performed as described above (WPR analysis).  
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Immunohistochemistry 
The mouse monoclonal anti-human PTEN antibody (Clone 6H2.1, Cascade 
Bioscience, Winchester, MA) was used for immunohistochemistry on formalin-fixed, 
paraffin- embedded tissue sections. The sections were pre-treated by a modified heat-
induced antigen-retrieval method 33 in 10 mM citrate buffer, pH 6.0. PTEN antibody 
(1:200) incubation was overnight at room temperature. As a secondary antibody, 
biotinylated rabbit-anti-mouse was used (DAKO, Glostrup, Denmark). Signals were 
visualized using the avidin-biotin-Horse Radish Peroxidase complex (DAKO). PTEN 
staining was independently scored by 2 observers (ThHvdK, PCMSV). The 
cytoplasmic staining intensity was estimated as absent (0), weak (1), normal (2) or 
strong (3). In case of heterogeneity, the range was indicated. 
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Figure 3.  Examples of PTEN  exon 9 analyzed by WPR. T10-7 contains one PTEN  allele. T1-1 and 
T10-12 contain a homozygous deletion of PTEN. T30-0 shows the presence of two PTEN alleles. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Immunohistochemical staining of PTEN (brown) in (A) a positive control prostate. (B) Absence 
of PTEN expression in the tumor cells in T10-12. Note PTEN expression in stromal cells. (C) 
Heterogeneous cytoplasmic staining with locally complete absence of PTEN expression in prostate tumor 
T1-8. 
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Abstract 
The cancer genome is characterized by various structural alterations. Here, we 
describe a simple and accurate method, denoted quantitative Wild-type to 
Pseudogene Ratio (q-WPR) analysis, to detect gene copy number changes, utilizing 
PTEN in prostate cancer as a model system. Q-WPR applies a highly homologous 
pseudogene as an internal control, in a single step PCR based assay with one 
primer set, to assess the copy number of the corresponding functional gene. This 
omits the need for normal DNA and unrelated internal reference markers as 
controls. In many tumors, including prostate cancer, PTEN is frequently lost by 
small deletions. PTEN maps to 10q23 and its closely related pseudogene ψPTEN 
on 9p13. In q-WPR, simultaneously amplified PTEN and ψPTEN fragments are 
discriminated by annealing to gene specific fluorescent-tagged oligonucleotide 
probes. PTEN exon 5 and 6 specific assays were developed and subsequently 
validated on both normal DNAs and on DNA from previously genotyped prostate 
cancer cell lines and xenografts. Next, the assays were tested on clinical prostate 
cancer samples. Q-WPR detected mono- and bi-allelic losses of PTEN and was 
applicable on genomic DNA from frozen and formalin-fixed tumor tissues. The 
method will allow very accurate and simple high-throughput analysis of gene copy 
number changes of any gene with a highly homologous structurally related gene.       
 
Introduction 
Genetic alterations like mutations, translocations and gene copy number changes 
are characteristic features of various genetic disorders, including cancer. During the 
last decades many different technologies, varying from genome wide approaches to 
small scale gene-specific methods, have been developed to analyze changes of 
gene copy numbers 1-3. Most recently, sophisticated array-CGH (Comparative 
Genomic Hybridization) and high density SNP (Single Nucleotide Polymorphism) 
arrays have been generated, allowing high-throughput genotyping of the whole 
genome 4-7.  
   Other techniques to determine gene copy numbers, like loss of heterozygosity 8 of 
polymorphic microsatellite markers are more suited for screening of specific, small 
chromosomal regions 9. Recently developed Multiplex Ligation-dependent Probe 
Amplification (MLPA) can detect semi-quantitatively gene copy number changes 
simultaneously in up to 40 loci 1,10. For the detection of amplification and losses of 
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specific genes in individual cells laborious interphase Fluorescent In Situ 
Hybridization (FISH) is the most frequently applied method 11,12.  
   In the present study we describe a novel, high-throughput assay, denoted 
quantitative Wild-type to Pseudogene Ratio analysis (q-WPR), to detect copy 
number changes of individual genes. Q-WPR applies a highly homologous 
pseudogene as an internal control to determine the copy number of the 
corresponding functional gene. Wild-type gene and pseudogene fragments are 
simultaneously amplified and discriminated by specific fluorescent-labeled 
oligonucleotide probes that hybridize to their target sequence during the 
amplification. In q-WPR reference normal control DNAs and unrelated internal 
controls can be omitted. 
   Pseudogenes are highly similar to their corresponding functional counterparts but 
are generally not transcribed or translated to functional proteins due to the lack of 
functional promoters or other regulatory elements and the presence of premature 
stop codons and frameshift mutations 13. Retrotransposition and duplication of 
genomic DNA are the two major mechanisms giving rise to pseudogenes 13,14. Non-
processed pseudogenes often have retained the original exon-intron structures of 
the parental gene because they arise from genomic DNA duplication or unequal 
crossing over and are thus mostly located at the same chromosomal site as their 
functional counterpart. Retro-pseudogenes or processed pseudogenes have arisen 
from the reverse transcription of a mRNA transcript followed by random 
integration of the resulting cDNA into the genome.  Mammalian genomes contain a 
large number of pseudogenes of which processed pseudogenes form the majority. 
In the human genome the number of processed pseudogenes is estimated to be 
3,600 – 20,000 depending on the search methodology and stringency used 14-18. 
Approximately 10% of cellular genes are thought to have at least one 
retrotransposed pseudogene 14,16,18. Genes encoding ribosomal proteins, 
housekeeping genes like GAPDH and genes that code for metabolic enzymes 
frequently have multiple processed pseudogenes 13,14. This has been ascribed to the 
high mRNA expression level of these genes, thereby increasing the chances of 
generating a processed pseudogene.   
   In this study we utilized the tumor suppressor PTEN located on chromosomal 
band 10q23 and its pseudogene ψPTEN on 9p13 to develop and validate the q-
WPR assay. PTEN antagonizes the action of PI3K, in regulating the intracellular 
PIP3 concentration, thereby negatively regulating important biological processes 
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like cell growth, proliferation and survival 19. The PTEN gene is frequently 
inactivated in various human tumors including prostate cancer 20-22. The assessment 
of PTEN copy number changes requires sensitive methods because PTEN loss 
might involve only small genomic regions 23. In most prostate cancers chromosome 
9p copy number is unchanged, allowing the use of ψPTEN as internal control 24,25. 
Our data show that q-WPR is able to detect homozygous deletions and mono-
allelic losses of PTEN. Q-WPR requires only small amounts of DNA and is 
suitable for fragmented DNA samples. In combination with the high-throughput 
format of the assay this method is very useful for the screening of large series of 
archival formalin-fixed paraffin-embedded patient material, allowing correlations 
of gene copy number changes with long-term clinical follow-up.  
 
Results 
Principle of q-WPR analysis 
Q-WPR is a novel high-throughput method to detect gene copy number changes, 
modified from the 5’-nuclease Taqman assay 26. The q-WPR method makes use of 
small structural differences between two further highly identical genes, e.g. a 
functional gene and a corresponding pseudogene located on a different 
chromosome (see Materials and Methods and Figure 1A). Importantly, 
amplification primers perfectly match both the normal wild-type gene and its 
pseudogene. Fluorescent-labeled wild-type (FAM) and pseudogene (VIC) specific 
probes are used to discriminate between the two simultaneously amplified gene 
fragments (Figure 1A). Genotypes are then assessed based on the ratio between the 
wild-type gene and the pseudogene fluorescence that is generated during the PCR 
amplification. These ratios are depicted by fluorescence clustering patterns in a 
bivariate plot (Figure 1A, right panel).  
      Q-WPR analysis can detect gene copy number changes of virtually every gene 
with a corresponding closely related gene and may be widely applicable in genetic 
screening and diagnostic studies. In cancer diagnostics q-WPR can be used to score 
(high level) amplifications of oncogenes and loss of tumor suppressor genes, both 
common features of the cancer genome. Amplification of genes causes an excess of 
wild-type gene fluorescence (Figure 1A, right panel).  Specific clusters that 
represent mono- and bi-allelic loss of the wild-type gene will be obtained if loss of 
a tumor suppressor gene is assayed (Figure 1A, right panel). 
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Assay development 
In this study a q-WPR assay was developed for the PTEN tumor suppressor gene 
located at 10q23 and its highly homologous processed pseudogene ψPTEN that 
maps to 9p13. In prostate cancer loss of one or two copies of PTEN is frequently 
observed allowing the use of prostate cancer cell lines, xenografts and clinical 
prostate cancer specimens for the testing and validation of the assay 20,23. Due to 
the absence of introns in the processed pseudogene primers and probes must be 
designed on exon sequences. PTEN is composed of 9 exons and the coding 
sequence differs at nineteen positions from ψPTEN. The exons 1-4 and exon 9 of 
PTEN were excluded from the assay design because specific hybridization probes 
could not be developed for these exons. To increase reliability, q-WPR assays were 
developed for two exons of PTEN, exon 5 and exon 6.  Previously, it was shown 
for prostate cancer xenograft DNAs that loss of PTEN always affected exon 5 20. 
Exon 6 was chosen as a second assay because it shows the least homology with 
mouse Pten at the position of the probe, avoiding possible false genotyping of 
human tumors transplanted on mice (compare mouse controls, Figure 2A). Figure 
1B shows the alignment between PTEN exon 5 and exon 6 and ψPTEN sequences, 
and the localization of the primers and probes. 
   To test the specificity of the probes, we generated separate PTEN and ψPTEN 
exon 5 and exon 6 specific fragments by molecular cloning of PCR amplified 
fragments.  In both the PTEN exon 5 and exon 6 assay the probes were found to be 
specific for either PTEN or ψPTEN as indicated by the green and red clusters of 
spots (Figure 1C, and data not shown). The yellow cluster of spots represents 
equally mixed PTEN and ψPTEN specific fragments, as present in normal genomic 
DNA (Figure 1C). In case of 1:2 (PTEN:ψPTEN)  mixed fragments, representing 
mono-allelic loss of the wild-type gene, the fluorescent signal had shifted towards 
the ψPTEN control (Figure 1C). Taken together, our data showed that the designed 
probes were PTEN and ψPTEN specific and that separate genotype clusters could 
be detected.  
   Next, a set of 20 normal genomic DNAs was tested in duplicate to verify the 
specificity and reproducibility of the assay. In both exon 5 and exon 6 PTEN assays 
all normal DNAs clustered together (Figure 1D, and data not shown). In addition, 
the normal genomic DNAs clustered together with the equally mixed PTEN and 
ψPTEN controls in both assays. 
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Validation of q-WPR analysis 
To test q-WPR on tumor DNAs we applied the PTEN exon 5 and exon 6 assays on 
14 prostate cancer cell lines and xenografts that were previously genotyped for 
PTEN by allelotype analysis and array-CGH 20,23. The xenograft PC295 is of 
particular interest because this xenograft contains a small homozygous deletion of 
PTEN exon 5, but loss of only one copy of exon 6. In Figure 2A,B the results of the 
q-WPR analysis are shown. The red, orange and yellow control clusters represent 
homozygous PTEN deletion, mono-allelic loss of PTEN and retention of both 
alleles, respectively. In both assays, most prostate cancer cell lines and xenografts 
clustered together with either one of the controls. Samples 2, 3 and 4 (PC310, 
PC329 and PC339) showed a 1:1 PTEN/ψPTEN ratio; 5, 6 and 7 (LNCaP, PC82 
and PC374) a 1:2 PTEN/ψPTEN ratio; samples 11, 12, 13 and 14 (PC3, PCEW, 
PC133 and PC324) generated only a ψPTEN fluorescence signal. In Table 1 the 
previously by array-CGH established PTEN copy numbers of all investigated 
xenografts are summarized 23. 
   To better compare the exon 5 and exon 6 data the PTEN/ψPTEN (FAM/VIC) 
ratio was determined for each cell line and xenograft, and normalized to the equally 
mixed control. In Figure 2C the average FAM/VIC ratios of three independent 
experiments are shown. Both assays confirmed the previously found homozygous 
PTEN deletions for PCEW, PC133, PC324 and PC3. Also the mono-allelic loss 
found in PC82, PC374 and LNCaP, and the normal genotype of PC310, PC329 and 
PC339 corresponded with the known genotypes, as assayed by array-CGH (Table 
1). In both assays the PC135 (sample 10) signal is located between the clusters of 
mono- and bi-allelic loss of PTEN. This xenograft is however, tetraploid and has 
lost 3 copies of PTEN, explaining the aberrant position of the PC135 signal. In case 
of the xenografts PC295 and PC346 (samples 8 and 9 respectively) the ratio 
obtained in the q-WPR exon 5 assay was significantly lower than the ratio found by 
exon 6 q-WPR analysis. As previously indicated, PC295 contains a small 
homozygous deletion of PTEN exon 5, explaining the difference between the 
PTEN exon 5 and exon 6 specific assays.  
   However, the FAM/VIC ratio of PC295 exon 5 is still higher compared to other 
samples with bi-allelic PTEN loss. At the wild-type probe binding site of PTEN 
exon 5 the mouse and human PTEN sequences are highly homologous and the 
relatively large contribution of mouse genomic DNA in this xenograft influences 
the outcome of the assay (compare FAM/VIC ratio of PC295 with mouse control, 
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Figure 2A). In PC346 the different results obtained in the PTEN exon 5 and exon 6 
q-WPR assays are due to a CGA130TGA nonsense mutation present in exon 5 of 
PTEN that is located at the probe binding site, causing less efficient binding of the 
PTEN (FAM) probe.  The significantly higher q-WPR ratio found in DU145 was 
due to amplification of PTEN as previously indicated by array-CGH (Table 1). 
 
Table 1. PTEN copy number of prostate cancer cell lines and xenografts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Contaminating mouse DNA in PC295 interferes with accurate copy number determination of   
   PTEN exon 5 
§ PTEN exon 5 of PC346 contains a CGA130TGA nonsense mutation at the probe binding site 
* PC135 is tetraploid for chromosome 10 and has lost 3 copies of PTEN 
 
 
Sensitivity of q-WPR analysis on DNA isolated from formalin-fixed, 
paraffin-embedded prostate cancer xenografts 
Paraffin-embedded formalin-fixed tissue specimens stored in archives are very 
valuable for studying the pathogenesis of many diseases. However, DNA extracted 
from these tissue samples is often of poor quality, limiting the accuracy of genome 
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analysis. To investigate whether q-WPR is accurate on DNA from archived 
material, we tested six prostate cancer xenografts from which both fixed and frozen 
material of the same tumor was available. These xenografts were split at 
harvesting, one half was directly frozen, whereas the other half was formalin-fixed 
and embedded in paraffin. For both the PTEN exon 5 and exon 6 q-WPR assays 
comparable results were found for DNA extracted from fresh frozen samples and 
DNA isolated from fixed tissues (Figure 3A,B). Slightly higher FAM/VIC ratios of 
PTEN exon 5 of PC310 and PC295 were proven to be caused by the high 
percentage of mouse cells in these tissue samples (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Application of q-WPR to DNA isolated from paraffin-embedded prostate cancer tissues. 
Xenograft material was split upon harvesting and either freshly frozen or formalin-fixed and paraffin-
embedded. DNA was isolated in parallel from both frozen and fixed material from the same 
xenograft. The average relative FAM/VIC ratios ± SD of three independent PTEN exon 5 (A) and 
exon 6 (B) q-WPR assays are shown. 
 
Analysis of clinical prostate cancers 
Next, q-WPR analysis was applied on clinical prostate cancer samples. The 
bivariate plots of the PTEN exon 5 and exon 6 q-WPR assays (Figure 4A,B) 
indicated the presence of different genotype clusters. The relative FAM/VIC ratios 
suggested a homozygous PTEN deletion in T1-1 and T1-7, mono-allelic loss in T1-
8, T2-9 and T8-4 and retention of both PTEN alleles in T1-4, T7-11 and T10-15 
(Figure 4C). Following q-WPR analysis array-CGH was performed on these 
clinical samples. In T1-1 and T1-7, array-CGH detected a homozygous deletion for 
PTEN, thereby confirming the q-WPR results. As an example the array-CGH 
profile of T1-7 is shown, indicating no alterations in chromosome 9 and a clear 
homozygous deletion of the PTEN region at 10q (Figure 4D). Array-CGH detected  
 142
                                                                                                                                                   Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. PTEN copy number analysis by q-WPR in clinical prostate cancer samples. Representative 
examples of a bivariate plot of the q-WPR PTEN exon 5 (A) and exon 6 (B) assay. Specific controls 
are depicted by red, orange and yellow circles indicating homozygous PTEN deletion, mono-allelic 
loss of PTEN and retention of both alleles, respectively. (C) The relative FAM/VIC ratio of three 
independent exon 5 and exon 6 q-WPR assays. Array-CGH was performed on all tumor DNAs and as 
examples the specific chromosome 9 and chromosome 10 profiles of T1-7 (D), T8-4 (E) and T10-15 
(F) are shown, representing tumors with a homozygous PTEN deletion, mono-allelic loss of PTEN 
and retention of both PTEN alleles, respectively. 
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loss of one PTEN allele in T1-8, T2-9 and T8-4, as determined by q-WPR analysis. 
The array-CGH profile of T8-4 is shown as a representative example and indicates 
retention of chromosome 9 and loss of a large part of chromosome 10q, including 
the region where PTEN is located (Figure 4E). Q-WPR analysis suggested a 
normal PTEN genotype for T1-4, T7-11 and T10-15 that was confirmed by array-
CGH (See T10-15, Figure 4F). Taken together q-WPR analysis is proven to be a 
fast, reproducible and reliable method to determine gene copy number changes 
even in clinical DNA samples and in DNA extracted from formalin-fixed and 
paraffin-embedded tissues. 
 
Discussion 
Gene deletions and amplifications are common features of the cancer genome 27. 
Here we describe the development and validation of q-WPR analysis, a novel, 
accurate high-throughput method to determine gene copy number changes that has 
some unique advantages over existing genotyping techniques such as FISH, 
allelotype analysis 8, MLPA, array-CGH and SNP-arrays 4,5,10,11. One major 
advantage is that a corresponding normal reference is not required because a 
pseudogene is used as internal control. Moreover, only a minimal quantity (<20 ng) 
of genomic DNA is required for each q-WPR assay, which is important when 
limited amounts of clinical materials are available. Further, q-WPR is applicable to 
DNA extracted from formalin-fixed paraffin-embedded tissue (Figure 3), which is 
often fragmented thereby affecting the efficiency of a PCR reaction 28. 
   Genome wide approaches to detect copy number changes like array-CGH and 
SNP arrays frequently use amplified genomic DNA, which involves the risk of 
increasing differences in DNA representation 29. Due to the small sample size 
required for q-WPR analysis this amplification step can be omitted. The recently 
developed MLPA technique that can determine copy number changes of up to 40 
loci in one PCR based assay 1,10 also requires only small amounts of DNA per 
assay but compared to q-WPR analysis MLPA still requires normal DNA controls, 
is  more  time  consuming  and  less quantitative. In addition, MLPA is a multi-step 
assay whereas q-WPR involves only one step thereby minimizing the risk of 
sample cross contamination. For the detection of single gene copy number changes 
FISH is the most frequently used method.   However, compared to q-WPR analysis 
FISH is much more laborious and has a much lower sample throughput. Recently, 
the Paralogue Ratio Test (PRT) has been described, based on the previously 
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published paralogous sequence quantification (PSQ) used in the diagnosis of 
trisomy 30,31. Like q-WPR, PSQ and PRT are based on the simultaneous 
amplification of both test and reference loci that are subsequently distinguished by 
minor internal sequence differences 30,31. However, q-WPR does not require further 
sample processing minimizing the risk of contamination and is more quantitative. 
Obviously, as in other genotyping methods the percentage of contaminating normal 
DNA in clinical tumor samples might affect the outcome of the assay.   
   Q-WPR analysis is not restricted to PTEN but can be applied to determine copy 
number alterations of virtually every gene with one or more corresponding and 
closely related genes such as processed pseudogenes, depending on their sequence 
and chromosomal location. The number of processed pseudogenes associated with 
a given gene can vary from one to multiple copies. Approximately 10% of human 
genes is thought to have at least one retrotransposed pseudogene indicating the 
applicability of q-WPR 14,16,18,32. The tumor suppressor gene MKK4, located on 
chromosome 17p11.2 with a corresponding pseudogene on chromosome Xq13.2, is 
also a suitable candidate for q-WPR analysis 33. Homozygous deletions of MKK4 
have been reported in a subset of pancreatic, biliary and breast carcinomas 34,35.  
   Apart from screening for loss of tumor suppressor genes q-WPR can also be used 
for amplification analysis, as shown by the high relative FAM/VIC ratio (>1) found 
in DU145 cells (Figure 2), indicating PTEN amplification as confirmed by array-
CGH (data not shown). A candidate gene for amplification analysis is PIK3CA 
located at 3q26.3, encoding the p110α subunit of PI3K. This gene is frequently 
amplified in various tumor types and a PIK3CA pseudogene was discovered at 
chromosome 22 36-40. Other possible candidates for amplification analysis by q-
WPR are MDM2 (12q15) and CDK4 (12q14.1) and their respective pseudogenes 
on chromosome 2p24.1 and 1p21.1. The MDM2 oncogene is often amplified in 
human cancers 41. In addition, several tumor types show co-amplification of MDM2 
and CDK4 42-44, a feature that  is used to distinguish lipomas from liposarcomas 
because histological diagnosis of these tumors is difficult 45,46.     
   In conclusion, q-WPR analysis has been shown to be a rapid and reliable method 
for the detection of gene copy number changes. Q-WPR can be very valuable in 
prognostic studies due to its high sample throughput and its suitability to be used 
on low quality DNA.  
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Materials and methods 
Samples 
The prostate cancer cell lines LNCaP, DU145 and PC3 were cultured under 
standard conditions. The prostate cancer xenografts PCEW, PC82, PC133, PC135, 
PC295, PC310, PC324, PC329, PC339, PC346 and PC374 were propagated on 
male nude mice, as previously described 47-49. Clinical prostate cancer tissues were 
collected by TURP (Trans Urethral Resection of the Prostate). Collection of patient 
samples has been performed according to national legislation concerning ethical 
requirements. Use of these samples has been approved by the ErasmusMC Medical 
Ethics Committee according to the Medical Research Involving Human Subjects 
Act (MEC-2004-261).  
 
DNA preparations 
Genomic DNA from cell lines, and frozen, or formalin-fixed and paraffin-
embedded xenograft tissues was isolated utilizing the Puregene system (Gentra 
Systems, Minneapolis, MN) according to the manufacturers description. Formalin-
fixed and paraffin-embedded xenograft tissue (five 20 µm tissue slides) were 
minced and de-paraffinized by xylene treatment prior to DNA isolation.  
   Genomic DNA from clinical tumor tissues was isolated from five consecutive 5 
µm cryostat sections containing at least 80% tumor. The isolation procedure 
included overnight proteinase K incubation at 55 ˚C, phenol extraction and ethanol 
precipitation. DNAs were dissolved in TE buffer (10 mM Tris HCl, pH 7.8, 1 mM 
EDTA). DNA was further purified by RNAse treatment. 
   The ECACC human random control DNA panel (HRC-1) was used as normal 
Genomic reference DNAs (Sigma, St. Louis, MO). These DNAs were extracted 
from lymphoblastoid cell lines obtained by EBV transformation of peripheral blood 
lymphocytes from fresh blood samples of healthy donors.  
 
Generation of PTEN fragments 
Fragments of wild-type PTEN exon 5 and exon 6 and the corresponding fragments 
in ψPTEN, containing the q-WPR primer and probe sequences were amplified by 
PCR on normal human genomic DNA (Sigma) as a template. Amplification 
settings were 35 cycles of 1 min at 95 ºC, 1 min at 50 ºC and 1 min at 72 ºC. 
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Amplification primers:  
PTENex5F2: 5’-CCA CAG CTA GAA CTT ATC–3’ 
PTENex5R2: 5’-GTC TCT GGT CCT TAC TTC-3’ 
PTENex6F: 5’-TCC CAG TCA GAG GCG CTA TG-3’ 
PTENex6R2: 5’-TTC CGC CAC TGA ACA TTG G–3’. 
PCR products were purified and inserted into pGEM-Teasy (Promega, Madison, 
WI). PTEN and ψPTEN fragments were separated by molecular cloning. Inserts 
were verified by sequencing utilizing the BigDye terminator v3.1 ready reaction 
cycle sequencing kit and the ABI Prism 3100 genetic analyzer (Applied 
Biosystems, Foster City, CA).  
 
Quantitative Wild-type to Pseudogene Ratio analysis (q-WPR) 
Q-WPR analysis is a modification of the 5’-nuclease Taqman assay 26.  In Figure 
1A, the principle of q-WPR, which is based on the simultaneous amplification of a 
gene and its corresponding pseudogene as an accurate internal standard, is 
illustrated. The single primer set perfectly matches both the wild-type and the 
pseudogene sequence, which in the amplified region differ at one or a few 
nucleotides. The either FAM or VIC fluorescently labeled wild-type or pseudogene 
specific hybridization probes, are complementary to an internal region of the PCR 
product, surrounding the single nucleotide difference between the wild-type gene 
and the pseudogene. The ratio of the wild-type and pseudogene fluorescent signals 
generated during the amplification is a direct measure for the copy number of the 
investigated gene.   
   Primers and probes for the PTEN specific q-WPR assays were designed with 
Primer Express software (Applied Biosystems). Reactions were performed in a 
total reaction volume of 5 µl containing 2,5 µl 2 x TaqMan Universal PCR master 
Mix (No Amperase UNG, Applied Biosystems), each primer at a final 
concentration of 900 nM, 200 nM of each probe and 20 ng genomic DNA. Thermal 
cycling parameters for the assay were 15 min 95 ˚C followed by 35 cycles for 15 
sec at 95 ˚C and 1 min at 60 ˚C. After amplification fluorescence was measured in 
an ABI PRISM 7900HT Sequence Detection System and analyzed using SDS 
software version 2.2.2 (Applied Biosystems).  
Fluorescent-labeled probes (Applied Biosystems): 
PTENex5-wt FAM ACG AAC TGG TGT AAT GA-MGB 
PTENex5-ψ VIC ACG AAC TGG TAT AAT GA-MGB 
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PTENex6-wt FAM CTA CCT GTT AAA GAA TC-MGB 
PTENex6-ψ VIC CTA CCT GGT AAA GAA T-MGB 
Amplification primers: 
PTENex5F 5’-ACC AAT GGC TAA GTG AAG ATG ACA-3’ 
PTENex5R 5’-CAT AGA AAT CTA GGG CCT CTT GTG-3’ 
PTENex6F 5’-TCC CAG TCA GAG GCG CTA TG-3’ 
PTENex6R 5’-CACTGAACATTGGAATAGTTTCAAACA-3’ 
 
Array-CGH 
Arrays were produced from the human 3600 bacterial artificial chromosome 
(BAC)/P1-derived artificial chromosome genomic clone set of the Welcome Trust 
Sanger Institute, covering the full genome at ~ 1Mb spacing. Degenerated 
oligonucleotide PCR products were prepared for spotting as described 50,51. DNA 
labeling and hybridization were done essentially as described 50 with minor 
modifications 52. After hybridization arrays were scanned in a ScanArray Express 
HT (Perkin-Elmer, Freemont, CA). The resulting images were analyzed with 
GenePix Pro 5.0 software (Axon Instruments, Foster City, CA) and subsequently 
visualized with an excel macro 51.  
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General discussion and future directions 
As the second cause of male cancer deaths in the Western world, prostate cancer is 
a serious health problem, however, treatment options of advanced disease are still 
limited. The tumor suppressor PTEN is the most frequently inactivated gene in 
prostate cancer and a good understanding of its molecular functions in prostate 
cancer is therefore of utmost importance for the development of novel, targeted 
therapies. In addition, it may reveal whether PTEN, like in other types of cancer, 
can serve as a novel prognostic marker for prostate cancer progression or 
recurrence.  
 
Activation of PTEN signaling by genetic alterations 
Genetic and epigenetic changes of members of the PTEN/PI3K pathway can result 
in constitutive activation of this signaling cascade, a feature that is frequently 
observed in a variety of sporadic human tumor types. Interestingly, deregulation of 
PTEN/PI3K signaling appears to occur in a tissue-specific manner. In addition each 
tumor type might have a predominant mechanism of (in)activation of PTEN and 
PIK3CA, encoding the p110α catalytic subunit of PI3K.  
   PI3KCA was mapped to chromosome 3q26, an area frequently amplified in 
various human cancers including ovarian, thyroid and cervical cancers 1-3. Instead 
of PIK3CA copy number changes several other tumor types such as liver, colon, 
gastric, brain and breast cancers display high rates of PIK3CA point mutations, 
which are predominantly clustered at two mutational hot spots located in the exons 
9 and 20 4.  
   Somatic PTEN abnormalities have been found in many tumors but the highest 
frequencies of PTEN inactivation are found in glioblastomas, endometrial 
carcinomas and prostate cancers 5. An important mechanism of PTEN inactivation 
is homozygous deletion. Unfortunately homozygous deletions are difficult to detect 
in clinical tumor samples due to the presence of contaminating normal DNA in 
these samples. Chapter 4 of this thesis describes a comprehensive analysis of the 
PTEN status in locally progressive prostate cancers, which revealed that in this 
tumor type the PTEN gene is preferentially inactivated by bi-allelic loss. From the 
12, out of the 40 investigated tumor specimens, in which complete PTEN 
inactivation was found, 9 displayed bi-allelic loss of the gene. The other three 
samples contained an inactivating PTEN mutation in either exon 7 or exon 8 of the 
gene. Although point mutations in PTEN have been detected in prostate cancer 
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their frequency is far less compared to glioblastomas and endometrial carcinomas 
(Table 3 of the general introduction). Most of the point mutations in the prostate 
cancer samples are scattered over the exons 5-9.   
   As previously mentioned, PTEN inactivation in glioblastomas and endometrial 
carcinomas predominantly occurs by point mutations 6. A large number of 
mutations in both tumor types are found in exon 5, which encodes the catalytic 
core motif of PTEN. In glioblastomas also a high proportion of the mutations was 
found in exon 6, whereas endometrial carcinomas showed a high mutation 
frequency of the exons 7 and 8 6. Exon 6 encodes a part of the so-called TI loop of 
PTEN, which is responsible for the larger width of the active site pocket of PTEN 
compared to other protein phosphatases 7. Therefore, the exon 6 mutations 
observed in glioblastomas may also affect the phosphatase activity of PTEN. The 
exons 7 and 8 encode elements that are involved in the membrane binding of 
PTEN, thus an altered membrane binding due to mutation of these elements could 
also affect the function of PTEN 7. The point mutations found in the exons 7 and 8 
are located in repetitive motifs. In addition, the endometrial carcinomas in which 
PTEN mutations were found displayed a high frequency of microsatellite 
instability. It is therefore thought that the defect of mismatch repair in these tumors 
could be responsible for the high mutation rates of the exons 7 and 8 6.  
   In many cancers simultaneous alteration of PIK3CA and PTEN has been thought 
to be mutually exclusive 8-10. However, a recent study reports coexistent mutations 
of PIK3CA and PTEN in endometrial carcinoma. In a small subset of breast cancers 
PTEN loss was found to be associated with PIK3CA mutations 11,12. These findings 
are unexpected because loss of PTEN function and activation of PI3K are thought 
to have similar effects on the PIP3 pool, and thereby the activation of the 
downstream signaling pathway. It might however be that more than one event is 
required for the complete activation of this pathway. In favor of this hypothesis is 
the report of Velasco et al. (2006) showing that PIK3CA mutations predominantly 
co-exist with mono-allelic inactivation of PTEN thereby supporting the hypothesis 
that PIK3CA mutations may have an additive effect on PTEN alterations in certain 
tumor types 13.  
   Various molecular mechanisms are thus involved in activating the PTEN/PI3K 
driven tumorigenesis. A helpful tool in determining the underlying inactivation 
mechanism of certain genes is the q-WPR assay as described in chapter 5 of this 
thesis. This is a modification of the wild-type to pseudogene ratio assessment 
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(WPR) assay used in chapter 4 to determine the mechanism of PTEN inactivation 
in primary prostate cancers. Whereas WPR makes use of a sequencing reaction to 
obtain a semi-quantitative estimate of DNA copy number, the q-WPR assay as 
described in chapter 5 is based on the previously described 5’-nuclease Taqman 
assay 14. Compared to the initial WPR assay, q-WPR analysis is even faster, 
applicable in a high-throughput format, does not require further sample processing 
minimizing the risk of contamination and is much more quantitative.  
   The enhanced sensitivity of q-WPR analysis compared to the previous described 
WPR technique is further demonstrated by the observation that for one of the 
tumor specimens investigated in chapter 4 (T8-4) q-WPR analysis predicted loss of 
one PTEN allele whereas the former WPR technique and even the FISH and LOH 
studies predicted complete loss of PTEN in this tumor. Array-CGH, which is a 
powerful tool to detect copy number changes at high resolution, then showed that 
in T8-4 there is indeed loss of one PTEN allele. Moreover, also in case of T10-15 
q-WPR was proven to be more sensitive than the initial WPR method that 
predicted loss of one allele of PTEN. However, q-WPR analysis indicated a normal 
PTEN copy number for this tumor, which was later confirmed by array-CGH.  
   The q-WPR assay cannot only be used for the detection of gene deletions but is 
also suitable for amplification analysis of any gene with a highly homologous 
structurally related gene. A recent study described the discovery of a PIK3CA 
pseudogene spanning exons 9-13 on chromosome 22 15, which opens perspectives 
for the application of q-WPR in studies investigating the mechanism underlying 
activation of the PTEN/PI3K pathway.  
 
PTEN dosage  
A phenomenon closely related with the PTEN copy number is haploinsufficiency. 
In mice a study investigating the effect of Pten dose on cancer progression using a 
so-called hypomorphic mouse mutant series, in which the Pten dose was decreased 
even below heterozygous levels, revealed that Pten plays a crucial dose-dependent 
role in prostate cancer progression 16. Whereas the prostates of the Pten 
heterozygous mice were not enlarged and displayed only moderate/low grade PIN 
foci further reduction of the Pten dose in resulted in markedly enlarged prostates 
and moreover 25% of these mice showed histological signs of local invasion at 6 
months of age. In human prostate cancer specimens representing various stages of 
the disease it was recently showed that PTEN is more frequently lost in prostate 
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cancer samples compared to precursor lesions implicating a role for PTEN 
haploinsufficiency in the transition from preneoplastic PIN to prostate cancer 17. 
Thus although there are indications that reduced PTEN function is important in the 
progression of prostate cancer further research is needed to elucidate the question 
whether PTEN haploinsufficiency is indeed critical in prostate tumor progression. 
Further insight into the role of PTEN dosage in human prostate cancer development 
may be obtained by a gradually knock down of PTEN expression in normal 
prostate cells using a tightly controlled, inducible short hairpin RNA (vector based 
siRNA) expression system.  
 
Model systems to study PTEN function 
An important issue in unraveling the cell biological and molecular functions of 
PTEN in prostate cancer is the choice of the model system. Prostate-specific Pten 
knock-out mice are a major component of the current prostate cancer research. 
However, the onset and progression of tumor formation upon Pten inactivation in 
mice seem to occur earlier than in humans. Whereas in human prostate tumors 
complete loss of PTEN function is associated with the later stages of the disease, in 
the PB-Cre;Pten-loxP/loxP mice invasive carcinomas had already developed at 9 
weeks of age 18. The process of prostate cancer development in PSA-Cre;Pten-
loxP/loxP mice was slower, massive hyperplasia and focal PIN were first observed 
at 4-5 months of age while carcinomas were detected at 10-14 months 19. Recently, 
a mouse model was described in which prostate carcinogenesis is initiated after 
puberty which may more closely resemble the course of human prostate cancer 
development 20. Moreover, it must be kept in mind that PTEN might also display 
species specific functions. Therefore caution must be taken in interpreting the 
observed functions of Pten in mouse model systems with respect to the significance 
of these functions in human cancer.  
   In the studies described in chapters 2 and 3 of this thesis tumor derived cell lines 
were used to study PTEN function. Since cell lines can be easily propagated large 
amounts of material are available. In addition, in cell lines manipulation of 
signaling pathways is relatively easy to perform and in contrast to mouse models 
results can be obtained within a few days. However, it must be noted that tumor 
derived cell lines display multiple genetic alterations, which adds another level of 
complexity in the identification of PTEN regulated processes. Normal prostate cell 
lines might therefore be the most preferred model system to investigate the role of 
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PTEN in prostate cancer. Only a few reports describe the use of non tumorigenic 
PNT1a or PNT2 prostate cells with respect to PTEN research 21,22. However, most 
times small molecules or PTEN over-expression was used to manipulate 
PTEN/PI3K signaling, which would not be the preferred method of choice in cell 
lines with a wild-type PTEN background. In one study PTEN expression was also 
knocked down by siRNA, which resulted in high steady state levels of active Akt 
but thus far no functional PTEN studies were performed in these cell lines 21.  
   Recently, the fusion of the androgen regulated gene TMPRSS2 to genes encoding 
members of the ETS transcription factor family, such as ERG, has been identified 
as a frequently occurring rearrangement in prostate cancer 23-25. Overexpression of 
the TMPRSS2:ERG gene fusion product in normal prostate cells promoted 
invasion, and expression in transgenic mice initiated the development of PIN 
lesions 26,27. These models provide valuable information concerning the 
significance of the TMPRSS2:ERG rearrangement in prostate cancer tumorigenesis. 
Together with the inactivation of PTEN it is the most common genetic alteration in 
prostate cancer. Since complete loss of PTEN function is correlated with later 
stages of the disease it would be interesting to investigate the effect of additional 
PTEN loss in the further progression of prostate cancer in the TMPRSS2:ERG 
model systems.  
 
Modulation of PTEN signaling 
The PTEN/PI3K signal transduction cascade is very complex and modulation of 
this signaling pathway by over-expression of PTEN, inducible systems or small 
molecules that inhibit PI3K function has been proven to be very useful to increase 
the insight in the cell biological functions of PTEN and its downstream targets. 
However, drawbacks of these methods are the non-specific side effects of small 
molecules and the non-physiological expression of the protein of interest in over-
expression studies, thereby complicating the identification of normal cell biological 
functions and direct downstream signaling targets. The last few years RNA 
interfering as a method for specific post-transcriptional gene silencing has been 
proven to be a new potent tool to analyze signal transduction cascades. By 
systematically targeting a specific member of a certain signal transduction cascade 
much can be learned about its role in that particular pathway. For example, the 
specific knockdown of the three Akt isoforms in various tumor cell lines revealed 
that the relative importance of the different isoforms is cell line specific 28. In 
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chapter 2 of this thesis siRNA technology was used to investigate the role of 
PTEN/Akt signaling in the regulation of p27kip1 and in chapter 3 Akt specific 
siRNA was used to discriminate between Akt dependent and independent 
mechanisms of PTEN mediated transcription regulation.  
   Thus, RNAi technology facilitates complex pathway analysis by dissecting 
signaling cascades in a systematic way. The functional pathway analysis can even 
be improved by the combinatorial use of several siRNAs within one cell 29. Also 
the development of inducible short hairpin RNA (vector based siRNA) expression 
systems especially in combination with lenti-viral delivery systems for an efficient 
and stable expression of the siRNA, will enhance the research studying complex 
biological processes 30.  
   Next to the exogenously applied siRNAs also the recently discovered miRNAs 
could have an important function in gene silencing and introduce a new level and 
mechanism of regulation 31. MiRNAs are an abundant class of endogenously 
expressed noncoding RNAs of approximately 22 nucleotides in length that can 
function as negative regulators of gene expression by inducing degradation or 
inhibiting translation of select mRNAs 32. As previously described in the general 
introduction of this thesis, to date miR-21, miR-214, and the miR17-92 cluster are 
reported to function in the regulation of PTEN 33-35. In addition, the miR17-92 
cluster was also found to suppress the expression of the pro-apoptotic factor BIM, a 
putative target of FOXO transcription factors 35,36.  
   There are only a limited number of studies that have investigated the role of 
miRNAs in prostate cancer but interestingly the expression of miR-125b was 
frequently altered 37-39. Down-regulation of miR-125b in tumor samples was 
associated with an increased expression of the Akt/mTOR pathway target      4E-
BP1 38. Furthermore, in prostate cancer cell lines the miRNAs miR-221 and miR-
222 were implicated in the regulation of p27kip1 40. In the investigated cell lines 
miR-221 and miR-222 expression seemed to correlate with the growth rate of the 
cell line; whereas they were highly detectable in PC3 cells they were almost absent 
in the slow growing LNCaP and 22Rv-1 cell lines 40. Moreover, their expression 
inversely correlated with the p27kip1 expression level. As described previously in 
chapter 2 of this thesis, in our panel of prostate cancer cell lines the p27kip1 
expression level more strongly correlated with the growth rate than with the 
PTEN/Akt status of a particular cell line. Thus maybe, apart from the described 
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role of Skp2 in p27kip1 regulation, miR-221 and miR-222 have also a role in the 
regulation of p27kip1 in prostate cancer cell lines.  
 
Cross-talk of PTEN/PI3K signaling with other signal transduction cascades 
PTEN might display at least part of its function through cross-talk with other 
signaling pathways. Since both the AR and activation of PTEN/PI3K signaling 
have a major function in prostate cancer growth many efforts have been put in the 
investigation of a functional link between these two signal transduction cascades. 
Although in vitro Akt has been found to phosphorylate the AR, in vivo the effect of 
Akt dependent phosphorylation in transactivation of the AR is still a matter of 
debate 41-44.  
   Since both PTEN inactivation and fusion of TMPRSS2 to ETS genes are 
frequently occurring alterations in prostate cancer it might be of interest to study 
cross-talk between PTEN and ETS pathways. ETS transcription factors are 
involved in the regulation of various biological processes 45. A study by Iljin et al., 
(2006) aiming to identify ETS regulated processes in prostate cancer revealed that 
the WNT and PITX2 cascades were the most highly enriched pathways in ERG 
positive tumors 46. In addition, these ERG positive tumors also displayed over-
expression of HDAC1 46.  Parallel knockdown of several targets using RNAi 
technology will be a valuable tool to study cross-talk between PTEN/AR and 
PTEN/ETS pathways in a systematic way and help to elucidate their role in the 
development and progression of prostate cancer.  
 
PTEN in cell cycle regulation   
Progression through the cell cycle is a highly complex and tightly coordinated 
process. The role of PTEN therein is observed at several levels of regulation 47. At 
the protein level direct phosphorylation by Akt alters the cellular distribution and 
thereby the activity of p21Cip1/Waf and p27kip1 48,49. In addition, Akt dependent 
phosphorylation of these cell cycle inhibitors can also target them for degradation 
by the ubiquitin-proteasome system. Moreover, cyclin D1 is targeted for 
degradation by the ubiquitin-proteasome system upon phosphorylation by the Akt 
target GSK3 50.  
   Protein degradation by the ubiquitin-proteasome system is an important aspect in 
cell cycle regulation. One of the major E3 ubiquitin ligases involved in the 
proteolysis of many cell cycle proteins is Skp2 51. In chapter 2 we reported that in 
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PC3 and DU145 cells Skp2 is the main determinant of the Akt dependent p27kip1 
regulation. By that time the underlying mechanisms of Akt dependent Skp2 
regulation remained to be elucidated. Although many aspects are still unclear, roles 
for GSK3, mTOR and E2F transcription factors were suggested in the PTEN/PI3K 
dependent regulation Skp2 expression 52-54. Although E2F transcription factors 
were found to up-regulate Skp2 mRNA in pancreatic ductal adenocarcinoma 
cells53, we could not detect regulation of Skp2 expression at the transcriptional 
level in the prostate cancer cells PC3 and DU145. Since many proteins are 
regulated at various different levels it might very well be that cell-type specific 
regulatory mechanisms exist. This hypothesis is further strengthened by the 
observation that in intestinal cells over-expression of active GSK3 resulted in a 
reduced Skp2 expression and that inhibition of mTOR activity by rapamycin in 
breast cancer cells not only affected Skp2 mRNA expression but also enhanced the 
Skp2 protein degradation rate 52,54.   
   Next to PTEN/Akt mediated modulations at the protein level PTEN dependent 
transcription regulation is also important in cell cycle regulation as described in 
chapter 3 of this thesis.  PTEN is known to modulate transcription by affecting the 
activity of the FOXO family of transcription factors and in several cell types a 
contribution of FOXO to G1/S cell-cycle arrest by regulating the expression of 
negative cell-cycle regulators, such as p27kip1 and RBL2, has been described 55-58. 
However, we found that in prostate cancer cells Akt/FOXO signaling is not a major 
regulator of p27kip1 mRNA expression and also the observed PTEN dependent 
transcription regulation of RBL2 was independent of Akt/FOXO signaling (see 
chapters 2 and 3). Although FOXO transcription factors are probably implicated in 
the regulation of cyclin G2 the transcription factors responsible for the altered 
mRNA expression of the other genes remained to be identified. Screening a siRNA 
library targeting various transcription factors would be a useful tool to reveal which 
transcription factors are involved and shed a new light on PTEN dependent 
transcription regulation.   
 
Nuclear PTEN functions 
A critical part of the tumor suppressive function of PTEN is due to its lipid 
phosphatase activity, a process occurring at the cellular membrane 59. Despite the 
extensively studied role of PTEN in signaling at the cellular membrane the 
presence of PTEN in the nucleus of many different cell types suggested that also its 
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nuclear localization may contribute to its tumor suppressor activity 60,61. Many 
components of the PI3K signaling pathway are also found in the nucleus but a 
recent study indicated that nuclear PTEN does not dephosphorylate the nuclear 
PIP3 pool 62,63. The exact role of nuclear PTEN in its tumor suppressive function 
thus remains to be elucidated although nuclear PTEN has been proposed to act as a 
pro-apoptotic factor and a regulator of chromosomal integrity 64,65. Intriguingly, 
higher levels of nuclear PTEN were associated with G0-G1 phase, and lower 
nuclear PTEN levels were associated with S phase progression in MCF7 cells 66. 
Further research indicated that nuclear PTEN is required for PTEN mediated cell 
cycle arrest whereas cytoplasmic PTEN mainly regulates apoptosis 67. In chapter 3 
we reported that G0/G1 cell cycle arrest was one of the most prominent processes 
regulated by PTEN in LNCaP/PTEN cells. However, in this study no 
discrimination was made between nuclear and cytoplasmic PTEN functions. In 
these cells PTEN dependent transcription regulation, which is executed in the 
nucleus, was of particular importance in the regulation of the G0/G1 cell cycle 
arrest. Therefore, it may be interesting to investigate the role of nuclear PTEN in 
cell cycle regulation of prostate cancer cells.  
 
PTEN and DNA replication 
In the search for PTEN regulated processes altered expression of several genes 
involved in DNA replication was observed, such as CDC6, CDT1 and MCM10 
(chapter 3). Although the process of DNA replication is closely linked to cell cycle 
control as indicated by the function of CDKs both in cell cycle regulation and as 
initiator proteins of DNA replication, this seemed a more indirect regulated process 
since the expression of these genes first started to decrease at 24 h after PTEN 
induction 68. Thus far, less is known about the function of PTEN in DNA 
replication but interestingly, Skp2 was recently implicated in the regulation of 
CDT1 69,70. Since we and others have detected a PTEN mediated regulation of Skp2 
(71 and chapter 2 of this thesis) it may be interesting to further explore the role of 
PTEN and Skp2 in the regulation of DNA replication in prostate cancer.  It might 
be that although at the transcriptional level PTEN dependent regulation of DNA 
replication is a more indirect effect, PTEN is more directly involved in the 
regulation of DNA replication at the protein level via regulation of Skp2 
expression.  
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Concluding remarks 
The research described in this thesis increased the insight in the genetic and cell 
biological aspects of PTEN in prostate cancer. However, many issues remain to be 
elucidated, such as the question whether PTEN haploinsufficiency is indeed critical 
in prostate cancer tumor progression. At the cell biological level experiments in 
normal prostate cell lines will largely contribute to an increased understanding of 
normal PTEN function in the prostate. Inducible shRNA expression systems will 
be an essential tool to dissect the PTEN/PI3K signaling pathway and its possible 
interactions with other signal transduction cascades. Special interest may be paid to 
the role of nuclear PTEN in cell cycle regulation and also the question whether and 
by which regulatory mechanism PTEN might be involved in the regulation of DNA 
replication provides an interesting opportunity for future research. Thus although 
PTEN signaling pathway has been extensively studied and much progress has been 
made in defining the role of PTEN in tumor suppression continuing research will 
be essential in unraveling additional functions of PTEN. Further understanding of 
the possible tissue specific regulation of the PTEN pathway in prostate cancer may 
provide opportunities for the development of novel therapeutic options.  
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Summary 
Uncontrolled proliferation, enhanced migration and decreased apoptosis are 
important hallmarks of tumor cells. A major regulator of these biological processes 
is the PI3K/Akt signaling pathway, of which the tumor suppressor PTEN is a key 
player. Due to its ability to dephosphorylate PIP3, a lipid second messenger 
produced by PI3K, PTEN counteracts PI3K and functionally antagonizes signaling 
pathways that rely on the activity of PI3K. Thereby PTEN has a major influence on 
the regulation of various cell biological processes.  In prostate cancer PTEN is the 
most frequently inactivated gene. Complete PTEN inactivation is correlated with 
the later stages of the disease. The aim of the research described in this thesis was 
to gain further insight into the role of PTEN in the development and progression of 
prostate cancer. This will augment our understanding of prostate tumorigenesis and 
may result in novel treatment options for advanced disease.  
   In chapter 1 an overview of the cell biological and molecular properties of 
PTEN is presented. The chapter starts with a general description of its structure, 
cell biological and molecular functions. In the second part of this chapter the role 
of PTEN in prostate cancer is specifically emphasized. It discusses the rate and 
underlying mechanism of PTEN inactivation and addresses the presumed role of 
PTEN haploinsufficiency in the progression of prostate cancer. Further, it describes 
the cell biological processes that are affected by PTEN in prostate cancer, its role 
in androgen independence, and the cross talk between PTEN and AR signal 
transduction cascades. Moreover, several prostate cancer mouse models and the 
prognostic value of PTEN inactivation in prostate cancer will be discussed.  
   Chapter 2 is focused on the role of PTEN in the regulation of the cell cycle 
inhibitor p27kip1. In prostate cancer low expression of p27kip1 is a marker of poor 
prognosis. The expression level of p27kip1 is controlled by the integration of several 
signaling pathways, including the PTEN/Akt pathway. We described a differential 
effect of PTEN/Akt signaling on the expression of p27kip1 in the three PTEN 
negative prostate cancer cell lines LNCaP, PC3 and PC346, and the PTEN positive 
cell line DU145. PTEN/Akt signaling affects the p27kip1 expression in PC3 and 
DU145 cells but is not a major factor in the regulation of p27kip1 in LNCaP and 
PC346. In PC3 and DU145 cells PTEN mediated its effect on p27kip1 expression by 
PTEN/Akt dependent regulation of the E3 ubiquitin ligase Skp2.  
   Chapter 3 reported on the generation and characterization of the novel cell line 
LNCaP/PTEN, which stably expresses PTEN under inducible control. PTEN 
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expression strongly influenced proliferation by arresting the cells in the G0/G1 
phase of the cell cycle. Throughout the years, the role of the PTEN/Akt pathway in 
the regulation of cell cycle proteins at the protein level by altered distribution, or 
phosphorylation has been extensively studied. In this chapter we showed that 
PTEN dependent transcriptional regulation of specific cell cycle proteins might be 
involved in the PTEN mediated cell cycle arrest. Micro-array analysis and q-PCR 
showed that E2F2, Cdc25a, RBL2 and cyclin G2 are important transcriptional 
targets of PTEN signaling. This PTEN regulated transcription was mediated by 
both Akt dependent and independent mechanisms.  
   In this thesis we also focused on the mechanism of PTEN inactivation in prostate 
cancer. Chapter 4 presents a comprehensive study to detect PTEN inactivation in 
40 locally progressive prostate cancers obtained by TURP. To assess PTEN 
inactivation in these tumor samples we utilized a variety of complementary 
technical approaches including allelotype analysis, dual color FISH, array-CGH, 
IHC and the novel WPR (wild-type/pseudogene ratio analysis) technique. Overall, 
the various methods showed consistent results and complete inactivation of PTEN 
was found in 12 out of 40 tumor specimens, with bi-allelic deletion being the major 
mechanism of PTEN inactivation.  
   In chapter 5 the development and validation of quantitative wild-
type/pseudogene ratio analysis (q-WPR), a novel and accurate method to detect 
gene copy number changes, utilizing PTEN in prostate cancer as a model system is 
described. Sensitive methods are required to assess the PTEN copy number in 
tumor samples, since loss of PTEN frequently encompasses a small genomic 
region. Q-WPR is based on the 5’-nuclease taqman assay and applies a highly 
homologous pseudogene as internal control, which is a major advantage over 
already existing genotyping methods. The method will allow high-throughput 
analysis of gene copy number changes of any gene with a highly homologous 
structurally related gene. Q-WPR was very accurate in detection of mono- and bi-
allelic loss of PTEN and was applicable on genomic DNA from frozen and from 
formalin-fixed, paraffin-embedded tumor tissues. 
   In conclusion, the research described in this thesis has increased our knowledge 
about the genetic aspects, and the cell biological and molecular functions of PTEN 
in prostate cancer. A solid understanding of the prostate specific functions and 
regulation of PTEN signaling may provide opportunities for the development of 
novel therapeutic options. 
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Samenvatting 
Vergeleken met normale cellen worden kankercellen o.a. gekenmerkt door 
migratie, ongecontroleerde groei en een verminderde mate van  geprogrammeerde 
celdood. De PI3K/Akt signaaltransductieroute speelt een grote rol in de regulatie 
van deze celbiologische processen. Het tumorsupressor eiwit PTEN is een 
essentieel onderdeel van deze signaaltransductieroute. PTEN is een phosphatase 
met als belangrijkste substraat het phospholipide PIP3, een second messenger die 
geproduceerd wordt door PI3K. Door zijn vermogen om PIP3 te defosforyleren, en 
daarmee het effect van PI3K op de activatie van diverse signaaltransductieroutes 
teniet te doen, is PTEN direct betrokken bij de regulatie van verschillende 
celbiologische processen. Het PTEN gen is het meest geïnactiveerde gen in 
prostaatkanker. Volledige inactivatie van PTEN functie wordt vooral gevonden in 
de latere stadia van de ziekte. De in dit proefschrift beschreven studies naar de rol 
van PTEN in prostaatkanker dragen bij aan het vergroten van de kennis omtrent de 
moleculaire en celbiologische mechanismen die betrokken zijn bij de groei van 
prostaatkanker. Een beter begrip van deze mechanismen kan leiden tot de 
ontwikkeling van nieuwe en betere behandelingen van prostaatkanker.  
   Hoofdstuk 1 geeft een algemene beschrijving van de structuur en de 
celbiologische en moleculaire functies van PTEN. De door PTEN gereguleerde 
processen kunnen echter per celtype verschillen en in het tweede deel van 
hoofdstuk 1 wordt dan ook extra nadruk gelegd op de rol van PTEN in 
prostaatkanker. Belangrijke aspecten die besproken zullen worden zijn de 
frequentie en het mechanisme van PTEN inactivering en de veronderstelde rol van 
PTEN haplo-insufficiëntie in de progressie van prostaatkanker. Verder is er 
aandacht voor de door PTEN gereguleerde celbiologische processen in de prostaat, 
de rol van PTEN in het ontstaan van androgeen onafhankelijkheid, en de mogelijke 
overlap van de door PTEN, en de door de androgeenreceptor, gereguleerde 
signaaltransductieroutes. Tenslotte wordt de ontwikkeling van een aantal 
prostaatspecifieke muismodellen besproken en wordt de voorspellende waarde van 
een afwijking in PTEN op de progressie van prostaatkanker bediscussieerd.  
   In hoofdstuk 2 wordt de rol van PTEN in de regulatie van p27kip1 onderzocht. 
P27kip1 is een eiwit dat bijdraagt aan de remming van de celcyclus en daarmee 
ongecontroleerde celgroei, en dus tumorvorming tegen gaat. Bij prostaatkanker is 
een lage expressie van p27kip1 een indicatie voor een slechte prognose. Er zijn 
verschillende signaaltransductieroutes die een effect kunnen hebben op het 
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expressieniveau van p27kip1, waaronder de PI3K/Akt signaaltransductieroute. Het 
effect van deze route op de expressie van p27kip1 bleek nogal wisselend te zijn in de 
onderzochte prostaatkankercellijnen. In de PTEN negatieve prostaatkankercellijnen 
PC346 en LNCaP was de PI3K/Akt signaaltransductieroute geen belangrijke factor 
in de regulatie van p27kip1. Dit in tegenstelling tot het effect in de derde PTEN 
negatieve prostaatkankercellijn PC3 en de PTEN positieve lijn DU145, waarbij 
activatie van de PI3K/Akt signaaltransductieroute een verminderde expressie van 
p27kip1 tot gevolg had. Dit effect werd voornamelijk veroorzaakt door de 
PTEN/Akt afhankelijke regulatie van het E3 ubiquitine ligase Skp2, wat zorgt voor 
een verhoogde afbraak van p27kip1 eiwit in het proteasoom.  
    In hoofdstuk 3 wordt de ontwikkeling en de karakterisatie van de nieuwe cellijn 
LNCaP/PTEN beschreven. Deze cellen kunnen PTEN geïnduceerd tot expressie 
brengen. Expressie van PTEN in deze cellen bleek een sterk remmend effect te 
hebben op de celgroei, wat veroorzaakt werd door een remming van de cellen in de 
G0/G1 fase van de celcyclus. De afgelopen jaren is er veel onderzoek gedaan naar 
de rol van PTEN in de regulatie van de celcyclus op eiwitniveau, bijvoorbeeld door 
een veranderde fosforylatie of localisatie van bepaalde celcycluseiwitten. In dit 
hoofdstuk wordt aangetoond dat PTEN ook de transcriptie van een aantal 
belangrijke celcycluseiwitten kan reguleren. Micro-array analyse en q-PCR 
toonden aan dat de celcycluseiwitten E2F2, Cdc25a, RBL2 en cycline G2 op 
transcriptieniveau door PTEN gereguleerd kunnen worden. Verder onderzoek wees 
uit dat er zowel Akt afhankelijke als Akt onafhankelijke mechanismen betrokken 
zijn bij de PTEN afhankelijke transcriptieregulatie van deze genen. 
  Naast het bestuderen van de moleculaire functie van PTEN in prostaatkanker is er 
ook onderzoek gedaan naar de genetische aspecten van PTEN in prostaatkanker. 
En dan met name naar de frequentie en het mechanisme van PTEN inactivatie in 
klinische prostaattumoren. In de studie die beschreven wordt in hoofdstuk 4 is 
onderzoek gedaan naar de inactivatie van het PTEN gen in 40 locaal progressieve 
tumoren (TURP). Er werden verschillende, elkaar aanvullende, methoden gebruikt 
om de inactivatie van PTEN te kunnen detecteren waaronder FISH, array-CGH, 
immunohistochemie, en de nieuw ontwikkelde methode WPR (wild-
type/pseudogen ratio analyse). Over het algemeen gaven de verschillende 
technieken een vergelijkbaar beeld. In 12 van de 40 onderzochte tumoren werd een 
inactivatie van PTEN gevonden. De belangrijkste oorzaak van deze inactivatie 
bleek het verlies van beide kopieën van het PTEN gen te zijn.  
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   Hoofdstuk 5 beschrijft tenslotte de ontwikkeling van q-WPR (quantitatieve-
Wild-type/Pseudogen Ratio analyse), een nieuwe, gevoelige methode om het aantal 
kopieën van een gen te bepalen. Omdat in veel tumoren, waaronder prostaatkanker, 
verlies van één of twee kopieën van PTEN word gevonden, wordt het PTEN gen in 
prostaatkanker gebruikt als modelsysteem om de methode te valideren. Q-WPR is 
gebaseerd op de eerder beschreven 5’-nuclease taqman assay. Een groot voordeel 
van q-WPR ten opzichte van al bestaande methoden is het gebruik van een sterk 
homoloog pseudogen als interne controle. Q-WPR bleek zeer nauwkeurig in het 
bepalen van het verlies van één of twee kopieën van PTEN. Verder is de methode 
goed toepasbaar op genomisch DNA verkregen uit gefixeerd en in paraffine 
ingebed weefsel, wat vaak van mindere kwaliteit is. Tenslotte is q-WPR niet alleen 
toepasbaar op PTEN maar op vrijwel elk gen met een bijbehorend structureel 
verwant pseudogen.  
   Samenvattend kan gezegd worden dat de in dit proefschrift beschreven studies 
een belangrijke bijdrage hebben geleverd aan het vergroten van het inzicht in de rol 
van PTEN in prostaatkanker. Een goed inzicht in de prostaat specifieke functies 
van PTEN kan op termijn resulteren in de ontwikkeling van nieuwe en verbeterde 
therapiën voor prostaatkanker.  
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List of abbreviations 
AR                        Androgen receptor 
BPH                      Benign prostatic hyperplasia 
BZS                      Bannayan-zonana syndrome 
CaP                       Carcinoma of the prostate 
CD                        Cowden disease 
CDC6                   Cell division cycle 6 
Cdc25a                Cell division cycle 25 homolog A 
CDK                     Cyclin dependent kinase 
CDKI                    Cyclin dependent kinase inhibitor 
cDNA                    Copy DNA    
CDT1                    Chromatin licensing and DNA replication factor 1 
CGH                      Comparative genomic hybridization 
E2F2                     E2F transcription factor 2 
ERG                      ETS related gene 
ES cells                 Embryonic stem cells 
ETS                       E26 transforming sequence  
FACS                    Fluorescent activated cell sorting 
FISH                     Fluorescent in situ hybridization 
FOXO                   Forkhead box O 
GSK3                   Glycogen synthase kinase-3 
HD                        Homozygous deletion 
IGF                        Insulin growth factor 
IHC                        Immunohistochemistry 
IPA                        Ingenuity pathway analysis 
IRS2                      Insulin receptor substrate 2 
LDD                      Lhermitte-duclos disease 
LOH                      Loss of heterozygosity 
MCM10                 Minichromosome maintenance 10 
MDM2                   Mouse double-minute 2 
MEF                     Mouse embryonic fibroblast 
miRNA                 Micro RNA 
MLPA                   Multiplex ligation-dependent probe amplification 
MPAKT                Murine prostate restricted Akt kinase model 
mRNA                   Messenger RNA 
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mTOR                    Mammalian target of rapamycin 
NLS                      Nuclear localization signal 
PB                        Probasin 
PDK1                   3-Phosphoinositide-dependent protein kinase-1  
PDZ domain        Acronym of PSD95, DlgA, Zo-1 proteins, also known as GLGF  
                             domain (Glycine Leucine Glycine Phenylalanine) 
PEST motif          Proline-Glutamic acid-Serine-Threonine motif 
PHTS                   PTEN hamartoma tumor syndrome 
PI3K                     Phosphatidyl inositol- 3 kinase 
PIN                      Prostatic intraepithelial neoplasia 
PSA                      Prostate specific antigen 
PTEN                   Phosphatase and tensin homologue deleted on chromosome 10 
PTP                      Protein tyrosine phosphatases 
Q-PCR                 Quantitative polymerase chain reaction 
Q-WPR                Quantitative wild-type to pseudogene ratio 
RBL2                    Retino blastoma-like 2 
RP                        Radical prostatectomy 
RT-PCR               Reverse transcription polymerase chain reaction 
siRNA                  Small interfering RNA 
Skp2                     S-phase kinase associated protein 2 
SNP                      Single nucleotide polymorphism 
SSCP                    Single strand conformation polymorphism 
TMPRSS2            Transmembrane Protease, Serine 2 
TRAMP                Transgenic adenocarcinoma mouse prostate 
TURP                    Trans urethral resection of the prostate 
UTR                      Untranslated region 
WPR                     Wild-type to pseudogene ratio 
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